Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity

Beata Gryzło, Paula Zaręba,* Katarzyna Malawska, Gabriela Mazur, Anna Rapacz, Kamil Łątka, Georg C. Höfner, Gniewomir Latacz, Marek Bajda, Kinga Sałat, Klaus T. Wanner, Barbara Malawska, and Katarzyna Kulig



ABSTRACT: Neuropathic pain resistance to pharmacotherapy has encouraged researchers to develop effective therapies for its treatment. γ -Aminobutyric acid (GABA) transporters 1 and 4 (mGAT1 and mGAT4) have been increasingly recognized as promising drug targets for neuropathic pain (NP) associated with imbalances in inhibitory neurotransmission. In this context, we designed and synthesized new functionalized amino acids as inhibitors of GABA uptake and assessed their activities toward all four mouse GAT subtypes (mGAT1-4). According to the obtained results, compounds $2RS_4RS$ -39c (pIC₅₀ (mGAT4) = 5.36), **50a** (pIC₅₀ (mGAT2) = 5.43), and **56a** (with moderate subtype selectivity that favored mGAT4, pIC₅₀ (mGAT4) = 5.04) were of particular interest and were therefore evaluated for their cytotoxic and hepatotoxic effects. In a set of *in vivo* experiments, both compounds **50a** and **56a** showed antinociceptive properties in three rodent models of NP, namely, chemotherapy-induced neuropathic pain models (the oxaliplatin model and the paclitaxel model) and the diabetic neuropathic pain model induced by streptozotocin; however compound **56a** demonstrated predominant activity. Since impaired motor coordination is also observed in neuropathic pain conditions, we have pointed out that none of the test compounds induced motor deficits in the rotarod test. **KEYWORDS:** *GABA transporters, mGAT1-4 inhibitors,* [³H]GABA uptake, neuropathic pain models, antiallodynic activity, antihyperalgesic activity

1. INTRODUCTION

The γ -aminobutyric acid (GABA) is a neurotransmitter known for its inhibitory modulation of neuronal networks.^{1,2} Endogenous GABA is synthesized from glutamate^{3,4} and controls the generation of membrane potential oscillations by acting on two types of receptors, ionotropic (GABA_A) and metabotropic (GABA_B) as summarized in Figure 1.⁵ Plasma membrane transporters of GABA (GATs) are components of one of the pathways responsible for terminating inhibitory signaling. GATs expression in different cell types is highly dynamic and can be modified depending on the activity. Reuptake achieved through GATs occurs in nerve terminals (allowing GABA to be recycled as a neurotransmitter) and/or the surrounding glial cells, whereby glial GATs are responsible for 20% reuptake of GABA, Figure 1.⁶ GABA specific transport systems represent a mechanism that regulates the efficiency of GABA transmission; thus, since 1990, the family of GAT sodium symporters has become an interesting biological target. Cloning of several GATs has led to a better understanding of the molecular properties of this solute carrier family, Figure 1. GATs have a confusing numbering system; hence, we present a summary of the current nomenclature based on that from the International

 Received:
 May 29, 2021

 Accepted:
 July 16, 2021



A



Postsynaptic

Figure 1. Diagram of GABA transport systems in neurons and glia (A) and stoichiometry between GABA and co-ions in GAT1 and GAT3 (B).



Figure 2. Structures and inhibitory activities (pIC₅₀ values) of GAT substrates $(1, {}^{18} 2, {}^{18} 3, {}^{19} 4^{19})$ and GAT inhibitors (5-12) separated according to their transporter subtype selectivity: mGAT1 (tiagabine $(5), {}^{20}$ DDPM-2571 $(6), {}^{20} 7, {}^{21}$ NO711 $(8)^{19}$) and mGAT4 ((S)-SNAP-5114 $(9), {}^{22}$ DDPM-859 $(10), {}^{22} 11, {}^{23} 12^{24}$).

Union of Basic and Clinical Pharmacology (IUPHAR). Human (and rat) GAT1 (SLC6A1), GAT2 (SLC6A13), GAT3 (SLC6A11), and BGT1 (SLC6A12)⁷ correspond to mouse mGAT1, mGAT2, mGAT3, and mGAT4, respectively.⁸ In this paper, we present the results of an *in vitro* test on murine GATs, and the mouse nomenclature (mGAT1–GAT4) will be used in a later section.

mGAT1 (representing neuronal uptake) and mGAT4 (mediating transport into glial cells) are mainly localized in the central nervous system (CNS). The peripherally located mGAT2 (BGT1) is largely expressed in the liver, with lower

levels observed in the kidneys and at the brain surface in the leptomeninges.^{9,10} mGAT3 is a second GABA transporter distributed mainly in the peripheral tissues, and since there is a lack of selective and potent mGAT3 inhibitors, the function of mGAT3 remains unclear.^{9–11} Due to the diversity in GAT subtype localization and function, researchers have focused on the synthesis of subtype-selective inhibitors.

Small amino acids are known to be GAT substrates; moreover, some substrate preferences toward GAT subtypes are well established. All four GATs can transport GABA (1). Additionally, β -alanine (2) is a substrate for both mGAT3 and



Figure 3. Schematic summary of the structural modification approach from parent compound 13.²⁵

Scheme 1. Synthesis of the 4-Hydroxypentanamide (37a-c, 39a-c, 41, 43a, b, 45) and 4-Hydroxybutanamide (47a-c) Derivatives^{*a*}



^aReagents and conditions: (a) suitable amine (17 (A), 21 (C), 25 (D), 26 (E), or 32 (F)), TBAB, K_2CO_3 , CH_3CN , 15 min at 0 °C and 16 h at rt; (b) argon, dry THF, reflux, 48 h.

mGAT4 with a low affinity for mGAT1 and mGAT2. A functional approach based on small molecules, such as (R)-nipecotic acid (3) or guvacine (4), has resulted in the synthesis of many subtype-selective inhibitors (Figure 2). Effective blockade of the uptake toward GAT is believed to have therapeutic value for not only epileptic seizures but also neuropathic pain (NP) and several abnormalities, including tremors, ataxia, and nervousness.¹² mGAT1 inhibitors are the most potent compounds, and a wide range of these subtype-selective inhibitors are known (5–8, Figure 2). One example is the mGAT1 selective compound tiagabine (5), which has been approved by the FDA for adjunctive treatment of seizures. Furthermore, tiagabine (5) turned out to be highly effective in various rodent neuropathic pain models.^{13,14} The guvacine derivative DDPM-257 (6) is another selective mGAT1

inhibitor that is effective in mouse models of seizures, anxiety, depression, and acute and tonic pain.¹⁵ Moreover, mGAT4 remains also a challenging target, especially since mGAT4 inhibitors seem to be suitable for antinociceptive activity.^{16,17} In this context, the GABA transporters were found to be interesting biological targets in the search for new treatment of NP. Nevertheless, due to the low to moderate subtype selectivity of 9-12, the development of new selective inhibitors remains an important approach for distinguishing non-mGAT1 pharmacology (Figure 2).

We previously obtained a series of GABA analogs with mGAT3/4 subtype preference with the most interesting compound 13 that could reduce tactile allodynia in neuropathic mice.²⁵ In this paper, we present a continuation of our previous work with new derivatives that can be classified as

Scheme 2. Synthesis of the 4-Aminobutanamide (50a,b) and 4-Acetamidobutanamide (51a,b) Derivatives^a



"Reagents and conditions: (a) KI, K₂CO₃, CH₃CN, reflux, 24 h; (b) NH₂NH₂ (50–60%), EtOH, 2 h at 60 °C and 5 h at rt; (c) DMAP, DCC, CH₃COOH, DCM, 10 min at 0 °C and 20 h at rt.

Scheme 3. Synthesis of 3-Hydroxypropanamide Derivatives (54a-c, 55a-e, 56a-e, 57, 58, and 59a-c)^a



^aReagents and conditions: (a) T3P, TEA, N-benzylamine derivative, dry DCM, -17 °C for 30 min and rt for 1 h, argon; (b) suitable amine (17 (A), 20 (B), 21 (C), 25 (D), 26 (E), or 32 (F)), DIPEA, TBAB, dry DMF, reflux, 12 h.

analogs of parent compound 13. A summary of these modifications is presented in Figure 3. The first purpose of this study was to investigate how stiffening the lipophilic fragment in the second position of the N-benzylamide derivatives affects subtype preference and/or mGAT1-4 transporter inhibition compared to the more flexible analogs. Therefore, we introduced a piperidine ring to replace the flexible carbon chain (the lipophilic fragment; blue rectangle, Figure 3). To maintain an analogous structure, bisthiophene, fluorenyl, or suberenone was introduced in the 4-position of the piperidine ring (fragment 3, Figure 3). Moreover, motivated by the inhibitory activity of NO711 (8), we decided to introduce an oxime subunit into the 4-position of the 4hydroxy- and 4-aminobutanamide derivatives. This moiety is interesting for the structure-activity relationship (SAR) discussion due to its potential ability to impact the binding mode of mGAT1 inhibitors.²⁶ Second, on the basis of the fact that a large number of mGAT1 ligands possess a carboxylic acid fragment, we previously synthesized propanoic acid ethyl and benzyl ester derivatives for hydrolysis into the corresponding carboxylic analogs of the parent *N*-benzamides (fragment 1, Figure 3). The last structural change was to introduce variation into the length of the main carbon chain. Therefore, the synthesized compounds are 3-5 carbon atoms in length. We exchanged the hydroxyl/amino groups for methyl or isopropyl groups to determine whether the presence of hydrogen bond donors affects GAT inhibitory potency in the present group of compounds. To explore the molecular interactions of novel obtained GABA uptake inhibitors with GABA transporters, computational docking and molecular dynamics studies have been performed. Finally, to confirm the therapeutic potential of the obtained compounds, we tested selected the most potent compounds in *in vitro* assays, for their antiallodynic and antihyperalgesic activities in three rodent models of NP.

2. RESULTS AND DISCUSSION

2.1. Chemistry. To synthesize the target compounds, we used secondary amines 17 (A), 20 (B), 21 (C), 25 (D), 26 (E), 32 (F), and 33 (G). Amines were prepared according to





"Reagents and conditions: (a) T3P, TEA, N-benzylamine derivative, dry DCM, -17 °C for 30 min and 1 h at rt, argon; (b) suitable amine (17 (A), 32 (F), or 33 (G)), DIPEA, TBAB, dry DCM, reflux, 12 h; (c) suitable amine (20 (B) or 33 (G)), K₂CO₃, DCM reflux, 12 h; (d) MeOH, 10 wt % NaOH, 35 °C, 4.5 h.

the synthetic route presented in Scheme S1 (see Supporting Information). $^{\rm 27-30,32-39}$

2.1.1. Synthesis of the 4-Hydroxypentanamide (37a-c, **39a–c**, **41**, **43a**,**b**, **45**), 4-Hydroxybutanamide (**47a–c**), 4-Aminobutanamide (50a.b), and 4-Acetamidobutanamide (51a,b) Derivatives. The designed target 4-hydroxypentanamide (37a-c, 39a-c, 41, 43a,b, 45) and 4-hydroxybutanamide (47a-c) derivatives were obtained in the two main steps. First, nucleophilic substitution between building blocks 17 (A), 21 (C), 25 (D), 26 (E), or 32 (F) and 3-bromo-5methyldihydrofuran-2(3H)-one (34) or 3-bromodihydrofuran-2(3H)-one (35) was performed to obtain compounds 36, 38, 40, 42, 44, and 46 (Scheme 1).⁴⁰ Then, aminolysis was conducted following previously described synthetic procedures.^{25,40-43} Compounds 37a-c, 39a-c, 41, 43a,b, and 45 were isolated in pure form as a mixture of racemic diastereomers, e.g., 2RS,4RS-45 and 2RS,4SR-45, with a diastereoselectivity (ds) of approximately 7:3 (see the experimental section).

The 4-aminobutanamide derivatives (50a,b) and 4-acetamidobutanamide derivatives (51a,b) were prepared according to the synthetic route shown in Scheme 2. Compounds 50a and 50b were obtained from previously described synthetic procedures^{44,45} via the N-alkylation of 32 (F) with 48a,b and the hydrazinolysis of 49a,b. Acetylation of 50a and 50b gave 51a and 51b, respectively (Scheme 2).^{25,46}

2.1.2. Synthesis of 3-Hydroxypropanamide Derivatives (54a-c, 55a-e, 56a-e, 57, 58, and 59a-c). 3-Hydroxypropanamide derivatives were obtained according to a previously reported synthetic route shown in Scheme 3.^{25,47} 2-Bromo-3-hydroxypropanoic acid (52) has been obtained from unprotected serine. Designed amides (53a-e) were formed after activation of acid 52 by *n*-propanephosphoric acid anhydride (T3P).

Alkylation of amine 17 (A), 20 (B), 21 (C), 25 (D), 26 (E), or 32 (F) by 2-bromo-3-hydroxypropanoic acid N-benzylamide (53a-e) was carried out overnight at reflux in dry dimethylformamide (DMF) with N,N-diisopropylethylamine (DIPEA) and tetra-*n*-butylammonium bromide (TBAB). 2.1.3. Synthesis of Propanoic Acid and Butanoic Acid Derivatives (64a,b, 65, 66a,b, 67, 68, and 71–75). The 2substituted derivatives of propanoic acid and butanoic acid (64a,b, 65, 66a,b, 67, 68, and 71–75) were formed from Nbenzylamides (62 or 63a,b, Scheme 4 panel A) or commercially available esters (69 or 70, Scheme 4 panel B) following the synthetic route shown in Scheme 4. Alkylation of amines 17 (A), 32 (F), or 33 (G) with 2-bromo-3-propanoic acid (60) or 2-bromobutanoic acid (61) gave N-benzylamides 64a,b, 65, 66a,b, 67, and 68. A similar reaction was carried out for amines 20 (B) and 33 (G) with 2-bromo-3-propanoic ethyl ester (69) or 2-bromo-3-propanoic benzyl ester (70) to obtain desired compounds 71–73. Carboxylic acid analogs 74 and 75 were the alkaline hydrolysis products of parent compounds 71 and 73.

2.2. In Vitro Evaluation and SAR. The inhibitory potencies of all obtained final compounds were determined for the four mouse GABA transporter subtypes (mGAT1-4). The assay utilized was based on [3H]GABA uptake using human embryonic kidney cells (HEK-293) stably expressing mouse GATs according to the literature.¹⁹ Specific binding affinity toward mGAT1 was determined via a competitive mass spectrometry (MS) binding assay quantified by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) with NO711 as an unlabeled marker.⁴⁸ The compounds that could reduce GABA uptake or NO711 binding by at least 50% at an inhibitor concentration of 100 μ M were considered active. The pIC₅₀ or pK_i values from the [3H]GABA uptake or MS binding assays were determined in triplicate samples for competition and in three independent experiments only for compounds with $pIC_{50} \ge$ 5.00. If at a screening concentration of 100 μ M the test compounds could not reduce [3H]GABA uptake or NO711 binding below 50% (pIC₅₀ = 4.00), the percent of remaining ^{[3}H]GABA uptake or NO711 binding is given in the presence of 100 μ M inhibitor.

In the current approach, we focused on diversifying lipophilic side chain substituents at the α position of *N*-benzylamides. Newly synthesized 4-hydroxypentanoic acid derivatives possessing a suberone-*N*-methylpropan-1-amine

Table 1. Inhibitory Potencies (pIC₅₀ ± Standard Error of the Mean (SEM)) toward mGAT1-4 Determined by the [³H]GABA Uptake Experiments and mGAT1 Binding Affinities ($pK_i \pm SEM$) from the MS Binding Assays of the Obtained Compounds

	c)		
D 1	Ū			
n	\checkmark	`N^	\searrow	- 2
4	b 2	н		-R°
ĸ	R			

					$pIC_{50}^{a} \pm SEM$				$pK_i^a \pm SEM$
compd	\mathbb{R}^1	\mathbb{R}^2	R ³	\mathbb{R}^4	mGAT1	mGAT2	mGAT3	mGAT4	mGAT1
2RS,4RS- 37a	Me	Α	Н	ОН	4.58	4.61	4.38	4.14	100 µM: 74%
2RS,4SR- 37a	Me	Α	Н	ОН	4.53	100 µM: 60%	4.21	4.56	100 µM: 78%
2RS,4RS- 37b	Me	Α	2-Cl	ОН	100 µM: 52%	100 µM: 58%	4.03	4.21	100 µM: 94%
2RS,4SR- 37b	Me	Α	2-Cl	ОН	100 µM: 50%	100 µM: 69%	4.14	100 µM: 56%	100 µM: 108%
2RS,4RS- 37c	Me	Α	4-F	ОН	4.75	4.80	4.94 ± 0.07	4.71	100 µM: 76%
2RS,4SR- 37c	Me	Α	4-F	ОН	4.71	4.23	4.55	4.8	100 µM: 73%
2RS,4RS- 39a	Me	С	4-F	ОН	100 µM: 51%	4.90	4.83	4.60	100 µM: 110%
2RS,4RS- 39b	Me	С	4-Cl	ОН	100 µM: 56%	100 µM: 73%	4.62	5.04 ± 0.10	100 µM: 84%
2RS,4SR- 39b	Me	С	4-Cl	ОН	100 µM: 51%	100 µM: 73%	4.99	5.04 ± 0.10	100 µM: 87%
2RS,4RS- 39c	Me	С	4-Me	ОН	100 µM: 52%	4.69	5.18 ± 0.07	5.36 ± 0.10	100 µM: 69%
2RS,4SR- 39c	Me	С	4-Me	ОН	100 µM: 51%	5.09	5.10 ± 0.07	5.16 ± 0.09	100 µM: 73%
2RS,4RS- 41a	Me	D	Н	ОН	100 µM: 49%	4.13	4.19	52%	100 µM: 92%
2RS,4SR- 41a	Me	D	Н	ОН	4.07	4.05	4.26	4.14	100 µM: 89%
2RS,4RS- 43a	Me	Е	Н	ОН	4.77	4.25	4.67	4.58	100 µM: 77%
2RS,4SR- 43a	Me	Е	Н	ОН	4.71	4.23	4.55	4.80	100 µM: 73%
2RS,4RS- 43b	Me	Е	4-F	ОН	4.15	100 µM: 59%	4.42	4.32	100 µM: 86%
2RS,4SR- 43b	Me	Е	4-F	ОН	100 µM: 54%	100 µM: 80%	100 µM: 87%	100 µM: 62%	100 µM: 102%
2RS,4RS- 45	Me	F	Н	ОН	4.36 ± 0.08	4.34 ± 0.07	4.70 ± 0.05	4.55 ± 0.12	100 µM: 100%
2RS,4SR- 45	Me	F	Н	ОН	4.24 ± 0.11	4.50 ± 0.18	4.74 ± 0.09	4.40 ± 0.06	100 µM: 86%
47a	Н	F	Н	ОН	4.78	4.44	4.74	4.83	100 µM: 87%
47b	Н	F	2-Cl	ОН	4.50 ± 0.12	4.86 ± 0.10	5.04 ± 0.04	4.73 ± 0.12	100 µM: 86%
47c	Н	F	2,4-di-Cl	ОН	4.66	4.99	4.96 ± 0.05	5.15 ± 0.04	100 µM: 82%
50a	Н	F	2-Cl	NH ₂	4.70 ± 0.06	5.43 ± 0.11	5.07 ± 0.10	4.69 ± 0.09	4.48 ± 0.13
50b	Н	F	3,4-di-Cl	NH ₂	4.91	5.31 ± 0.05	5.32 ± 0.10	5.31 ± 0.09	4.48
51a	Н	F	2-Cl	NH(CO)CH ₃	4.74	4.88	5.03 ± 0.05	4.90	100 µM: 74%
51b	Н	F	3,4-di-Cl	NH(CO)CH ₃	4.93	4.92 ± 0.06	5.17 ± 0.07	4.95	100 µM: 72%
tiagabine (5) ¹⁹					6.88 ± 0.12	100 µM: 52%	100 µM: 64%	100 µM: 73%	7.43 ± 0.11^{49}
(S)-SNAP-5114	(3) ¹⁹				4.07 ± 0.09	100 µM: 56%	5.29 ± 0.04	5.81 ± 0.10	4.56 ± 0.02
DDPM-859 (4)	22				4.19 ± 0.07	4.12 ± 0.08	4.85 ± 0.04	5.78 ± 0.03	nd
DDPM-2571 (5) ²⁰				8.27 ± 0.03	4.31	4.35	4.07	8.29 ± 0.02
13 ²⁵	_				4.86 ± 0.10	4.98 ± 0.05	5.31 ± 0.04	5.24 ± 0.05	100 µM: 77%

"Data are given as the mean \pm SEM of three independent experiments that were performed in triplicate. The results presented as a percent represent [³H]GABA uptake or NO711 binding in the presence of 100 μ M inhibitor. Data without the SEM imply that only one experiment was performed in triplicate. nd: not determined.

(C) moiety ((2RS,4RS/2RS,4SR)-39a-c) and diphenylmethanone O-(2-(methylamino)ethyl) oxime (F) moiety ((2RS,4RS/2RS,4SR)-45) in general showed inhibitory potency comparable with parent compound 13 except for compounds with a more rigid moiety such as 4-(bis(3methylthiophen-2-yl)methylene)piperidine (A) moiety ((2RS,4RS/2RS,4SR)-37a-c), 4-(suberone) piperidine (E) moiety ((2RS,4RS/2RS,4SR)-43a,b), or 4-(fluorene)piperidine (D) moiety ((2RS,4RS/2RS,4SR)-41), which displayed reduced activity toward all GABA transporter subtypes (Figure 4, Table 1). On the other hand, when we compared 4-hydroxybutanamide derivatives with diphenylmethanone O-(2-(methylamino)ethyl) oxime (F) moiety 47a-c with 4hydroxypentanoic acid analogs 2RS,4RS-45 and 2RS,4SR-45, slightly higher inhibitory activity was observed for the 4hydroxybutanamide analogs (Table 1, Figure 4). Moreover, in the group of oximes containing benzamides ((2RS,4RS/ 2RS,4SR)-45, 47a-c, 50a,b, and 51a,b), the 4-aminobutanamide derivatives (50a,b) also displayed slightly improved inhibitory activity. Hence, among the oxime

derivatives, compound 50a with a chlorine atom in the 2position of the benzyl moiety exhibited the highest inhibitory potency toward mGAT2 among all compounds obtained (50a, $pIC_{50}(mGAT2) = 5.43$). Acylation of the amino functionality at the 4-position of butanoic acid (51a,b) did not change the inhibitory potency profile against mGAT1-4 (Table 1, Figure 4). An interesting effect was observed for derivatives 39a-c with a suberone-N-methylpropan-1-amine (C) moiety. In this group of compounds, we identified two dual mGAT3/4 subtype selective inhibitors (2RS,4RS-39b and 2RS,4SR-39b) with a similar GAT preference to that of (S)-SNAP-5114 (9) but with reduced potency. On the other hand, compound 2RS,4RS-39c, with a methyl group in the para position of the benzyl moiety, was found to be the most potent mGAT4 inhibitor $(pIC_{50}(mGAT4) = 5.36)$ with favorable GAT subtype selectivity.

The exchange of a hydroxyl group for a methyl group is represented in many of the 3-hydroxypropanamide derivatives (54a-c, 55a-e, 56a-e, 57, 58, and 59a-c) and propanoic acid and butanoic acid derivatives (57, 64a,b, 65, 66a,b, 67,



Figure 4. Bar graphs of the pIC₅₀ values for the library of 4-hydroxypentanamide (37a-c, 39a-c, 41a, 43a, b, 45), 4-hydroxybutanamide (47a-c), 4-aminobutanamide (50a, b), and 4-acetamidobutanamide (51a, b) derivatives compared to the values for the reference compounds (S)-SNAP-S114 (9) and 13. Error bars are not present when only one experiment was performed in triplicate. Additionally, bars are not presented when the pIC₅₀ value is lower than 4.00.

68, and 71–75; Table 2, Figure 5). The most potent synthesized serine derivatives have a tricyclic building block as the lipophilic substituent (dibenzocycloheptadiene moiety; C) in the α position of the N-benzylamides, 56a–e (Table 2, Figure 5). 56a–e showed the highest inhibitory activity toward mGAT3/4 (pIC₅₀ in a range of 5.46–5.04). Notably, one mGAT1-selective butanoic acid derivative (64a, pIC₅₀(mGAT1) = 5.15) has a rigid bisthiophene moiety (A) in the α position. Surprisingly, the small structural change in 64a, with a hydrogen substituted for the chlorine atom in the N-benzylamide moiety (64b), results in a loss of activity. Unfortunately, we failed to observe an increase in inhibitory activity when the N-benzylamide moiety was exchanged for a carboxylic acid group (74 and 75), ethyl ester (71 and 73), or benzyl ester (72) (Table 3).

2.3. Molecular Modeling. To determine the binding mode of the tested compounds with GATs, molecular modeling calculations were performed. For this purpose, models of human GAT-1, BGT-1, GAT-2, and GAT-3 were used, as they are the targets for the new inhibitors. Although the activity of the compounds was tested on mouse transporters, we assumed that the compounds could bind to human and mouse in the same place and with comparable affinity due to only slight differences in the amino acid sequences, mainly concerning the N- and C-terminus.^{31,50} Homology modeling of the GABA transporters and the differences between the structures of the particular types of these proteins were described in more detail in our previous work.⁵¹

Molecular docking studies indicated that compounds generally bind in a similar manner in all types of transporters (Figure 6). The compounds are located along the vestibule of the transporters, which is consistent with our previous results obtained for similar 4-amino- and 4-hydroxybutanamide derivatives.⁵¹ Molecular dynamics simulations were performed

on representatives of the most active compounds toward particular types of transporters to confirm the stability of the presented binding modes and created interactions (Figure 7, Figure S1). For compounds with an undefined absolute configuration, all possible stereoisomers were investigated. For the tested compounds, more consistent arrangements and beneficial interactions among all types of transporters were generally observed for the α carbon S isomers.

In the case of GAT-1, the bisthiophene fragment in the most active compound 64a creates hydrophobic interactions and CH $-\pi$ stacking with TYR452 and PHE294 near the entrance to the transporter (Figure 6, panel A). The amino group of 64a is located between the aromatic ring of PHE294 and the carboxyl moiety of ASP451, i.e., residues that are part of the extracellular gate. This arrangement allows for the formation of a stable ionic bond with ASP451 and cation $-\pi$ interaction with PHE294. During molecular dynamics simulation, as a result of the bending of the nonhelical fragment of domain 10, the side chain of SER454 approached the protonated amino group of the compound. This enabled the creation of a stable hydrogen bond between these groups (Figure 7, panel A). The ethyl substituent in the α position reaches TRP68, creating hydrophobic interactions. The amide carbonyl group forms a hydrogen bond with the side chain of SER456. During the dynamic calculations, a hydrogen bond with the hydroxyl group of SER454 was also observed. The benzyl fragment reaches into the S1 site, creating hydrophobic interactions mainly with LEU300, LEU460, LEU136, and PHE294. This arrangement appears to be beneficial considering that the S1 site in GAT-1 is the most hydrophobic among all types of transporters.

The diphenylmethylidene fragment of compound **50a**, the most active toward BGT-1, locates itself in this transporter close to the EL6 loop compared to the poses observed in GAT-1. Compound **50a** participates in hydrophobic inter-

pubs.acs.org/chemneuro

	$pIC_{50}{}^a \pm SEM$								
compd	\mathbb{R}^2	\mathbb{R}^1	mGAT1	mGAT2	mGAT3	mGAT4	mGAT1		
54a	Α	Н	4.82	4.78	4.79	4.35	100 µM: 86%		
54b	Α	2-Cl	100 µM: 53%	4.36	4.2	4.02	100 μM: 100%		
54c	А	4 - F	4.77	4.86	4.79	4.54	100 µM: 96%		
55a	В	Н	4.76	4.58	4.80	5.08 ± 0.04	100 µM: 83%		
55b	В	2-Cl	4.59 ± 0.04	4.80 ± 0.18	4.97 ± 0.08	5.02 ± 0.10	100 µM: 65%		
55c	В	4 - Cl	4.54 ± 0.08	4.22 ± 0.09	4.82 ± 0.06	4.78 ± 0.07	100 μM: 49%		
55d	В	4 - F	4.58 ± 0.05	4.69 ± 0.11	4.98 ± 0.09	4.77 ± 0.01	100 μM: 90%		
55e	В	4-Me	4.57 ± 0.05	4.67 ± 0.10	4.80 ± 0.07	4.88 ± 0.08	4.53 ± 0.05		
56a	С	Н	4.67	4.56	4.64	5.04 ± 0.04	100 µM: 68%		
56b	С	2-C1	100 µM: 50%	4.59 ± 0.08	4.98 ± 0.02	4.56 ± 0.05	100 μM: 86%		
56c	С	4-C1	4.21	4.53	4.84	4.99 ± 0.13 n=4	100 μM: 87%		
56d	С	4 - F	4.75	4.67	4.89 ± 0.04	4.91 ± 0.09	100 μM: 96%		
56e	С	4-Me	4.73	4.54	4.69	4.95 ± 0.09	100 µM: 4.16		
57	D	Н	4.61	4.75	4.16	4.44	100 µM: 84%		
58	Е	Н	4.45	4.65	4.68	4.63	100 µM: 83%		
59a	F	Н	4.64	4.64	4.23	4.57	100 µM: 80%		
59b	F	2-Cl	4.35	4.89	4.8	4.89	100 µM: 92%		
59c	F	4 - F	4.58	4.77	4.71	4.78	100 μM: 84%		

					$pK_i^a \pm SEM$			
compd	\mathbb{R}^1	\mathbb{R}^2	n	mGAT1	mGAT2	mGAT3	mGAT4	mGAT1
64a	Н	А	1	5.15 ± 0.08	100 µM: 108%	100 µM: 69%	100 μM: 77%	100 μM: 81%
64b	2-C1	А	1	100 µM: 66%	100 µM: 101%	100 µM: 61%	100 μM: 64%	100 µM: 108%
65	Н	F	0	4.23	4.58	4.86	4.58	100 µM: 104%
66a	Н	F	1	100 µM: 50%	100 μM: 55%	4.78	4.86	100 µM: 104%
66b	2-Cl	F	1	100 µM: 69%	100 μM: 59%	4.34	100 μM: 50%	100 µM: 107%
67	Н	G	0	4.61	4.88	4.87	4.92	100 μM: 83%
68	Н	G	1	4.57	4.4	4.51	4.89	100 μM: 81%

"Data are given as the mean \pm SEM of three independent experiments that were performed in triplicate. The results presented as a percent represent [³H]GABA uptake or NO711 binding in the presence of 100 μ M inhibitor. Data without the SEM imply that only one experiment was performed in triplicate. n.d.: not determined.

actions mainly with TYR520, TRP540, TYR454, ILE459, and TYR453 as well as $\pi - \pi$ stacking with TYR453 (Figure 6, panel B). The protonated primary amine is engaged in a salt bridge with ASP452. The amide group is located close to SER457, which enables the creation of a hydrogen bond during molecular dynamics simulation (Figure 7, panel B). During the simulation, a change in the conformation of the ARG61 side chain was also observed. This provided an additional hydrogen bond with the aforementioned amide group. The 2chlorobenzyl fragment is located, contrary to that observed in the GAT-1 transporter, above the extracellular gate in the S2 site, creating hydrophobic interactions mainly with TYR133, TYR132, and TRP60. This arrangement is beneficial because the S1 site in BGT-1 is more polar than in other types of transporters. Additionally, a halogen bond between the chlorine atom of 50a and the carboxyl group of ASP452 was observed. In the case of another relatively highly active compound 50b, the diphenylmethylidene and 4-aminobutanamide fragment retain the interactions described above, whereas the 3,4-dichlorobenzyl fragment is located at the level of the extracellular gate, creating hydrophobic and CH- π interactions with TYR133.

In GAT-2, the most active compound **50b** is placed similarly as in the BGT-1 transporter. The diphenylmethylidene fragment forms hydrophobic interactions mainly with TYR448, TYR515, and MET454. The protonated amino group of this compound creates a stable salt bridge with ASP447 (Figure 6, panel C). The amide moiety is located near the nonhelical fragment of TM10. During the molecular dynamics simulation, the fragment containing this moiety rotates which enables creation of a hydrogen bond between the carbonyl oxygen of the amide group and the hydroxyl group of SER452. In contrast to the position in the BGT-1 transporter, the 3,4-dichlorobenzyl fragment reaches the inside of the S1 site in GAT-2. It forms hydrophobic interactions mainly with LEU294, LEU456, and PHE288.

In the case of GAT-3, the diaromatic fragments of the most active compounds **50b** and 2*RS*,4*RS*-**39c** are in a similar position compared to that observed in the GAT-2 transporter. However, due to the presence of SER468 and PHE531, which are replaced by tyrosine and serine residues, respectively, in the other transporters, the diphenylmethylidene and dibenzocycloheptadiene fragments are bound slightly higher within the vestibule. These moieties engage in hydrophobic interactions mainly with the above-mentioned PHE531, as well as with

Research Article

pubs.acs.org/chemneuro



Figure 5. Bar graphs of the pIC_{50} values for the library of 3-hydroxypropanamide (54a–c, 55a–e, 56a–e, 57, 58, and 59a–c), propanoic acid, and butanoic acid derivatives (64a,b, 65, 66a,b, 67, and 68) compared to the values for the reference compounds (*S*)-SNAP-5114 (9) and 13. Error bars are not present when only one experiment was performed in triplicate. Additionally, bars are not presented when the pIC_{50} value is lower than 4.00.

Table 3. Inhibitory Potencies (pIC₅₀ \pm SEM) toward mGAT1-4 Determined from the [³H]GABA Uptake Experiments and mGAT1 Binding Affinities (pK_i \pm SEM) from the MS Binding Assays of the Obtained Compounds



				$pK_i^a \pm SEM$			
compd	\mathbb{R}^1	R ²	mGAT1	mGAT2	mGAT3	mGAT4	mGAT1
71	$-CH_2CH_3$	В	100 µM: 52%	100 µM: 54%	4.66	4.20	100 µM: 103%
72	$-CH_2Ph$	В	100 µM: 98%	100 µM: 63%	100 µM: 86%	100 µM: 97%	100 µM: 109%
73	$-CH_2CH_3$	G	100 µM: 55%	100 µM: 52%	4.6	4.28	100 µM: 94%
74	Н	G	100 µM: 55%	100 µM: 55%	100 µM: 62%	100 µM: 77%	4.54
75	Н	В	100 µM: 71%	100 µM: 59%	100 µM: 52%	100 µM: 60%	100 µM: 81%
tiagabine	$(5)^{19}$		6.88 ± 0.12	100 µM: 52%	100 µM: 64%	100 µM: 73%	7.43 ± 0.11^{49}
(S)-SNA	P-5114 (3) ¹⁹		4.07 ± 0.09	100 µM: 56%	5.29 ± 0.04	5.81 ± 0.10	nd
DDPM-	$859 (4)^{22}$		4.19 ± 0.07	4.12 ± 0.08	4.85 ± 0.04	5.78 ± 0.03	nd
DDPM-2	$2571 (5)^{20}$		8.27 ± 0.03	4.31	4.35	4.07	8.29 ± 0.02
13 ²⁵			4.86 ± 0.10	4.98 ± 0.05	5.31 ± 0.04	5.24 ± 0.05	100 μ M: 77%

^{*a*}Data are given as the mean \pm SEM of three independent experiments that were performed in triplicate. The results presented as a percent represent [³H]GABA uptake or NO711 binding in the presence of 100 μ M inhibitor. Data without the SEM imply that only one experiment was performed in triplicate. nd: not determined.

TYR535 and TYR469. The protonated amino group forms an ionic bond (compound 2RS,4RS-**39c**) or a salt bridge (compound **50b**) with ASP467, similar to the previously described compounds (Figure 6, panel D). During the molecular dynamics simulation performed for compound 2RS,4RS-**39c**, this protonated amino group slightly moves away from ASP467 while simultaneously approaching the aromatic ring of PHE308, which enables cation— π interaction while maintaining an ionic bond with ASP467 (Figure 7, panel D). At the same time the hydroxyl moiety creates a stable hydrogen bond with ASP467. The amide groups of both described compounds are also located close to ASP467 being involved in the hydrogen bond with this residue. However, over the course of the dynamics simulation for 2RS,4RS-**39c** it

was observed that the amide moiety can move closer to the side chain of TYR146, creating a hydrogen bond. The 4-methylbenzyl and 3,4-dichlorobenzyl fragments are located at the level of the lower part of the extracellular gate, creating hydrophobic and CH $-\pi$ interactions with TYR147. Compound **50b** additionally forms a halogen bond with the amide moiety of GLY71.

2.4. Hepatotoxicity and Cytotoxicity. In this study we investigated three representative compounds, 2*RS*,4*RS*-**39c**, **50a**, and **56a**, for *in vitro* studies to verify their safety in HepG2 and HEK-293 cells. Among all obtained compounds, compound 2*RS*,4*RS*-**39c**, a 4-hydroxypentanamide derivative, and compound **50a**, a 4-aminobutanamide derivative, were selected for further studies because they provided the highest

ACS Chemical Neuroscience

pubs.acs.org/chemneuro

Research Article



Figure 6. Binding modes of compound (S)-64a in GAT-1 (A); compound (S)-50a in BGT-1 (B); compound (S)-50b in GAT-2 (C); compound (2S,4S)-39c in GAT-3 (D). CH $-\pi$ and $\pi-\pi$ interactions are marked with blue dashes, ionic interactions with pink dashes, cation $-\pi$ interactions with green dashes, and hydrogen bonds with yellow dashes.

inhibitory activity toward mGAT4 (pIC₅₀ = 5.36 ± 0.10) or mGAT2 (pIC₅₀ = 5.43 ± 0.11), respectively. Compound **56a**, a 3-hydroxypropanamide derivative, was selected as one of two compounds with moderate subtype selectivity for mGAT4.

To investigate the safety of compounds 2*RS*,4*RS*-**39c**, **50a**, and **56a**, a HepG2 hepatoma cell-based hepatotoxicity assay was used. Compounds were tested at six concentrations $(0.1-100 \ \mu\text{M})$. The results showed that at lower compound concentrations $(0.1 \text{ and } 1 \ \mu\text{M})$, none of the tested compounds caused a statistically significant decrease in HepG2 cell viability and thus were not hepatotoxic in comparison to doxorubicin (DX) at 1 μ M (Figure 8, panel A). However, only compound **56a** did not induce significant hepatotoxicity after 72 h of incubation at concentrations up to 25 μ M. A statistically significant (p < 0.0001) decrease in HepG2 cell viability was observed for **56a** only at the highest concentrations of 50 and 100 μ M (Figure 8, panel A). Compound 2*RS*,4*RS*-39c was slightly more toxic than 56a, as it showed a statistically significant (p < 0.0001) decrease in HepG2 cell viability at 25 μ M, whereas 56a showed 100% viability compared to the control at this concentration (1% DMSO in culture media). Compound 50a significantly eradicated cell viability at concentrations between 10 and 100 μ M (p < 0.0001). Nevertheless, these results are in accordance with the hepatotoxicity examination of thioridazine, an antipsychotic agent that is still in use (Figure 8, panel C).⁵²

Subsequently, a similar study was performed with the HEK-293 cell line. Overall, compounds 2RS,4RS-**39c** and **56a** showed stronger toxic effects than in the HepG2 assay, where a significant (****p < 0.0001) decrease in HEK-293 cell viability was observed at the concentration of 25 μ M. On

pubs.acs.org/chemneuro



Figure 7. Distance changes between the particular transporter residues and ligand moieties during molecular dynamics simulations for compound (*S*)-**64a** in GAT-1 (A), compound (*S*)-**50a** in BGT-1 (B), compound (*S*)-**50b** in GAT-2 (C), and compound (2*S*,4*S*)-**39c** in GAT-3 (D).

the other hand, compound **50a** showed a comparable safety profile in HEK-293 and HepG2 cells.

Considering the observed antiproliferative effects of compounds 2RS,4RS-39c and 56a at 25 μ M and at 1 μ M for compound 50a, it can be generalized that these effects were still lower than those for DX (at 1 μ M) or comparable with those of thioridazine (over the concentration range of 10–100 μ M). In this respect and based on the very promising biological results, compounds 2RS,4RS-39c, 50a, and 56a were selected for further investigation to elevate their antinociceptive activity in mouse models of NP. However, taking into account the obtained range of toxicity of the tested compounds, we assumed that further drug-like property optimization is required to obtain an acceptable safety profile, which will be the next stage of our research.

2.5. *In Vivo* Pharmacological Evaluation (Mouse Models of Neuropathic Pain). In this part of the present research, we assessed if the compounds 2*RS*,4*RS*-39*c*, 50a, and 56a display analgesic (antiallodynic and antihyperalgesic) properties in NP conditions.

For this purpose, we used three mouse models of NP, namely, chemotherapy-induced NP models (i.e., the oxaliplatin model and the paclitaxel model) and the diabetic NP model induced by streptozotocin (STZ). We assessed the effect of the test compounds on tactile allodynia and thermal (heat or cold)

hyperalgesia in the von Frey, hot plate, or cold plate tests, respectively. Since oxaliplatin is responsible for inducing cold hypersensitivity, in both humans and experimental animals, ^{53,54} the cold plate test was used to assess the effect of the test compounds on the thermal pain threshold in oxaliplatin-treated mice. In the two other NP models the hot plate test was applied to measure heat pain threshold in paclitaxel- and STZ-treated mice. ^{55,56} Since impaired motor coordination is also observed in NP conditions, we additionally tested the influence of compounds 2RS,4RS-**39c**, **50a**, and **56a** on motor coordination in the rotarod test.

2.5.1. Oxaliplatin-Induced Peripheral Neuropathy: Influence on Tactile Allodynia (von Frey Test). In the early phase of oxaliplatin-induced neuropathy, an overall effect of treatment on the mechanical nociceptive threshold was observed (2RS,4RS-39c, F[1.904, 23.80] = 180.6, p < 0.0001; 50a, F[3.037, 24.30] = 136.7, p < 0.0001; 56a, F[2.371, 21.34] = 83.50, p < 0.0001). In this early phase of neuropathy, the administration of oxaliplatin significantly lowered the pain threshold for mechanical stimulation (p < 0.0001 vs vehicle-treated nonneuropathic mice) (Figure 9). Compound 2RS,4RS-39c was not effective in this phase of oxaliplatin-induced neuropathy (Figure 9, panel A). Compound 50a at both doses significantly elevated the pain threshold for mechanical stimulation (p < 0.01 vs predrug paw withdrawal



Figure 8. Influence of 2*RS*,4*RS*-3**9c**, **50a**, **56a**, and the reference cytostatic drug DX on the viability of hepatoma HepG2 cells (A) and HEK-293 cells (B) after 72 h of incubation. The influence of thioridazine on the viability of hepatoma HepG2 cells (C) after 72 h of incubation. Statistical significance (****p < 0.0001) was analyzed by GraphPad Prism 8.0.1 software using one-way ANOVA and Bonferroni's multiple comparison post hoc test.

threshold) (Figure 9, panel B). Additionally, both doses of compound **56a** reduced tactile allodynia in the acute phase of oxaliplatin-induced neuropathy (p < 0.05 vs predrug paw withdrawal threshold) (Figure 9, panel C).

In the late phase of oxaliplatin-induced neuropathy, an overall effect of treatment on the mechanical nociceptive threshold was observed (2*R*S,4*R*S-**39c**, *F*[1.705, 13.64] = 282.0, p < 0.0001; **50a**, *F*[2.354,18.83] = 83.09, p < 0.0001; **56a**, *F*[2.651, 23.86] = 108.3, p < 0.0001). In this phase, only compound **56a** at a dose of 10 mg/kg showed antiallodynic properties (significant at p < 0.05 vs predrug paw withdrawal threshold) (Figure 9, panel C).

2.5.2. Oxaliplatin-induced Peripheral Neuropathy: Influence on Cold Hyperalgesia (Cold Plate Test). In the early phase of oxaliplatin-induced neuropathy, an overall effect of treatment on the thermal (cold) nociceptive threshold was observed (2RS,4RS-39c, F[1.393, 16.02] = 30.05, p < 0.0001; **50a**, F[2.634, 21.07] = 16.57, p < 0.0001; **56a**, F[2.701, 24.31] = 27.96, p < 0.0001). In this phase, the administration of oxaliplatin significantly lowered the pain threshold for cold stimulation (p < 0.001 vs vehicle-treated nonneuropathic mice) (Figure 10). Compounds 2RS,4RS-39c and 50a were not effective in this phase of oxaliplatin-induced neuropathy (Figure 10, panels A and B). Compound 56a at a dose of 30 mg/kg reduced cold hyperalgesia in the acute phase of oxaliplatin-induced neuropathy (p < 0.05 vs predrug paw withdrawal threshold) (Figure 10, panel C).

In the late phase of oxaliplatin-induced neuropathy, an overall effect of treatment was observed (2*RS*,4*RS*-**39c**, F[1.171, 14.64] = 23.22, p < 0.001; **50a**, F[3.125, 24.38] = 9.974, p < 0.001; **56a**, F[2.508, 22.57] = 16.37, p < 0.0001). In



Figure 9. Effects of intraperitoneally administered 2*RS*,4*RS*-39c (A), 50a (B), and 56a (C) on the mechanical nociceptive threshold in a mouse oxaliplatin-induced NP model measured using the von Frey test in the early phase (on the day of oxaliplatin injection) and in the late phase (7 days after oxaliplatin injection) of neuropathy. The results are shown as the mean (±SEM) force applied to elicit paw withdrawal. Statistical analysis: one-way analysis of variance followed by Tukey's post hoc comparison. Significance vs paw withdrawal threshold of control, nonneuropathic mice: ####p < 0.0001. Significance vs predrug (after oxaliplatin) paw withdrawal threshold: *p < 0.05, **p < 0.01. In vehicle-treated mice (VEH), pain sensitivity threshold measurements were taken in the same manner and at the same time points as in the oxaliplatin-treated groups, but vehicle-treated mice were not treated with oxaliplatin; n = 8-10.

10

30 [mg/kg]

VEH

10

30

oxaliplatin







Figure 10. Effects of intraperitoneally administered 2RS,4RS-39c (A), 50a (B), and 56a (C) on the thermal (cold) pain threshold in a mouse oxaliplatin-induced NP model measured using the cold plate test in the early phase (on the day of oxaliplatin injection) and in the late phase (7 days after oxaliplatin injection) of neuropathy. The results are shown as the mean (±SEM) latency to pain reaction.

Figure 10. continued

Statistical analysis: one-way analysis of variance followed by Tukey's post hoc comparison. Significance vs latency of control, non-neuropathic mice: ### p < 0.001, ####p < 0.0001. Significance vs predrug (after oxaliplatin) latency to pain reaction: *p < 0.05. In the vehicle-treated mice (VEH), measurements of the pain sensitivity threshold were taken in the same manner and at the same time points as in the oxaliplatin-treated groups, but vehicle-treated mice were not treated with oxaliplatin; n = 8-10.

this phase, none of the tested compounds showed antihyperalgesic properties (Figure 10).

On the basis of the results obtained in the oxaliplatininduced neuropathic pain model, i.e., due to lack of activity of 2RS,4RS-39c, for further pain tests and NP models, only the compounds 50a and 56a were selected.

2.5.3. Paclitaxel-Induced Peripheral Neuropathy: Influence on Tactile Allodynia (von Frey Test). In the paclitaxelinduced NP model, the effect of 50a and 56a on mechanical nociceptive threshold was assessed at two time points, i.e., on the day of paclitaxel administration (4 h after paclitaxel administration) and 7 days later. On the day of paclitaxel administration, in the von Frey test an overall effect of treatment was observed for **50a** (F[4, 35] = 4.854, p < 0.01)and 56a (F[4, 37] = 5.655, p < 0.01). The post hoc analysis revealed that compared to vehicle-treated nonneuropathic mice, paclitaxel significantly lowered mechanical nociceptive threshold in mice (p < 0.05). The comparison between predrug and postdrug paw withdrawal thresholds in each experimental group revealed that on the day of paclitaxel administration neither 50a nor 56a at doses 10 and 30 mg/kg was able to elevate the mechanical nociceptive threshold in paclitaxel-treated mice (Figure 11, panel A).

Seven days after paclitaxel administration, an overall effect of treatment was noted for **50a** and **56a** (F[4, 35] = 13.76, p < 0.0001, and F[4, 37] = 18.69, p < 0.0001, respectively). On this day of experiment vehicle-treated nonneuropathic mice had still significantly elevated mechanical nociceptive threshold as compared to paclitaxel treated mice (p < 0.01 vs predrug, i.e., before compound **50a** or **56a** administration, values of paw withdrawal thresholds). Of note, the comparison of predrug and postdrug paw withdrawal thresholds in **50a**-treated neuropathic mice showed that on day 7 after paclitaxel injection both compounds **50a** and **56a** at the dose of 30 mg/kg elevated mechanical nociceptive threshold (p < 0.05). The lower dose of **50a** or **56a** was not effective in the von Frey test (Figure 11, panel B).

2.5.4. Paclitaxel-Induced Peripheral Neuropathy: Influence on Heat Nociceptive Threshold (Hot Plate Test). Both compounds **50a** and **56a** were also assessed for their ability to affect thermal (heat) nociceptive threshold in paclitaxel-treated mice. As shown in Figure 12 (panel A), on the day of paclitaxel administration a significantly prolonged latency to pain reaction and an increased heat nociceptive threshold were noted in all groups treated with this taxane derivative (p < 0.05 vs vehicle-treated nonneuropathic mice). This effect indicated that paclitaxel induced hypoalgesia in mice, which was noted on the day of paclitaxel administration but not 7 days later (Figure 12, panel A vs panel B).

On the day of paclitaxel administration, in the hot plate test, one-way ANOVA showed an overall effect of treatment for **50a** (F[4, 39] = 6.075, p < 0.001) and **56a** (F[4, 39] = 14.27, p < 0.001)



Figure 11. Effects of intraperitoneally administered **50a** and **56a** on the mechanical nociceptive threshold in a mouse paclitaxel-induced NP model measured using the von Frey test on the day of paclitaxel injection A) and 7 days after single-dose paclitaxel injection (B). The results are shown as the mean (\pm SEM) force applied to elicit paw withdrawal. Statistical analysis: one-way analysis of variance followed by Tukey's post hoc comparison. Significance vs paw withdrawal threshold of control, nonneuropathic mice: ${}^{\#}p < 0.05$, ${}^{\#\#}p < 0.01$. Significance vs predrug (after paclitaxel) paw withdrawal threshold: ${}^{*}p < 0.05$. In vehicle-treated mice (VEH), pain sensitivity threshold measurements were taken in the same manner and at the same time points as in the paclitaxel-treated groups, but vehicle-treated mice were not treated with paclitaxel; n = 8-10.



Figure 12. Effects of intraperitoneally administered **50a** and **56a** on the thermal (heat) pain threshold in a mouse paclitaxel-induced NP model measured using the hot plate test on the day of paclitaxel injection (A) and 7 days after paclitaxel injection (B). The results are shown as the mean (\pm SEM) latency to pain reaction. Statistical analysis: one-way analysis of variance followed by Tukey's post hoc comparison. Significance vs latency of control, nonneuropathic mice: p < 0.05. Significance vs predrug (after paclitaxel) latency to pain reaction: p < 0.05, p < 0.01. In the vehicle-treated mice (VEH), measurements of the pain sensitivity threshold were taken in the same manner and at the same time points as in the paclitaxel-treated groups, but these vehicle-treated mice were not treated with paclitaxel; n = 8-10.



Figure 13. Effects of intraperitoneally administered **50a** and **56a** on the mechanical nociceptive threshold measured using the von Frey test (A) and effects of **50a** and **56a** on the thermal nociceptive threshold measured using the hot plate test (B) in a mouse STZ-induced NP model. The results are shown as the mean (\pm SEM) force applied to elicit paw withdrawal or the mean (\pm SEM) latency to pain reaction. Statistical analysis: one-way analysis of variance followed by Tukey's post hoc comparison. Significance vs paw withdrawal threshold of control, normoglycemic (nonneuropathic) mice: ^{#####} *p* < 0.0001. Significance vs predrug (after STZ) paw withdrawal threshold: ****p* < 0.001, *****p* < 0.0001. In vehicle-treated mice (VEH), pain sensitivity threshold measurements were taken in the same manner as in the STZ-treated groups, but vehicle-treated mice were not treated with STZ; *n* = 8–10.

0.0001). The post hoc analysis demonstrated that in paclitaxeltreated mice the compound **50a** reduced latency to pain reaction at the dose of 30 mg/kg (p < 0.05 vs predrug latency to pain reaction; Figure 12, panel A) and 56a reduced latency

to pain reaction at doses 10 mg/kg (p < 0.001 vs predrug

latency to pain reaction) and 30 mg/kg (p < 0.01 vs predrug latency to pain reaction; Figure 12, panel A).

Seven days after paclitaxel administration, one-way ANOVA did not show an overall effect of treatment for **50a** (F[4,35] = 1.407, p > 0.05) in the hot plate test. In contrast to this, in this assay, an overall effect of treatment was noted for **56a** (F[4, 37] = 2.765, p < 0.05). At this time point of testing, Tukey's post hoc analysis did not reveal the effect of paclitaxel and compounds **50a** and **56a** on the thermal nociceptive threshold in the hot plate test (Figure 12, panel B).

2.5.5. Diabetic, STZ-Induced Peripheral Neuropathy: Influence on Tactile Allodynia (von Frey Test). In the mouse model of painful diabetic neuropathy induced by STZ, an overall effect of treatment was demonstrated for both **50a** and **56a** in the von Frey test (F[4, 42] = 33.02, p < 0.0001, and F[4, 40] = 26.59, p < 0.0001, respectively). As shown in Figure 13 (panel A), STZ lowered mechanical nociceptive threshold in mice (p < 0.0001 vs normoglycemic control). In the von Frey test, compounds **50a** and **56a** were effective only at the dose of 30 mg/kg (**50a**, p < 0.001; **56a**, p < 0.0001 vs predrug paw withdrawal in the individual group).

2.5.6. Diabetic, STZ-Induced Peripheral Neuropathy: Influence on Heat Hyperalgesia (Hot Plate Test). In the mouse model of painful diabetic neuropathy induced by STZ, an overall effect of treatment on the heat nociceptive threshold was not demonstrated for both **50a** and **56a** in the hot plate test (F[4,38] = 0.9254, p > 0.05, and F[4,40] = 1.589, p > 0.05, respectively). As shown in Figure 13 (panel B), STZ slightly increased thermal nociceptive threshold in mice but this effect compared to that of normoglycemic control did not reach statistical significance. In the hot plate test, neither **50a** nor **56a** was effective.

2.5.7. Effects on Motor Coordination (Rotarod Test). In the rotarod test, the effect of the test compounds on motor coordination of mice was assessed. Compared to the vehicletreated group, none of the test compounds induced motor deficits in the rotarod test.

3. CONCLUSIONS

Neuropathic pain is a global public health problem and is most frequently caused by chronic, progressive nerve disease after surgery or trauma and viral infections in the course of diabetes or could be induced by chemotherapy. It is worth pointing out that painful diabetic neuropathy is a major complication of diabetes and a cause of increased mortality. Unfortunately, currently used drugs have limited efficacy and patients remain refractory to existing pharmacological treatment. Hence, there is a substantial need for further development of new and effective drugs for NP therapy. Considering the above, the present work describes SAR studies of new functionalized amino acids as inhibitors of GATs, the biological targets in the search for new treatment of NP. A series of 56 novel derivatives of 3-hydroxypropanamide, 4-hydroxybutanamide, and 4-hydroxypentamide were synthesized and evaluated toward all four mouse GAT subtypes (mGAT1-4). On the basis of the obtained in vitro results, we selected three compounds $2RS_{4}RS_{3}$ (pIC₅₀(mGAT4) = 5.36 ± 0.10), 50a (pIC₅₀(mGAT2) = 5.43 \pm 0.11), and 56a $(pIC_{50}(mGAT4) = 5.04 \pm 0.04)$ for further investigation. The obtained results indicated a negligible hepatotoxic and cytotoxic effect of the tested compounds at 0.1 and 1 μ M on HepG2 and HEK-293 cells. Their safety profile was also examined in in vivo studies, where the tested compounds did

not show a neurotoxic effect in mice at the doses displaying analgesic effect. In a set of in vivo experiments, two compounds, 50a and 56a at doses of 10 and 30 mg/kg, showed antiallodynic properties in rodent models of NP induced by oxaliplatin. Interestingly, compound 56a at a dose of 10 mg/kg showed antiallodynic properties in the acute and late phases of oxaliplatin-induced neuropathy, and additionally at the dose of 30 mg/kg 56a reduced cold hyperalgesia in the acute phase. In the paclitaxel model of NP both 50a and 56a were able to reduce tactile allodynia when administered 7 days after paclitaxel injection. This effect was noted for the dose of 30 mg/kg of both test compounds. Interestingly, in this model of NP, on the day of paclitaxel administration, both 50a and 56a reduced hypoalgesia induced by paclitaxel and they restored a physiological heat nociceptive threshold in paclitaxel-treated mice. The compound 56a was more effective in reducing heat hypoalgesia than **50a**. As for the STZ model of NP. both compounds were able to reduce tactile allodvnia in diabetic, neuropathic mice. Finally, compound 56a demonstrated predominant antinociceptive properties in rodent models of NP and has provided a great contribution to the current knowledge on the importance of GABA reuptake in the pathophysiology and pharmacotherapy of NP.

4. METHODS

4.1. Chemistry. Commercially available reagents were purchased from Merck, Aldrich, Acros, or ChemPur and were used without further purification. Solvents for reactions carried out under inert gas (argon), such as tetrahydrofuran (THF) and DCM, were dried, distilled, and collected under argon before use. THF was distilled from a mixture of sodium and benzophenone, while DCM was distilled from calcium hydride. Triethylamine (TEA) was distilled under vacuum before use. Reactions carried out under microwave irradiation used a Discover LabMate (CEM Corporation, USA). Purification of chemical compounds by column chromatography was carried out using Sigma-Aldrich silica gel (mesh 0.063-0.200 mm) as the stationary phase. Reactions were monitored by thin-layer chromatography (TLC) (aluminum sheets precoated with silica gel 60 F₂₅₄ (Merck)). Compounds were visualized with UV light (254 nm). Additionally, the plates were stained with a 0.5% solution of ninhydrin in *n*-propanol or a solution of 5% $(NH_4)_6Mo_7O_{24}$ and 0.2% $Ce(SO_4)_2$ in 5% H_2SO_4 . The retention factor (R_f) was defined using the following solvent systems: S_1 (petroleum ether (PE)/EtOAc 7:3, v/v), S2 (PE/EtOAc 1:1, v/v), S3 (n-hexane/ethanol (EtOH)/TEA 7:2:1, v/v/v), S₄ (DCM/methanol (MeOH)/NH₃ 9.5:0.5:0.1, v/v/v), S₅ (NH₃/MeOH/DCM/PE 9:45:120:18, v/v/v/v), S₆ (DCM/ acetone (Ace) 9:1, v/v), S₇ (n-hexane/ethyl acetate (EtOAc) 1:1, v/v), S₈ (DCM/MeOH, 95:5, v/v), S₉ (chloroform (Chl)/Ace 9:1, v/ v), S₁₀ (DCM/EtOAc 3:2, v/v) S₁₁ (Chl/Ace 1:1, v/v), S₁₂ (DCM/ Ace 7:3, v/v), S_{13} (25% NH₃/MeOH/DCM/PE = 640:140:100:25, v/v/v/v). ¹H NMR and ¹³C NMR spectra were recorded on a Varian Mercury-VX 300, with $^1\mathrm{H}$ at 300.08 MHz and $^{13}\mathrm{C}$ at 75.46 MHz or a JEOL ÉCA400II or ECX500 at magnetic field strengths of 11.75 T corresponding to ¹H and ¹³C resonance frequencies of 500.16 and 125.77 MHz at ambient temperature (25 °C). Chemical shifts (δ) are reported in parts per million (ppm), and coupling constants (J) are reported in hertz (Hz). High-resolution (HR) MS was performed on a Synapt G2-S HDMS (Waters Inc.) mass spectrometer equipped with an electrospray ionization source and q-TOF type mass analyzer. The instrument was controlled, and recorded data were processed using the MassLynx v4.1 software package (Waters Inc.). Purities of the final compounds were determined with a Waters ACQUITY ultraperformance liquid chromatography (UPLC) instrument (Waters, Milford, MA, USA) coupled to a Waters TQD mass spectrometer (ESI-tandem quadrupole).

4.1.1.1. General Procedure for the Synthesis of the 3-Substituted 5-Methyldihydrofuran-2(3H)-one or Dihydrofuran-2(3H)-one De-

0

4.1.1.1.1. $3-\{4-[Bis(3-methylthiophen-2-yl)methylidene]-piperidin-1-yl\}-5-methyloxolan-2-one ($ **36**). According to GP1 with amine**A**(17) (0.86 mmol, 0.25 g, 1 equiv), 3-bromo-5-methyldihydrofuran-2(3*H*)-one (**34**) (0.86 mmol, 0.15 g, 1 equiv), TBAB (0.086 mmol, 27.7 mg, 0.1 equiv), and anhydrous K₂CO₃ (2.58 mmol, 0.36 g, 3 equiv) were combined in acetonitrile (7 mL). The crude product was purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield**36**(260 mg, 78%, R_f = 0.65 (S₉) as a yellow oil. Formula C₂₁H₂₅NO₂S₂, FW 387.56. ¹H NMR (300 MHz, chloroform-*d* $) <math>\delta$ ppm 1.43 (d, *J* = 5.86 Hz, 3H) 2.11 (s, 6H) 2.32–2.47 (m, 6H) 2.54–2.68 (m, 2H) 2.85 (dd, *J* = 10.84, 5.57 Hz, 2H) 3.72 (dd, *J* = 12.02, 8.50 Hz, 1H) 4.45 (dt, *J* = 10.99, 5.35 Hz, 1H) 6.77 (d, *J* = 5.28 Hz, 2 H) 7.13 (d, *J* = 4.69 Hz, 2H).

4.1.1.1.2. 3-((3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5ylidene)propyl)(methyl)amino)-5-methyldihydrofuran-2(3H)-one (38). According to GP1 with amine C (21) (5.47 mmol, 1.44 g, 1 equiv), 3-bromo-5-methyldihydrofuran-2(3H)-one (34) (5.47 mmol, 0.76 g, 1 equiv), TBAB (1.75 mmol, 0.56 g, 0.32 equiv), and anhydrous K₂CO₃ (5.47 mmol, 0.76 g, 1 equiv) were combined in acetonitrile (7 mL). The crude product was purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield 38 (1.88 g, 95%, $R_f = 0.74$ (S₁₀)) as a yellow oil. Formula C₂₄H₂₇NO₂, FW 361.49. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.30–1.43 (m, 3H (CHCH₃)) 1.61-1.88 (m, 2H (CHCH₂CH)) 2.22-2.36 (m, 5H (NCH₃, CHCH₂CH₂)) 2.59–2.88 (m, 3H (ArCH₂CH₂Ar, CHCH₂CH₂)) 2.96 (br s, 1H (ArCH₂CH₂Ar)) 3.28 (br s, 1H $(ArCH_2CH_2Ar)$ 3.37 (d, J = 9.96 Hz, 1H $(ArCH_2CH_2Ar)$ 3.60-3.70 (m, 1H (NCH)) 4.36 (dt, J = 10.99, 5.35 Hz, 1H (CHCH₃)) 5.81-5.89 (m, 1H (CHCH2CH2)) 6.99-7.07 (m, 1H (Ar)) 7.08-7.23 (m, 6H (Ar)) 7.24–7.31 (m, 1H (Ar)). LCMS $m/z [M + H]^+$ 362.20.

4.1.1.1.3. 3-[4-(9H-Fluoren-9-ylidene)piperidin-1-yl]-5-methyloxolan-2-one (**40**). According to GP1 with amine D (**25**) (1.17 mmol, 0.29 g, 1 equiv), 3-bromo-5-methyldihydrofuran-2(3H)-one (**34**) (1.17 mmol, 0.21 g, 1 equiv), TBAB (0.12 mmol, 40 mg, 0.1 equiv), and anhydrous K₂CO₃ (3.51 mmol, 0.48 g, 3 equiv) were combined in acetonitrile (10 mL). The crude product was purified by column chromatography over silica gel (Chl/Ace = 9:1) to yield **40** (289 mg, 71%, R_f = 0.61 (S₉)) as a yellow oil. Formula C₂₃H₂₃NO₂, FW 361.49. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.30–1.41 (m, 3H) 1.98– 2.54 (m, 6H) 2.88–2.98 (m, 4H) 3.43–3.59 (m, 1H) 4.40–4.52 (m, 1H) 7.19–7.45 (m, 6H (*Ar*)) 7.63–7.95 (m, 2H (*Ar*)).

4.1.1.1.4. 3-(4-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5ylidene)piperidin-1-yl)-5-methyldihydrofuran-2(3H)-one (**42**). According to GP1 with amine **E** (**26**) (0.22 mmol, 60 mg, 1 equiv), 3bromo-5-methyldihydrofuran-2(3H)-one (**34**) (0.22 mmol, 40 mg, 1 equiv), TBAB (0.022 mmol, 7 mg, 0.1 equiv), and anhydrous K₂CO₃ (0.65 mmol, 90 mg, 3 equiv) were combined in acetonitrile (7 mL). The crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **42** (40 mg, 49%, R_f = 0.46 (S₁)) as a yellow oil. Formula C₂₅H₂₇NO₂, FW 373.49. ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.70–1.85 (m, 2H) 2.15 (s, 4H) 2.34–2.54 (m, 4H) 2.76–2.93 (m, 4H) 3.47–3.57 (m, 1H) 3.62–3.76 (m, 3H) 4.30–4.42 (m, 1H) 7.07–7.27 (m, 8H).

4.1.1.1.5. $3-[(2-{[(Diphenylmethylidene)amino]oxy}ethyl)-(methyl)amino]-5-methyloxolan-2-one (44). According to GP1 with amine F (32) (2.16 mmol, 0.55 g, 1 equiv), 3-bromo-5-methyldihydrofuran-2(3H)-one (34) (2.16 mmol, 0.38 g, 1 equiv), TBAB (0.22 mmol, 69.5 mg, 0.1 equiv), and anhydrous K₂CO₃ (6.48 mmol, 0.90 g, 3 equiv) were combined in acetonitrile (10 mL). The crude product was purified by column chromatography over silica gel$

(DCM/EtOAc = 3:2) to yield 44 (500 mg, 66%, $R_f = 0.71$ (S₁₀)) as a yellow oil. Formula $C_{21}H_{24}N_2O_3$, FW 352.43. ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.34 (d, J = 6.16 Hz, 3H (CHCH₃)) 1.67 (td, J = 12.31, 10.52 Hz, 1H (CHCH₂CH)) 2.07–2.14 (m, 1H (CHCH₂CH)) 2.38 (s, 3H (NCH₃)) 2.85–3.03 (m, 2H (OCH₂CH₂N)) 3.67–3.79 (m, 1H (NCH)) 4.06–4.23 (m, 1H (CHCH₃)) 4.29–4.36 (m, 2H (OCH₂CH₂N)) 7.27–7.50 (m, 10H (Ar)).

4.1.1.1.6. 3-[(2-{[(Diphenylmethylidene)amino]oxy}ethyl)-(methyl)amino]oxolan-2-one (**46**). According to GP1 with amine F (**32**) (2.95 mmol, 0.75 g, 1 equiv), 3-bromodihydrofuran-2(3*H*)one (**35**) (2.95 mmol, 0.52 g, 1 equiv), TBAB (0.30 mmol, 93.2 mg, 0.1 equiv), and anhydrous K₂CO₃ (8.85 mmol, 1.23 g, 3 equiv) were combined in acetonitrile (10 mL). The crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **46** (520 mg, 52%, R_f = 0.65 (S₁)) as a yellow oil. Formula C₂₀H₂₂N₂O₃, FW 338.40. ¹H NMR (300 MHz, chloroform-*d*) δ ppm 2.26–2.31 (m, 1H (CHCH₂)) 2.35–2.55 (m, 4H (Me; CHCH₂)) 2.63–2.74 (m, 2H (CH₂N)) 3.49–3.56 (m, 1H (NCH)) 3.64–3.71 (m, 2H (= NOCH₂)) 4.25–4.33 (m, 1H (OCH₂)) 4.35–4.45 (m, 1H (OCH₂)) 7.45–7.62 (m, 10H (Ar)).

4.1.1.2. General Procedure for the Synthesis of the 4-Hydroxypentanamide and 4-Hydroxybutanamide Derivatives 37a-c, 39a-c, 41, and 43a,b (GP2). The corresponding 3-substituted 5-methyldihydrofuran-2(3H)-one or dihydrofuran-2(3H)-one derivative (1 equiv), relevant 1-phenylmethanamine hydrochloride derivative (1.5 equiv), and sodium 2-ethylhexanoate (2.5 equiv) were dissolved in dry THF under Ar and stirred at 66 °C for 16 h. Then, the mixture was cooled to rt, and EtOAc (5 mL/1 mmol) and 30% K₂CO₃ (5 mL/1 mmol) were added. The mixture was stirred at rt for 15 min and was extracted with EtOAc (2 × 5 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography.

4.1.1.2.1. N-Benzyl-2-{4-[bis(3-methylthiophen-2-yl)methylidene]piperidin-1-yl}-4-hydroxypentanamide ((2RS,4RS)-37a and 2RS,4SR)-37a). Compounds (2RS,4RS)-37a and (2RS,4SR)-37a were prepared according to GP2 with 3-{4-[bis(3methylthiophen-2-yl)methylidene]piperidin-1-yl}-5-methyloxolan-2one (36) (0.67 mmol, 0.26 g), 1-phenylmethanamine hydrochloride (1 mmol, 0.14 g), and sodium 2-ethylhexanoate (1.68 mmol, 0.28 g) in 4 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-37a (180 mg, 54%, $R_f = 0.56$ (S₆) and (2RS,4SR)-37a (80 mg, 24%, $R_f = 0.33$ (S₆)) as yellow oil. ds: (2RS,4RS)-37a/(2RS,4SR)-37a = 69:31. Formula $C_{28}H_{34}N_2O_2S_2$, FW 494.71. Compound (2RS,4RS)-37a ¹H NMR (300 MHz, chloroform-d) δ ppm 7.92-8.03 (m, 1H), 7.18–7.42 (m, 5H), 7.12 (d, J = 5.27 Hz, 1H), 6.76 (d, J = 5.28 Hz, 1H), 6.56–6.70 (m, 1H), 6.48–6.60 (m, 1H), 5.33–5.45 (m, 1H), 4.44 (s, 2H), 3.69-3.99 (m, 1H), 2.43-2.65 (m, 1H), 2.15-2.40 (m, 2H), 1.98 (ddd, J = 4.98, 9.82, 14.51 Hz, 1H), 1.71-1.93 (m, 1H), 1.40-1.66 (m, 4H), 1.14-1.32 (m, 6H), 0.76-0.96 (m, 5H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 175.6, 175.6, 170.4, 137.6, 137.5, 133.8, 129.4, 128.8, 128.8, 128.7, 127.7, 127.6, 127.5, 124.0, 71.6, 64.1, 50.5, 47.3, 47.2, 43.5, 43.3, 41.8, 31.9, 31.6, 29.6, 29.5, 25.4, 25.4, 24.5, 23.6, 22.5, 14.6, 13.9, 13.8, 11.8. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₈H₃₄N₂O₂S₂, 495.2134; found, 495.2133. Compound (2RS,4SR)-37a ¹H NMR (300 MHz, chloroform-d) δ ppm 7.21–7.41 (m, 8H), 7.13 (d, J = 5.28 Hz, 1H), 6.77 (d, J = 5.27 Hz, 1H), 4.42-4.55 (m, 2H), 3.39-3.57 (m, 1H), 2.50-2.68 (m, 2H), 2.30 (br s, 3H), 2.08 (s, 6H), 1.64-1.90 (m, 2H), 1.09-1.35 (m, 6H), 0.76-0.92 (m, 1H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 175.5, 175.5, 170.3, 137.5, 137.4, 133.6, 129.2, 128.9, 128.9, 128.1, 127.6, 127.5, 127.4, 124.0, 71.6, 64.1, 50.4, 47.2, 47.1, 43.5, 43.2, 41.7, 31.8, 31.7, 29.7, 29.6, 25.5, 25.3, 24.6, 23.6, 22.8, 14.5, 13.8, 13.8, 11.7. HRMS-ESI⁺ m/z [M + H]⁺ calcd for $C_{28}H_{34}N_2O_2S_2$, 495.2134; found, 495.2139.

4.1.1.2.2. 2-{4-[Bis(3-methylthiophen-2-yl)methylidene]piperidin-1-yl}-N-[(2-chlorophenyl)methyl]-4-hydroxypentanamide ((2RS,4RS)-**37b** and (2RS,4SR)-**37b**). Compounds (2RS,4RS)-37b

and (2RS,4SR)-37b were prepared according to GP2 with 3-{4-[bis(3-methylthiophen-2-yl)methylidene]piperidin-1-yl}-5-methyloxolan-2-one (36) (2.12 mmol, 0.83 g), 1-(2-chlorophenyl)methanamine hydrochloride (3.18 mmol, 0.56 g), and sodium 2ethylhexanoate (5.34 mmol, 0.95 g) in 10 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9.1) to yield (2RS,4RS)-37b (533 mg, 47%, $R_f = 0.58$ (S₆)) and (2RS,4SR)-37b (238 mg, 21%, $R_f = 0.35$ (S_6)) as a yellow oil. ds: (2RS,4RS)-37b/(2RS,4SR)-37b = 69:31. Formula C₂₈H₃₃ClN₂O₂S₂, FW 529.15. Compound (2RS,4RS)-37b: ¹H NMR (300 MHz, chloroform-d) δ ppm 7.58–7.68 (m, 1H), 7.35-7.43 (m, 2H), 7.21-7.28 (m, 2H), 7.11-7.16 (m, 2H), 6.76-6.80 (m, 2H), 4.36-4.64 (m, 3H), 3.98-4.07 (m, 1H), 3.31-3.40 (m, 1H), 2.54 (d, J = 4.11 Hz, 4H), 2.26–2.37 (m, 4H), 2.10 (s, 6H), 1.74 (t, J = 6.16 Hz, 2H), 1.18 (d, J = 6.46 Hz, 3H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 173.1, 143.1, 137.9, 135.5, 133.8, 133.7, 130.5, 129.7, 129.5, 129.3, 127.3, 123.9, 120.2, 65.5, 65.2, 51.0, 41.6, 34.2, 32.0, 22.9, 14.7. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₈H₃₃ClN₂O₂S₂, 529.1745; found, 529.1747. Compound (2RS,4SR)-37b: ¹H NMR (300 MHz, chloroform-d) δ ppm 7.57-7.67 (m, 1H), 7.34-7.42 (m, 2H), 7.20-7.27 (m, 2H), 7.10-7.15 (m, 2H), 6.75-6.79 (m, 2H), 4.35-4.63 (m, 3H), 3.97-4.06 (m, 1H), 3.30-3.39 (m, 1H), 2.53 (d, J = 4.10 Hz, 4H), 2.25-2.36 (m, 4H), 2.09 (s, 6H), 1.73 (t, I = 6.15 Hz, 2H), 1.17 (d, I = 6.45 Hz, 3H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 173.0, 143.1, 137.8, 135.5, 133.7, 133.6, 130.5, 129.6, 129.4, 129.2, 127.2, 123.9, 120.1, 65.4, 65.1, 51.0, 41.5, 34.2, 32.0, 22.9, 14.6. HRMS-ESI+ m/z [M + H]⁺ calcd for C₂₈H₃₃ClN₂O₂S₂, 529.1745; found, 529.1747.

4.1.1.2.3. 2-{4-[Bis(3-methylthiophen-2-yl)methylidene]piperidin-1-yl}-N-[(4-fluorophenyl)methyl]-4-hydroxypentanamide ((2RS,4RS)-37c and (2RS,4SR)-37c). Compounds (2RS,4RS)-37c and (2RS,4SR)-37c were prepared according to GP2 with 3-{4-[bis(3methylthiophen-2-yl)methylidene]piperidin-1-yl}-5-methyloxolan-2one (36) (2.12 mmol, 0.83 g), 1-(4-fluorophenyl)methanamine hydrochloride (3.18 mmol, 0.51 g), and sodium 2-ethylhexanoate (5.34 mmol, 0.95 g) in 10 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-37c (527 mg, 48%, $R_f = 0.55$ (DCM/Ace = 9:1)) and (2RS,4SR)-37c (230 mg, 21%, $R_f = 0.37$ (DCM/Ace = 9:1) as a vellow oil. ds: (2RS,4RS)-23a/(2RS,4SR)-37c = 70:30. Formula $C_{28}H_{33}FN_2O_2S_2$, FW 512.70. Compound (2RS,4RS)-37c: ¹H NMR (300 MHz, chloroform-d) δ ppm 7.50-7.59 (m, 1H), 7.20–7.29 (m, 2H), 7.12 (d, J = 5.29 Hz, 2H), 7.01 (s, 2H), 6.77 (d, J = 5.29 Hz, 2H), 4.28-4.54 (m, 3H), 3.97-4.08 (m, 1H), 3.34-3.43 (m, 1H), 2.50-2.66 (m, 4H), 2.24-2.38 (m, 4H), 2.09 (s, 6H), 1.71–1.81 (m, 2H), 1.13–1.21 (m, 3H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 172.8, 163.8, 160.6, 143.0, 137.8, 134.3, 134.3, 133.8, 129.4, 129.4, 129.3, 124.1, 120.4, 115.8, 115.6, 65.7, 65.3, 51.1, 42.5, 34.5, 31.9, 31.7, 29.8, 23.2, 14.7. HRMS-ESI⁺ *m*/*z* [M + H]⁺ calcd for $C_{28}H_{33}FN_2O_2S_2$, 513.2040; found, 513.2045. Compound (2RS,4SR)-37c: ¹H NMR (300 MHz, chloroform-d) δ ppm 7.49-7.58 (m, 1H), 7.19-7.28 (m, 2H), 7.11 (d, J = 5.28 Hz, 2H), 7.00 (s, 2H), 6.76 (d, J = 5.28 Hz, 2H), 4.27–4.53 (m, 3H), 3.96-4.07 (m, 1H), 3.33-3.42 (m, 1H), 2.49-2.65 (m, 4H), 2.23-2.37 (m, 4H), 2.08 (s, 6H), 1.70-1.80 (m, 2H), 1.12-1.20 (m, 3H). $^{13}\mathrm{C}$ NMR (75 MHz, chloroform-d) δ ppm 172.7, 163.7, 160.5, 143.0, 137.7, 134.2, 134.2, 133.7, 129.4, 129.4, 129.3, 124.0, 120.3, 115.7, 115.5, 65.6, 65.3, 51.0, 42.5, 34.4, 31.9, 31.7, 29.7, 23.1, 14.6. HRMS- ESI^+ m/z [M + H]⁺ calcd for C₂₈H₃₃FN₂O₂S₂, 513.2040; found, 513.2045.

4.1.1.2.4. 2-((3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5ylidene)propyl)(methyl)amino)-N-(4-fluorobenzyl)-4-hydroxypentanamide ((2RS,4RS)-**39a**). Compound (2RS,4RS)-**39a** was prepared according to GP2 with 3-((3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-5-methyldihydrofuran-2(3H)-one (**38**) (1.66 mmol, 0.60 g), 1-(4-fluorophenyl)methanamine hydrochloride (2.49 mmol, 0.31 g) and sodium 2ethylhexanoate (4.15 mmol, 0.69 g) in 4 mL of dry THF. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-**39a** (249 mg, 31%, R_f = 0.74 (DCM/Ace = 7:3) as a yellow oil. Formula $C_{31}H_{35}FN_2O_2$, FW 486.27.¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.18–1.34 (m, 4H (CCH₃)) 1.59–1.79 (m, 2H (CHCH₂CH)) 2.03 (br s, 3H (NCH₃)) 2.18–2.35 (m, 2H (CHCH₂CH₂)) 2.44 (br s, 2H (CHCH₂CH₂)) 2.76 (br s, 1H (ArCH₂CH₂Ar)) 2.86–3.08 (m, 1H (ArCH₂CH₂Ar)) 3.08–3.37 (m, 3H (ArCH₂CH₂Ar, NCH)) 3.63–3.76 (m, 1H (CHOH)) 4.06–4.38 (m, 2H (NHCH₂)) 5.70 (br s, 1H (CHCH₂CH₂)) 6.94 (br s, 3H (Ar)) 6.99–7.09 (m, 3H (Ar)) 7.10–7.24 (m, 6H (Ar)) 7.97 (br s, 1H (NHCH₂)). ¹³C NMR (75 MHz, chloroform-*d*) δ ppm 24.61, 31.96, 33.69, 42.51, 54.38, 66.99, 67.48, 115.29, 115.58, 125.78, 126.13, 127.27, 127.65, 128.10, 128.42, 129.22, 129.33, 130.20, 133.86, 133.91, 139.71, 163.70, 174.81. LCMS *m*/z [M + H]⁺ = 487.22. HRMS-ESI⁺ *m*/z [M + H]⁺ calcd for C₃₁H₃₅FN₂O₂, 487.2755; found, 487.2758.

4.1.1.2.5. N-(4-Chlorobenzvl)-2-((3-(10.11-dihvdro-5H-dibenzo-[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-4-hydroxypentanamide ((2RS,4RS)-39b and (2RS,4SR)-39b). Compounds (2RS,4RS)-39b and (2RS,4SR)-39b were prepared according to GP2 with 3-((3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5vlidene)propyl)(methyl)amino)-5-methyldihydrofuran-2(3H)-one (38) (1.66 mmol, 0.60 g), 1-(4-chlorophenyl)methanamine hydrochloride (2.73 mmol, 0.43 g), and sodium 2-ethylhexanoate (4.55 mmol, 0.76 g) in 4 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-39a (358 mg, 41%, $R_f = 0.33$ (DCM/Ace = 9:1)) and (2RS,4SR)-39b (114 mg, 13%, $R_f = 0.18$ (DCM/Ace = 9:1)) as a yellow oil. ds: (2RS,4RS)-39a/(2RS,4SR)-39a = 76:24. Formula C₃₁H₃₅ClN₂O₂, FW 503.08. Compound (2RS,4RS)-39b: ¹H NMR (300 MHz, chloroform-d) δ ppm 1.20–1.27 (m, 2H (CHCH₃)) 1.46–1.78 (m, 2H (CHCH₂CH)) 2.03 (br s, 3H (NCH₃)) 2.20-2.33 (m, 2H (CHCH₂CH₂)) 2.42 (br s, 2H (CHCH₂CH₂)) 2.75 (br s, 1H (ArCH₂CH₂Ar)) 2.93 (br s, 1H $(ArCH_2CH_2Ar)$ 3.16 (d, J = 13.48 Hz, 1H $(ArCH_2CH_2Ar)$ 3.27 (br s, 2H (ArCH₂CH₂Ar, NCH)) 3.65-3.77 (m, 1H (CHOH)) 4.06-4.40 (m, 2H (NHCH₂)) 5.69 (br s, 1H (CHCH₂CH)) 6.93 (br s, 1H (Ar)) 6.98-7.26 (m, 12H (Ar)) 7.99 (br s, 1H (NHCH₂)). ¹³C NMR (75 MHz, chloroform-d) δ ppm 22.67, 24.56, 31.98, 33.70, 38.42, 42.52, 47.18, 53.83, 66.99, 67.43, 121.78, 125.79, 126.14, 127.29, 127.67, 128.05, 128.11, 128.42, 128.72, 128.97, 130.23, 136.61, 136.90, 139.68, 174.86. LCMS $m/z [M + H]^+ = 503.23$. HRMS-ESI⁺ $m/z [M + H]^+$ calcd for C₃₁H₃₅ClN₂O₂, 503.2460; found, 503.2462. Compound (2RS,4SR)-39b: ¹H NMR (300 MHz, chloroform-d) δ ppm 1.14 (d, J = 6.45 Hz, 3H (CHCH₃)) 1.60 (ddd, J = 13.63, 6.59, 3.22 Hz, 1H (CHCH₂CH)) 1.83 (br s, 1H (CHCH₂CH)) 2.05 (s, 3H (NCH₃)) 2.26 (br s, 2H (CHCH₂CH₂)) 2.46 (br s, 2H (CHCH₂CH₂)) 2.75 (br s, 1H (ArCH₂CH₂Ar)) 2.88-3.04 (m, 1H $(ArCH_2CH_2Ar)$ 3.17 (br s, 1H $(ArCH_2CH_2Ar)$) 3.35 (dd, J = 9.38, 2.93 Hz, 2H (ArCH₂CH₂Ar, NCH)) 4.04 (br s, 1H (CHOH)) 4.13-4.40 (m, 2H (NHCH₂)) 5.74 (br s, 1H (CHCH₂CH₂)) 6.91-7.24 (m, 12H (Ar)) 7.69 (br s, 1H (NHCH₂)). ¹³C NMR (75 MHz, chloroform-d) δ ppm 22.82, 27.86, 29.28, 31.98, 33.72, 42.46, 64.88, 125.79, 126.13, 127.26, 127.62, 128.02, 128.17, 128.45, 128.74, 129.01, 130.19, 136.92, 139.77, 174.19. LCMS $m/z [M + H]^+ =$ 503.23. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₃₁H₃₅ClN₂O₂, 503.2460; found, 503.2462.

4.1.1.2.6. 2-((3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5ylidene)propyl)(methyl)amino)-4-hydroxy-N-(4-methylbenzyl)pentanamide ((2RS,4RS)-**39c** and (2RS,4SR)-**39c**). Compounds (2RS,4RS)-**39c** and (2RS,4SR)-**39c** were prepared according to GP2 with 3-((3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-5-methyldihydrofuran-2(3H)-one (**38**) (1.66 mmol, 0.60 g), 1-(4-methylphenyl)methanamine hydrochloride (2.73 mmol, 0.43 g), and sodium 2-ethylhexanoate (2.73 mmol, 0.43 g) in 4 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-**39c** (114 mg, 13%, $R_f = 0.32$ (DCM/Ace = 9:1)) and (2RS,4SR)-**39c** (114 mg, 13%, $R_f = 0.32$ (DCM/Ace = 9:1)) as a yellow oil. ds: (2RS,4RS)-**39c**/(2RS,4SR)-**39c** = 76:24. Formula C₃₂H₃₈N₂O₂, FW 482.67. Compound (2RS,4RS)-**39c**: ¹H NMR (300 MHz, chloroform-d) δ ppm 1.21–1.27 (m, 3H (CHCH₃)) 1.64–1.73

(m, 2H (CHCH₂CH)) 2.05 (s, 3H (ArCH₃)) 2.18-2.29 (m, 2H (CHCH₂CH₂)) 2.32 (s, 3H (NCH₃)) 2.44 (br s, 2H (CHCH₂CH₂)) 2.75 (br s, 1H (ArCH₂CH₂Ar)) 2.94 (br s, 1H (ArCH₂CH₂Ar)) 3.12-3.39 (m, 3H (ArCH₂CH₂Ar, NCH)) 3.67-3.74 (m, 1H (CHOH)) 4.13-4.40 (m, 2H (NHCH₂)) 5.72 (br s, 1H $(CHCH_2CH_2)$ 6.91–7.24 (m, 12H (Ar)) 7.87 (br s, 1H ($NHCH_2$)). ¹³C NMR (75 MHz, chloroform-d) δ ppm 21.11, 24.67, 28.04, 31.99, 33.72, 43.03, 66.90, 67.48, 125.78, 126.10, 127.61, 128.07, 128.45, 129.32, 130.17, 135.02, 136.93, 139.30, 139.79, 174.64. LCMS $m/z [M + H]^+ = 483.29$. HRMS-ESI⁺ $m/z [M + H]^+$ calcd for C31H35ClN2O2, 483.3006; found, 483.3003. Compound (2RS,4SR)-23a: ¹H NMR (300 MHz, chloroform-d) δ ppm 1.13 (d, J = 6.45 Hz, 3H (CHCH₃)) 1.61 (ddd, J = 14.07, 7.03, 3.52 Hz, 1H (CHCH₂CH)) 1.79-1.89 (m, 1H (CHCH₂CH)) 2.07 (s, 3H (ArCH₂)) 2.21-2.29 (m, 2H (CHCH₂CH₂))) 2.32 (s, 3H (NCH₃)) 2.42-2.50 (m, 2H (CHCH₂CH₂)) 2.75 (br s, 1H (ArCH₂CH₂Ar)) 2.94 (br s, 1H (ArCH₂CH₂Ar)) 3.20 (br s, 1H (NCH) 3.33 (dd, I = 9.38, 3.52 Hz, 2H (ArCH₂CH₂Ar)) 4.00-4.08(m, 1H (CHOH)) 4.22-4.37 (m, 2H (NHCH₂)) 5.76 (t, J = 7.03Hz, 1H (CHCH₂CH₂)) 6.94-7.24 (m, 12H (Ar)) 7.50 (br s, 1H (NHCH₂)). ¹³C NMR (75 MHz, chloroform-d) δ ppm 21.10, 22.75, 27.95, 29.28, 31.96, 33.70, 42.94, 64.90, 125.78, 126.07, 127.16, 127.56, 127.65, 128.00, 128.11, 128.46, 129.30, 130.13, 135.19, 136.95, 139.85, 173.94. LCMS $m/z [M + H]^+ = 483.29$. HRMS-ESI⁺ $m/z [M + H]^+$ calcd for $C_{31}H_{35}ClN_2O_2$, 483.3006; found, 483.3003.

4.1.1.2.7. N-Benzyl-2-[4-(9H-fluoren-9-ylidene)piperidin-1-yl]-4hydroxypentanamide ((2RS,4RS)-41 and (2RS,4SR)-41). Compounds (2RS,4RS)-41 and (2RS,4SR)-41 were prepared according to GP2 with 3-[4-(9H-fluoren-9-ylidene)piperidin-1-yl]-5-methyloxolan-2-one (40) (0.59 mmol, 0.23 g), 1-phenylmethanamine hydrochloride (0.89 mmol, 0.19 g), and sodium 2-ethylhexanoate (1.45 mmol, 0.285 g) in 4 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-41 (150 mg, 50%, $R_f = 0.48$ (DCM/Ace = 9:1) and (2RS,4SR)-41 (51 mg, 17%, $R_f = 0.29$ (DCM/Ace = 9:1)) as a yellow oil. ds: (2RS,4RS)-41/(2RS,4SR)-41= 75:25. Formula C₃₀H₃₂N₂O₂, FW 452.59. Compound (2RS,4RS)-41: ¹H NMR (300 MHz, chloroform-d) δ ppm 1.17–1.31 (m, 3H) 1.69-1.89 (m, 2H) 1.96-2.57 (m, 2H) 2.70-2.87 (m, 2H) 3.08-3.44 (m, 4H) 3.70-3.88 (m, 1H) 4.19-4.65 (m, 3H) 7.04-7.46 (m, 10H) 7.69-7.86 (m, 3H) 7.99 (br s, 1H). Compound (2RS,4SR)-41: ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.14–1.24 (m, 3H) 1.68– 1.88 (m, 2H) 2.38-2.54 (m, 1H) 2.67-2.89 (m, 3H) 2.95 (br s, 2H) 3.18-3.25 (m, 2H) 3.26-3.53 (m, 2H) 3.96-4.10 (m, 1H) 4.40-4.45 (m, 1H) 4.51 (s, 1H) 7.22-7.41 (m, 11H) 7.71-7.86 (m, 3H).

4.1.1.2.8. N-Benzyl-2-(4-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1-yl)-4-hydroxypentanamide ((2RS,4RS)-43a and (2RS,4SR)-43a). Compounds (2RS,4RS)-43a and (2RS,4SR)-43a were prepared according to GP2 with 3-(4-(10,11dihydro-5*H*-dibenzo[*a*,*d*][7]annulen-5-ylidene)piperidin-1-yl)-5methyldihydrofuran-2(3H)-one (42) (0.48 mmol, 0.18 g), 1-phenylmethanamine hydrochloride (0.72 mmol, 0.10 g), and sodium 2ethylhexanoate (1.80 mmol, 0.30 g) in 4 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-43a (120 mg, 52%, $R_f = 0.48$ (DCM/Ace = 9:1)) and (2RS,4SR)-43a (30 mg, 13%, $R_f = 0.29$ (DCM/Ace = 9:1)) as a yellow oil. ds: (2RS,4RS)-43a/ $(2RS_{4}4SR)$ -43a = 80:20. Formula: $C_{32}H_{36}N_{2}O_{2}$, FW 480.65. Compound (2RS,4RS)-43a: ¹H NMR (300 MHz, chloroform-d) δ ppm 8.02 (t, J = 5.86 Hz, 1H), 7.21–7.46 (m, 5H), 6.99–7.20 (m, 8H), 4.35-4.62 (m, 2H), 3.72-3.87 (m, 1H), 3.28-3.46 (m, 3H), 2.76-2.93 (m, 2H), 2.57-2.69 (m, 2H), 2.39-2.55 (m, 3H), 2.28-2.39 (m, 3H), 1.69–1.87 (m, 2H), 1.28 (d, J = 5.86 Hz, 3H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 174.3, 150.0, 140.4, 138.1, 138.1, 137.9, 135.7, 132.7, 129.4, 129.3, 128.8, 128.7, 127.8, 127.6, 127.5, 127.0, 126.9, 125.8, 125.5, 67.6, 67.4, 53.9, 51.8, 50.3, 43.5, 33.6, 32.5, 31.3, 31.3, 29.7, 29.3, 24.6. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C32H37N2O2, 481.2855; found, 481.2855. Compound (2RS,4SR)-43a: ¹H NMR (300 MHz, chloroform-d) δ ppm 7.42 (t, J = 5.57 Hz, 1H), 7.24–7.39 (m, 5H), 7.06–7.16 (m, 6H), 6.99–7.06

(m, 2H), 4.47 (dd, J = 6.15, 14.95 Hz, 2H), 3.99–4.11 (m, 1H), 3.28–3.45 (m, 3H), 2.75–2.89 (m, 2H), 2.67 (dd, J = 4.40, 14.95 Hz, 2H), 2.29–2.44 (m, 6H), 1.69–1.82 (m, 2H), 1.18 (d, J = 6.45 Hz, 3H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 173.0, 140.5, 140.4, 138.2, 137.9, 135.5, 133.0, 129.3, 128.8, 128.7, 127.6, 127.6, 126.9, 125.5, 65.5, 65.3, 51.9, 51.1, 43.3, 34.2, 32.4, 31.2, 22.9.

4.1.1.2.9. 2-(4-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5ylidene)piperidin-1-yl)-N-(4-fluorobenzyl)-4-hydroxypentanamide ((2RS,4RS)-43b and (2RS,4SR)-43b). Compounds (2RS,4RS)-43b and (2RS,4SR)-43b were prepared according to GP2 with 3-(4-(10,11-dihydro-5*H*-dibenzo[*a*,*d*][7]annulen-5-ylidene)piperidin-1yl)-5-methyldihydrofuran-2(3H)-one (42) (0.63 mmol, 0.24 g), 1-(4fluorophenyl)methanamine hydrochloride (0.95 mmol, 0.15 g), and sodium 2-ethylhexanoate (1.60 mmol, 0.27 g) in 4 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-43b (120 mg, 38%, $R_f = 0.54$ (DCM/Ace = 9:1)) and (2RS,4SR)-43b (40 mg, 12%, $R_f = 0.33$ (DCM/Ace = 9:1)) as a yellow oil. ds: (2RS,4RS)- $43b/(2RS_{4}4SR)-43b = 75:25$. Formula $C_{32}H_{35}FN_{2}O_{2}$, FW 498.64. Compound (2RS,4RS)-43b: ¹H NMR (300 MHz, chloroform-d) δ ppm 6.90-7.38 (m, 12H), 4.25-4.72 (m, 4H), 3.87-4.09 (m, 1H), 3.70-3.84 (m, 1H), 3.25-3.54 (m, 2H), 2.74-2.89 (m, 1H), 2.65 (d, J = 17.58 Hz, 1H), 2.29–2.50 (m, 3H), 1.42–2.20 (m, 4H), 1.02– 1.33 (m, 5H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 169.2, 163.8, 140.1, 137.9, 133.4, 129.4, 129.3, 129.3, 129.2, 128.5, 127.1, 125.5, 115.8, 115.7, 115.5, 115.4, 65.8, 65.6, 48.1, 47.3, 46.4, 44.8, 44.5, 43.3, 43.2, 42.8, 42.6, 32.4, 31.6, 25.3, 24.3, 23.9, 23.6, 23.4, 22.5, 11.8. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₃₂H₃₆N₂O₂F, 499.2773; found, 499.2761. Compound (2RS,4SR)-43b: ¹H NMR (300 MHz, chloroform-d) δ ppm 6.90-7.38 (m, 12H), 4.25-4.72 (m, 4H), 3.87-4.09 (m, 1H), 3.70-3.84 (m, 1H), 3.25-3.54 (m, 2H), 2.74–2.89 (m, 1H), 2.65 (d, J = 17.58 Hz, 1H), 2.29–2.50 (m, 3H), 1.42-2.20 (m, 4H), 1.02-1.33 (m, 5H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 169.3, 163.9, 140.1, 137.8, 133.4, 129.4, 129.3, 129.3, 129.2, 128.5, 127.1, 125.4, 115.8, 115.7, 115.5, 115.4, 65.8, 65.6, 48.2, 47.3, 46.4, 44.8, 44.5, 43.4, 43.2, 42.8, 42.5, 32.4, 31.6, 25.3, 24.3, 23.9, 23.5, 23.4, 22.5, 11.7.

4.1.1.3. General Procedure for the Synthesis of the 4-Hydroxypentanamide and 4-Hydroxybutanamide Derivatives 45 and 47a-c (GP3). These reactions were performed under an argon atmosphere. The relevant 3-substituted 5-methyldihydrofuran-2(3H)one or dihydrofuran-2(3H)-one derivative (1 equiv) was heated with the corresponding N-benzylamine (2 equiv) in dry THF at reflux for 48 h. When the reaction was complete, the mixture was cooled on ice, quenched with a 1 M aqueous solution of HCl (1.5 mL), and extracted with dichloromethane (3 × 10 mL). The combined organic fractions were dried over Na₂SO₄ and evaporated under vacuum. The crude product was purified by column chromatography.

4.1.1.3.1. N-Benzyl-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-4-hydroxypentanamide ((2RS,4RS)-45 and (2RS,4SR)-45). Compounds (2RS,4RS)-45 and (2RS,4SR)-45 were prepared according to GP3 with 3-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-5-methyloxolan-2-one (44) (1.33 mmol, 0.47 g) and N-benzylamine (1.59 mmol, 0.17 g) in 10 mL of dry THF. The obtained crude products were purified by column chromatography over silica gel (DCM/Ace = 9:1) to yield (2RS,4RS)-**45** (309 mg, 48%, $R_f = 0.48$ (S₁)) and (2RS,4SR)-**45** (103 mg, 16%, R_f $= 0.25 (S_1)$) as a yellow oil. ds: (2RS,4RS)-45/(2RS,4SR)-45 = 75:25. Formula C₂₈H₃₃N₃O₃, FW 459.58. Compound (2RS,4RS)-45: ¹H NMR (300 MHz, chloroform-d) δ ppm 1.20-1.26 (m, 4H (CHCH₃)) 1.71-1.84 (m, 2H (CHCH₂CH)) 2.24-2.30 (m, 3H (NCH_3) 2.77 (t, J = 5.26 Hz, 2H (OCH_2CH_2N) 3.33–3.42 (m, 1H (NCHCO)) 3.66-3.82 (m, 1H (OHCH)) 4.09-4.36 (m, 4H (NHCH₂, OCH₂CH₂N)) 7.07-7.12 (m, 2H (Ar)) 7.20-7.24 (m, 3H (Ar)) 7.27-7.47 (m, 10H (Ar)) 7.84-7.92 (m, 1H (NHCH₂)). HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₈H₃₄N₃O₃, 460.2640; found, 460.2621. Compound (2RS,4SR)-45 ¹H NMR (300 MHz, chloroform-d) δ ppm 1.22-1.31 (m, 3H (CHCH₃)) 1.62-1.89 (m, 3H (CHCH₂CH)) 1.97-2.05 (m, 2H (NCH₃)) 2.26-2.31 (m, 1H (NCH_3) 2.70–2.89 (m, 2H (OCH_2CH_2N)) 3.45 (dd, J = 8.72, 4.36

Hz, 1H (NCHCO)) 3.96–4.17 (m, 2H (NHCH₂)) 4.20–4.34 (m, 3H (OCH₂CH₂N)) 4.38–4.46 (m, 1H (OHCH)) 7.08–7.14 (m, 2H (*Ar*)) 7.20–7.47 (m, 13H (*Ar*)). ¹³C NMR (126 MHz, chloroform-*d*) δ ppm 170.0, 157.6, 138.4, 136.1, 133.3, 129.7, 129.1, 129.0, 128.8, 128.7, 128.4, 128.3, 128.0, 127.9, 127.6, 127.6, 127.3, 65.1, 63.9, 53.4, 43.9, 38.6, 31.5, 29.8, 23.4. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₈H₃₄N₃O₃, 460.2595; found, 460.2591.

4.1.1.3.2. N-Benzyl-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-4-hydroxybutanamide (47a). Compound 47a was prepared according to GP3 with 3-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]oxolan-2one (46) (1.33 mmol, 0.45 g) and 1-phenylmethanamine (1.59 mmol, 0.17 g) in 10 mL of dry THF. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3)to yield 47a (332 mg, 56%, $R_f = 0.50$ (DCM/Ace = 7:3)). Formula $C_{27}H_{31}N_3O_3$, FW 445.55. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.83-1.94 (m, 2H (CH₂CH₂OH)) 2.28 (s, 3H (Me)) 2.79 (t, J = 5.39 Hz, 2H (CH₂N)) 3.28-3.35 (m, 1H (NCH)) 3.52-3.62 (m, 1H (CH_2OH) 3.78–3.87 (m, 1H (CH_2OH)) 4.19 (dd, J = 14.88, 6.41Hz, 2H (CH₂O)) 4.23-4.31 (m, 2H (NHCH₂)) 7.07-7.13 (m, 2H (Ar)) 7.18-7.47 (m, 13H (Ar)) 7.78 (t, J = 5.90 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 14.20, 27.29, 38.49, 43.02, 53.37, 60.40, 61.68, 67.48, 72.43, 127.21, 127.33, 127.83, 128.13, 128.30, 128.54, 128.93, 129.06, 129.49, 133.13, 136.14, 138.26, 157.15, 174.07. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₇H₃₂N₃O₃, 446.2444; found, 446.2447.

4.1.1.3.3. N-[(2-Chlorophenvl)methvl]-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-4-hydroxybutanamide (47b). Compound 47b was prepared according to GP3 with 3-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]oxolan-2-one (46) (1.33 mmol, 0.45 g) and 1-(2chlorophenyl)methanamine (1.59 mmol, 0.23 g) in 10 mL of dry THF. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 47b $(223 \text{ mg}, 35\%, R_f = 0.52 \text{ (DCM/Ace} = 7:3)).$ Formula $C_{27}H_{30}CIN_3O_3$, FW 480.01. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.82-1.92 (m, 2H (CH₂CH₂OH)) 2.28 (s, 3H (Me)) 2.80 (t, J $= 5.51 \text{ Hz}, 2 \text{H} (CH_2 \text{N}) 3.28 - 3.36 \text{ (m, 1H (NCH))} 3.50 - 3.60 \text{ (m, n)}$ 1H (CH_2OH)) 3.81 (dt, J = 11.09, 4.58 Hz, 1H (CH_2OH)) 4.18-4.34 (m, 4H (NHCH₂; CH₂O)) 7.10–7.49 (m, 14H (Ar)) 7.86 (t, J = 5.90 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 27.22, 29.69, 38.54, 41.17, 53.38, 61.68, 67.31, 72.57, 126.91, 127.81, 128.08, 128.25, 128.57, 128.91, 129.02, 129.05, 129.39, 129.47, 133.09, 133.21, 135.54, 136.12, 157.18, 174.31. HRMS-ESI⁺ m/z [M + H]⁺ calcd for $C_{27}H_{31}N_3O_3Cl$, 480.2054; found, 480.2056.

4.1.1.3.4. N-[(3,4-Dichlorophenyl)methyl]-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-4-hydroxybutanamide (47c). Compound 47c was prepared according to GP3 with 3-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]oxolan-2-one (46) (1.33 mmol, 0.45 g) and 1-(3,4dichlorophenyl)methanamine (1.59 mmol, 0.30 g) in 10 mL of dry THF. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 47c $(369 \text{ mg}, 54\%, R_f = 0.49 \text{ (DCM/Ace} = 7:3)).$ Formula $C_{27}H_{29}Cl_2N_3O_3$, FW 514.44. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.84-1.92 (m, 2H (CH₂CH₂OH)) 2.32 (s, 3H (Me)) 2.71-2.81 (m, 2H (CH₂N)) 3.29-3.35 (m, 1H (NCH)) 3.54-3.64 (m, 1H (CH₂OH)) 3.82 (dt, J = 11.09, 4.58 Hz, 1H (CH₂OH)) 3.95 (d, J = 6.16 Hz, 1H (CH₂O)) 4.01 (d, J = 6.67 Hz, 1H (CH₂O)) 4.26-4.32 $(m, 2H (NHCH_2)) 6.89 (dd, J = 8.21, 2.05 Hz, 1H (Ar)) 7.08 (d, J =$ 2.05 Hz, 1H (Ar)) 7.23-7.46 (m, 11H (Ar)) 7.86 (t, J = 6.28 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 14.20, 27.23, 38.42, 41.81, 53.33, 61.62, 67.25, 71.99, 126.63, 127.86, 128.17, 128.36, 129.05, 129.15, 129.21, 129.59, 130.36, 131.03, 132.36, 133.08, 136.09, 138.73, 157.13, 174.45. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₇H₃₀N₃O₃Cl₂, 514.1664; found, 514.1666.

4.1.1.4. General Procedure for the Synthesis of N-Benzyl-4-(1,3dioxoisoindolin-2-yl)-2-(4-(diphenylmethylene)piperidin-1-yl)butanamide derivatives (**49a**,**b**) (GP4). Anhydrous K_2CO_3 (4.40 mmol, 0.61 g, 2.5 equiv) and KI (1.7 mmol, 0.29 g) were added to a solution of amine F (diphenylmethanone O-(2-(methylamino)ethyl) oxime (32)) (1.76 mmol, 0.44 g, 1 equiv) in acetonitrile (10 mL). Then, the relevant N-benzyl-2-bromo-4-(1,3-dioxoisoindolin-2-yl)-butanamide derivative (48a,b) (1.76 mmol, 1 equiv) was added, and the reaction mixture was stirred at reflux for 24 h. Then, the precipitate was filtered, the filtrate was concentrated under vacuum, and the product was purified by column chromatography.

4.1.1.4.1. N-[(2-Chlorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)-(methyl)amino]butanamide (49a). According to GP4, amide 48a (1.35 mmol, 0.59 g), amine F (diphenylmethanone O-(2-(methylamino)ethyl) oxime (32)) (1.35 mmol, 0.34 g), KI (1.22 mmol, 0.20 g), and anhydrous K₂CO₃ (3.11 mmol, 0.43 g) were combined in acetonitrile (15 mL). The obtained crude product was purified by column chromatography over silica gel (PE/EtOAc = 1:1) to yield 49a (346 mg, 42%, $R_f = 0.49$ (PE/EtOAc (1:1)) as a yellow oil. Formula C₃₅H₃₃ClN₄O₄, FW 609.11. ¹H NMR (chloroform-d) δ ppm 2.19 (dtd, J = 13.75, 8.06, 8.06, 6.03 Hz, 2H (CH_2CH_2NH)) 2.29 (s, 3H (Me)) 2.83 (t, J = 5.51 Hz, 2H (CH₂N)) 3.26 (dd, J =7.95, 4.87 Hz, 1H (NCH)) 3.76 (ddd, J = 14.04, 8.01, 6.41 Hz, 1H (OCH₂)) 3.92 (ddd, J = 13.85, 8.21, 5.90 Hz, 1H (OCH₂)) 4.18-4.33 (m, 4H (NHCH₂; CH₂phthalimide)) 7.13-7.35 (m, 12H (Ar)) 7.37-7.47 (m, 3H (Ar; CONH)) 7.65-7.72 (m, 2H (phthalimide)) 7.79-7.85 (m, 2H (phthalimide)).

4.1.1.4.2. N-[(3,4-Dichlorophenvl)methvl]-4-(1,3-dioxo-2,3-dihvdro-1H-isoindol-2-yl)-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]butanamide (49b). According to GP4, amide 48b (1.35 mmol, 0.63 g), amine F (diphenylmethanone O-(2-(methylamino)ethyl) oxime (32)) (1.35 mmol, 0.34 g), KI (1.22 mmol, 0.20 g), and anhydrous K2CO3 (3.11 mmol, 0.43 g) were combined in acetonitrile (15 mL). The obtained crude product was purified by column chromatography over silica gel (PE/EtOAc = 1:1) to yield **49b** (317 mg, 37%, $R_f = 0.47$ (PE/EtOAc (1:1)) as a yellow oil. Formula C35H32Cl2N4O4, FW 643.57. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.84–1.97 (m, 1H (CH₂CH₂NH)) 2.14–2.23 (m, 1H (CH_2CH_2NH)) 2.32 (s, 3H (Me)) 2.80 (t, J = 5.26 Hz, 2H (CH_2N) 3.77 (ddd, J = 13.91, 7.76, 6.54 Hz, 1H (NCH)) 3.85–3.99 $(m, 2H (OCH_2))$ 3.99–4.09 $(m, 2H (CH_2phthalimide))$ 4.25 (t, J =5.26 Hz, 2H (NHCH₂)) 6.91 (dd, J = 8.21, 2.05 Hz, 1H (Ar) 7.10 (d, I = 2.05 Hz, 1H (Ar)) 7.20–7.44 (m, 11H (Ar)) 7.44–7.50 (m, 1H (CONH)) 7.66-7.74 (m, 2H (phthalimide)) 7.78-7.86 (m, 2H (phthalimide)).

4.1.1.5. General Procedure for the Synthesis of 2-Substituted 4-Aminobutanamide Derivatives (**50a**,**b**) (GP5). Hydrazine hydrate (2 equiv) was added to a suspension of a 2-substituted 4phthalimidobutanoic acid derivative (1 equiv) in ethanol (10 mL). The solution was stirred at 60 °C for 2 h and at rt for 5 h. Then, the precipitate was filtered and washed with DCM (5 mL). The filtrate was evaporated, and the product was extracted two times with 8 mL of DCM. The combined organic fractions were dried over Na₂SO₄, and the obtained product was purified by column chromatography.

4.1.1.5.1. 4-Amino-N-[(2-chlorophenyl)methyl]-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]butanamide (50a). According to GP5, N-[(2-chlorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]butanamide (49a) (1 mmol, 0.61 g) and hydrazine hydrate (2 mmol, 0.11 g) were combined in ethanol (7 mL). The obtained crude product was purified by column chromatography over silica gel $(EtOAc/MeOH = 8:2 \rightarrow 25\% NH_3/MeOH/DCM/PE =$ 9:45:120:18) to yield 50a (325 mg, 68%, $R_f = 0.15$ (PE/EtOAc (1:1)) as a yellow oil. Formula $C_{27}H_{31}ClN_4O_{27}$ FW 479.01. ¹H NMR (chloroform-d) δ ppm 1.67–1.80 (m, 2H (CH₂CH₂NH₂)) 2.28 (s, 3H (Me) 2.67–2.78 (m, 1H (CH₂N)) 2.78–2.88 (m, 3H (CH₂NH₂; (CH_2N) 3.22 (dd, J = 7.82, 5.26 Hz, 1H (NCH)) 4.12–4.35 (m, 4H (NHCH₂; CH₂O)) 7.09–7.45 (m, 14H (Ar)) 7.58 (t, J = 6.16 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 29.93, 38.57, 40.44, 40.95, 53.82, 65.23, 72.82, 126.86, 127.81, 127.81, 128.05, 128.05, 128.23, 128.23, 128.40, 128.84, 129.07, 129.07, 129.13, 129.31, 129.39, 133.17, 133.20, 136.02, 136.20, 156.96, 173.47.

4.1.1.5.2. 4-Amino-N-[(3,4-dichlorophenyl)methyl]-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]butanamide (50b). According to GP5, N-(3,4-dichlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)-2-((2-(((diphenylmethylene)amino)oxy)ethyl)(methyl)amino)butanamide (49b) (1 mmol, 0.64 g) and hydrazine hydrate (2 mmol, 0.11 g) were combined in ethanol (7 mL). The obtained crude product was purified by column chromatography over silica gel (EtOAc/MeOH = $8:2 \rightarrow 25\%$ NH₃/MeOH/DCM/PE = 9:45:120:18) to yield 50b (442 mg, 86%, $R_f = 0.14$ (PE/EtOAc (1:1)) as a yellow oil. Formula $C_{27}H_{30}Cl_2N_4O_2$, FW 513.46. ¹H NMR (chloroform-d) δ ppm 1.73–1.97 (m, 2H $(CH_2CH_2NH_2)$ 2.31 (s, 3H (Me)) 2.73–2.81 (m, 2H (CH₂N)) 2.82-2.93 (m, 2H (CH₂NH₂)) 3.26 (dd, J = 8.21, 4.87 Hz, 1H (NCH)) 3.90 (dd, J = 15.39, 6.16 Hz, 1H (CH₂O)) 4.02 (dd, J =15.26, 6.54 Hz, 1H (CH_2O)) 4.27 (t, J = 5.13 Hz, 2H (NH CH_2)) 6.89 (dd, I = 8.34, 2.18 Hz, 1H (Ar)) 7.09 (d, I = 1.80 Hz, 1H (Ar))7.22–7.45 (m, 11H (Ar)) 7.73 (t, J = 6.41 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 27.70, 38.41, 39.88, 41.73, 53.59, 65.69, 72.16, 126.64, 127.84, 127.84, 128.17, 128.17, 128.33, 128.33, 129.03, 129.15, 129.15, 129.54, 130.34, 130.92, 132.30, 133.13, 136.09, 138.99, 138.99, 157.04, 173.61. HRMS-ESI⁺ m/z M $+ H^{+}$ calcd for C₂₀H₂₁N₄O₂Cl₂, 513.1824; found, 513.1818.

4.1.1.6. General Procedure for the Synthesis of 2-Substituted 4-Acetamidobutanamide Derivatives (**51a**,**b**) (GP6). A mixture of acetic acid (2 equiv) and N,N'-dicyclohexylcarbodiimide (DCC) (2 equiv) in 5 mL of DCM was stirred at 0 °C for 10 min. Then, a 4aminobutanamide derivative (1 equiv) and 4-dimethylaminopyridine (DMAP) (2 equiv) were added to the reaction mixture and stirring continued for 20 h at room temperature. The obtained N,Ndicyclohexylurea (DCU) was filtered, the filtrate was evaporated, and the product was purified by column chromatography over silica gel (S₁₁ (Chl/Ace 1:1)).

4.1.1.6.1. N-[(2-Chlorophenyl)methyl]-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-4-acetamidobutanamide (51a). According to GP6, acetic acid (0.63 mmol, 0.037 g, 36 µL), DCC (0.63 mmol, 0.13 g), 4-aminobutanamide (50a) (0.15 g, 0.32 mmol), and DMAP (0.63 mmol, 0.08 g) were combined in 5 mL of DCM. Compound 51a was obtained as a yellow oil (140 mg, 86%). $R_f = 0.45$ (Chl/Ace = 1:1). Formula $C_{29}H_{33}Cl_1N_4O_3$, FW 521.05. ¹H NMR (chloroform-d) δ ppm 1.78-1.93 (m, 5H (CH₂CH₂NH; Me)) 2.27 (s, 3H (Me)) 2.79 (t, $J = 5.39 \text{ Hz}, 2 \text{H} (CH_2 \text{N}) 3.11 - 3.23 \text{ (m, 2H} (CH_2 \text{NH}) 3.33 - 3.45$ (m, 1H (NCH)) 4.16-4.34 (m, 4H (NHCH₂; CH₂O)) 6.94 (br s, 1H (CONH)) 7.12-7.44 (m, 14H (Ar)) 7.75 (t, J = 6.03 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 23.25, 24.34, 38.53, 39.00, 41.10, 53.42, 66.52, 66.52, 72.54, 126.87, 127.80, 127.80, 128.06, 128.06, 128.24, 128.24, 128.54, 128.87, 128.88, 129.03, 129.03, 129.43, 129.45, 133.14, 133.21, 135.68, 136.11, 157.11, 170.30, 173.88. HRMS-ESI⁺ $m/z [M + H]^+$ calcd for C₂₉H₃₄N₄O₃Cl, 5521.2298; found, 521.22313.

4.1.1.6.2. N-[(3,4-Dichlorophenyl)methyl]-2-[(2-{[(diphenylmethylidene)amino]oxy}ethyl)(methyl)amino]-4-acetamidobutanamide (51b). According to GP6, acetic acid (0.63 mmol, 0.037 g, 36 µL), DCC (0.63 mmol, 0.13 g), 4-aminobutanamide (50b) (0.16 g, 0.32 mmol), and DMAP (0.63 mmol, 0.08 g) were combined in 5 mL of DCM. Compound 51b was obtained as a yellow oil (173 mg, 86%). $R_f = 0.47$ (Chl/Ace = 1:1). Formula $C_{29}H_{32}Cl_2N_4O_3$, FW 555.50 ¹H NMR (chloroform-d) δ ppm 1.77-1.89 (m, 5H ($CH_2CH_2NH_3$ Me)) 2.26 (s, 3H (Me)) 2.69 (t, J = 5.38Hz, 2H (CH₂N)) 3.09-3.26 (m, 2H (CH₂NH)) 3.31-3.44 (m, 1H (NCH)) 4.12-4.31 (m, 4H (NHCH₂; CH₂O)) 6.67 (br s, 1H (CONH)) 7.09-7.45 (m, 13H (Ar)) 7.73 (t, J = 6.07 Hz, 1H (CONH)). ¹³C NMR (300 MHz, chloroform-d) δ ppm 23.15, 24.44, 38.43, 39.10, 41.15, 53.42, 66.62, 66.68, 72.44, 126.77, 127.86, 127.99, 128.12, 128.12, 128.34, 128.34, 128.44, 128.89, 128.89, 129.03, 129.03, 129.53, 129.59, 133.14, 133.28, 135.78, 136.21, 157.31, 170.36, 173.90. HRMS-ESI⁺ $m/z [M + H]^+$ calcd for $C_{29}H_{33}N_4O_3Cl_2$, 555.1930; found, 555.1919.

4.1.1.7. General Procedures for the Synthesis of 2-Substituted 3-Hydroxypropanamide Derivatives 54a-c, 55a-f, 56a-f, 57, 58, 59a-c (GP7). The corresponding amine A-F (1.2 equiv), a relevant amide 53a-e (1 equiv), and TBAB (0.1 equiv) were dissolved in dry DMF (for 55a-e, 56a-e dry DCM was used), and DIPEA (1 equiv) was then added. After stirring at reflux for 16 h, extraction with DCM and deionized water was performed. The organic phase was washed with saturated NaHCO₃ and dried with anhydrous Na₂SO₄. The solvent was evaporated, and the product was purified by column chromatography over silica gel (S₁₂ DCM/Ace = 7:3).

chromatography over silica gel $(S_{12} \text{ DCM/Ace} = 7:3)$. 4.1.1.7.1. N-Benzyl-2-{4-[bis(3-methylthiophen-2-yl)methylidene]piperidin-1-yl}-3-hydroxypropanamide (**54a**). The synthesis was done according to GP7 with amine A (17) (1.39 mmol, 400 mg), amide 53a (1.16 mmol, 300 mg), TBAB (0.12 mmol, 40 mg), DIPEA (1.16 mmol, 201 μ L), and DMF (3 mL). The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 54a (260 mg, 48%, $R_f = 0.33$ and 0.51 (S₆) as a yellow oil. Formula $C_{26}H_{30}N_2O_2S_2$, FW: 466.66. ¹H NMR (300 MHz, chloroform-d) δ ppm 2.00–2.12 (m, 6 H) 2.25– 2.47 (m, 3 H) 2.67-2.82 (m, 2 H) 2.85-2.98 (m, 2 H) 3.44-3.55 (m, 1 H) 3.86–4.06 (m, 2 H) 4.47 (dd, J = 16.70, 6.15 Hz, 2 H) 5.30 (s, 1 H) 6.77 (d, J = 5.28 Hz, 2 H) 7.14 (d, J = 5.27 Hz, 1 H) 7.21-7.39 (m, 5 H) 7.97-8.09 (m, 1 H). ¹³C NMR (75 MHz, chloroformd) δ ppm 171.3, 141.6, 138.0, 137.4, 133.9, 129.7, 129.5, 128.8, 128.7, 127.7, 127.5, 127.5, 124.6, 124.1, 121.0, 68.1, 58.7, 53.6, 51.3, 43.2, 31.4, 14.7. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₃₀N₂O₂S₂, 467.1827; found, 467.1843.

4.1.1.7.2. 2-{4-[Bis(3-methylthiophen-2-yl)methylidene]piperidin-1-yl}-N-[(2-chlorophenyl)methyl]-3-hydroxypropanamide (**54b**). The synthesis was done according to GP7 with amine A (17) (1.64 mmol, 470 mg), amide **53b** (1.37 mmol, 400 mg), TBAB (0.14 mmol, 44 mg), DIPEA (1.37 mmol, 237 μ L), and DMF (5 mL). The obtained crude product was purified by column chromatography over silica gel (S₁₂) to yield **54b** (315 mg, 46%, R_f = 0.16 and 0.35 (S₉)) as a yellow oil. Formula C₂₆H₂₉ClN₂O₂S₂, FW: 501.10. ¹H NMR (300 MHz, chloroform-*d*) δ ppm 8.58–8.69 (m, 1H), 7.28–7.38 (m, 2H), 7.10–7.23 (m, 4H), 6.77 (d, J = 5.27 Hz, 2H), 4.51 (t, J = 5.27 Hz, 2H), 3.93–4.17 (m, 3H), 3.19 (s, 2H), 2.98–3.14 (m, 2H), 2.54 (d, J = 4.10 Hz, 4H), 2.07 (s, 6H). ¹³C NMR (75 MHz, chloroform-*d*) δ ppm 168.4, 139.1, 136.8, 134.9, 134.2, 133.4, 129.7, 129.6, 129.0, 127.1, 124.4, 122.3, 67.5, 58.7, 51.1, 41.3, 30.0, 14.6. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₂₉ClN₂O₂S₂, 501.1441; found, 501.1037.

4.1.1.7.3. 2-{4-[Bis(3-methylthiophen-2-yl]methylidene]piperidin-1-yl}-N-[(4-fluorophenyl)methyl]-3-hydroxypropanamide (54c). The synthesis was done according to GP7 with amine A (17) (0.70 mmol, 200 mg), amide 53c (0.58 mmol, 160 mg), TBAB (0.06 mmol, 19 mg), DIPEA (0.58 mmol, 100 μ L), and DMF (3 mL). The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **54c** (100 mg, 36%, R_f = 0.24 and 0.55 (S₁₂)) as a yellow oil. Formula C₂₆H₂₉FN₂O₂S₂, FW: 484.65. ¹H NMR (300 MHz, chloroform-d) δ ppm 8.25-8.40 (m, 1H), 7.19-7.33 (m, 2H), 7.13 (d, J = 4.69 Hz, 2H), 6.98 (s, 2H), 6.77 (d, J = 5.28 Hz, 2H), 4.39 (dd, J = 5.86, 11.14 Hz, 2H), 3.86-4.11 (m, 2H), 3.67-3.81 (m, 1H), 3.00-3.14 (m, 2H), 2.83-2.96 (m, 2H), 2.45 (t, J = 5.27 Hz, 4H), 2.07 (s, 6H). ¹³C NMR (75 MHz, chloroform-d) δ ppm 169.9, 163.7, 160.5, 140.2, 137.1, 134.0, 133.7, 133.7, 129.5, 129.3, 129.2, 124.3, 121.8, 115.7, 115.5, 67.8, 58.6, 51.2, 42.5, 30.8, 14.6. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₂₉FN₂O₂S₂, 485.1733; found, 485.1728.

4.1.1.7.4. 2-((3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-(methyl)amino)-N-benzyl-3-hydroxypropanamide (**55a**). The synthesis was done according to GP7 with amine **B** (**20**) (1.2 mmol, 313 mg), amide **53a** (1 mmol, 257 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **55a** (131 mg, 30%, $R_f = 0.65$ and 0.42 (S_{12})). ¹H NMR (chloroform-d): δ ppm 7.61 (t. 1H, NH), 7.40–7.05 (m, 10H, Ar), 6.98–6.89 (m, 1H, ArCH=CHAr), 6.88–6.63 (m, 4H, ArCH= CHAr, Ar), 5.42–5.22 (m, 1H, CH=), 4.38–4.16 (m, 2H, CH₂NH), 3.89 (ddd, 1H, J = 11.1; 7.7; 4.7 Hz, CH₂'OH), 3.74 (ddd, 1H, J = 11.1; 5.2; 4.2 Hz, CHNCH₃), 3.12 (dt, 1H, J = 8.0; 4.5 Hz, CH₂"OH), 2.71–2.38 (m, 2H, CH₂CH₂C=), 2.38–2.16 (m, 2H, CH₂CH₂C=), 1.97 (d, 3H, CH₃–N). OH proton was not detected. ¹³C NMR (chloroform-*d*): δ ppm 174.02 (CONH), 143.60 (Ph₂C=), 142.30 (C_{Dche}), 142.20 (C_{Dche}), 137.01(C_{Dche}), 136.96 (C_{Dche}), 134.81 (C_{Ph}), 133.70 (C_{Dche}), 133.24 (C_{Dche}), 131.21 (C_{Dche}), 131.11 (C_{Dche}), 130.96 (ArCH=CHAr), 130.88 (ArCH=CHAr), 129.50 (C_{Dche}), 129.42 (C_{Dche}), 129.48 (CH=CPh₂), 128.96 (C_{Dche}), 128.68 (C_{Dche}), 128.26 (C_{Ph}), 128.00 (C_{Ph}), 127.25 (C_{Ph}), 127.06-(C_{Ph}), 126.98 (C_{Ph}), 126.84 (C_{Dche}), 67.55 (CHNCH₃), 66.78 (CH₂OH), 53.26 (CH₂CH₂CH=), 40.68 (CH₂NH), 38.50 (CH₃N), 27.15 (CH₂CH₂CH=) HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₉H₃₀N₂O₂, 439.2386; found, 439.2374.

4.1.1.7.5. 2-((3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-(methyl)amino)-N-(2-chlorobenzyl)-3-hydroxypropanamide (55b). The synthesis was done according to GP7 with amine B (20) (1.2 mmol, 313 mg), amide 53b (1 mmol, 290 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 µL), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 55a (141 mg, 30%, $R_f = 0.65$ and 0.42 (S₁₂)). ¹H NMR (chloroform-*d*): δ ppm 7.66 (d, 1H, NH), 7.42–7.04 (m, 12H, Ar), 6.89-6.77 (m, 1H, ArCH=CHAr), 6.69 (dd, 1H, ArCH=CHAr), 5.46 (m, 1H, CH=), 4.46-4.18 (m, 2H, CH₂NH), 4.12 (q, 1H, J = 7.1 Hz, CH₂'OH), 3.91 (ddd, 1H, J = 10.2; 8.0; 2.0 Hz, CHNCH₃), 3.16 (tt, 1H, CH₂"OH), 2.78-2.44 (m, 2H, $CH_2CH_2C=$), 2.39–2.16 (m, 2H, $CH_2CH_2C=$), 2.10–1.99 (m, 3H, CH₃-N) ppm. OH proton was not detected. ¹³C NMR (chloroform-d): δ ppm 173.81 (CONH), 143.67 (Ph₂C=), 142.39 $(C_{\rm Ph})$, 135.40 $(C_{\rm Ph})$, 137.05 $(C_{\rm Dche})$, 137.00 $(C_{\rm Dche})$, 134.87 $(C_{\rm Dche})$, 134.74 (C_{Dche}), 133.68 (C_{Dche}), 131.16 (C_{Dche}), 131.04 (ArCH= CHAr), 131.00 (ArCH=CHAr), 128.82 (C_{Ph}), 128.68 (C_{Ph}), 128.44 $(C_{\rm Ph})$, 128.28 $(C_{\rm Ph})$, 128.03 $(C_{\rm Dche})$, 127.99 $(C_{\rm Dche})$, 127.40 $(C_{\rm Dche})$, 127.30 (C_{Dche}), 127.02 ($C=CPh_2$), 126.97 (C_{Dche}), 126.89(C_{Dche}), 67.81 (CHNCH₃), 58.55(CH₂OH), 57.67 (CH₂CH₂CH=), 42.73 (CH₂NH), 38.80 (CH₂N), 27.16 (CH₂CH₂CH=).

4.1.1.7.6. 2-((3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-(methyl)amino)-N-(4-chlorobenzyl)-3-hydroxypropanamide (55c). The synthesis was done according to GP7 with amine $B\ (20)\ (1.2$ mmol, 313 mg), amide 53c (1 mmol, 290 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 55a (141 mg, 30%, $R_f = 0.65$ and 0.41 (S_{12})). ¹H NMR (chloroform-d): δ ppm 7.53 (dt, 1H, NH), 7.41– 7.07 (m, 9H, Ar), 6.92-6.65 (m, 5H, ArCH=CHAr, Ar), 5.49-5.29 (m, 1H, CH=), 4.44-4.22 (m, 2H, CH₂NH), 4.06-3.91 (m, 1H, CH₂'OH), 3.92–3.65 (m, 1H, CHNCH₃), 3.10 (m, 1H, CH₂"OH), 2.55-2.38 (m, 2H, CH₂CH₂C=), 2.31-2.13 (m, 2H, CH₂CH₂C=), 2.04 (s, 3H, CH₃N) ppm. OH proton was not detected. ¹³C NMR (chloroform-d): δ ppm 173.92 (CONH), 143.81 (Ph₂C=), 143.24 (C_{Dche}), 142.39 (C_{Dche}), 137.00 (C_{Dche}), 136.93 (C_{Dche}), 134.75 (C_{Ph}), 133.85 (C_{Dche}), 133.64 (C_{Dche}), 133.14 (C_{Dche}), 133.11 (C_{Dche}), 131.36 ($C_{\rm Ph}$ -Cl), 131.29 ($C_{\rm Ph}$), 130.96 (ArCH=CHAr), 130.86 (ArCH=CHAr), 129.00 (CH=CPh₂), 128.68 (C_{Ph}), 128.51(C_{Ph}), 128.32 (C_{Ph}), 128.09 (C_{Ph}), 127.97 (C_{Dche}), 127.45 (C_{Dche}), 127.37 (C_{Dche}), 126.94 (C_{Dche}), 67.10 (CHNCH₃), 59.96 (CH₂OH), 57.35 (CH₂CH₂CH=), 42.07 (CH₂NH), 41.08 (CH₃N), 26.35 $(CH_{2}CH_{2}CH_{2})$

4.1.1.7.7. 2-((3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-(methyl)amino)-N-(4-methylbenzyl)-3-hydroxypropanamide (55d). The synthesis was done according to GP7 with amine B (20)(1.2 mmol, 313 mg), amide 53d (1 mmol, 276 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 55a (136 mg, 30%, R_f = 0.66 and 0.43 (S₁₂)). ¹H NMR (chloroform-d): δ ppm 7.62 (dt, 1H, NH), 7.44-7.12 (m, 8H, Ar), 7.08-6.63 (m, 6H, ArCH=CHAr, Ar), 5.41-5.06 (m, 1H, CH=), 4.32-4.15 (m, 2H, CH₂NH), 4.06-3.82 (m, 1H, CH₂'OH), 3.79-3.66 (m, 1H, CHNCH₃), 3.18-3.02 (m, 1H, CH₂"OH), 2.54–2.05 (m, 4H, CH₂CH₂C=), 1.93 (s, 3H, NCH₃). OH proton was not detected. ¹³C NMR (chloroform-d): δ ppm 173.84 (CONH), 161.89 (d, ${}^{1}J_{C-F}$ = 245.2 Hz, C_{Ar} -F), 143.79 $(Ph_2C=)$, 137.01 (C_{Dche}) , 136.95 (C_{Dche}) , 134.87 (C_{Dche}) , 134.24 $(C_{Ar}-CH_2)$, 134.17 (d, ${}^{4}J_{C-F} = 4.0$ Hz, C_{Ar}), 134.14 (C_{Dche}), 131.10

(ArCH=CHAr), 130.91 (ArCH=CHAr), 129.16 (C_{Ar}), 129.05, 128.94 (C_{Ar}), 128.64 (d, ${}^{3}J_{C-F}$ = 7.4 Hz, C_{Ar}), 128.59(C_{Dche}), 128.08 (C_{Dche}), 127,42 (C_{Ar}), 126.94 (C_{Ar}), 115.52 (C_{Ar} ortoF), 115.20 (d, ${}^{2}J_{C-F}$ = 21.5 Hz, C_{Ar}), 67.96 (CHNCH₃), 58.65 (CH₂OH), 55.19 (CH₂CH₂CH=), 42.00 (CH₂Ph), 36.92 (CH₃N), 26.61 (CH₂CH₂CH=)

4.1.1.7.8. 2-((3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-(methyl)amino)-N-(4-methylbenzyl)-3-hydroxypropanamide (55e). The synthesis was done according to GP7 with amine B (20) (1.2 mmol, 313 mg), amide 53e (1 mmol, 271 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 µL), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 55a (135 mg, 30%, R_f = 0.66 and 0.42 (S_{12})). ¹H NMR (chloroform-d): δ ppm 7.57 (t, 1H, NH), 7,43-7.11 (m, 10H, Ar), 7.07-6.95 (m, 2H, Ar), 6.91-6.79 (m, 1H, ArCH=CHAr), 6.77-6.67 (m, 1H, ArCH=CHAr), 5.52-5.26 (m, 1H, CH=), 4.50–4.03 (m, 2H, CH₂NH), 3.90 (ddd, 1H, I = 11.0; 8,0; 5.6 Hz, $CH_2'OH$), 3.74 (dt, 1H, J = 11.1; 4.5 Hz, $CHNCH_3$), 3.13 (td, 1H, J = 8.1; 3.8 Hz, CH2"OH), 2.74-2.37 (m, 2H, $CH_2CH_2C=$), 2.32 (d, 2H, $CH_2CH_2C=$), 2.10–1.95 (m, 6H, $CH_3=$ N, CH_3Ar). OH proton was not detected. ¹³C NMR (chloroform-*d*): δ ppm 173,80 (CONH), 143,66 (Ph₂C=), 137.07 (C_{Dche}), 137.03 (C_{Dche}) , 136.97 (C_{Dche}) , 136.78 (C_{Dche}) , 135.28 (C_{Dche}) , 135.26 (C_{Ar}) CH₂), 134.88 (C_{Ar}-CH₃), 134.75 (C_{Dche}), 133,77 (C_{Dche}), 133,72-(C_{Dche}), 131.19 (ArCH=CHAr), 131.07 (ArCH=CHAr), 129.29 (C_{Dche}) , 128,79 (C_{Dche}) , 128,66 (C_{Dche}) , 128,28 (C_{Dche}) , 128,02 (C_{Ar}) , $127.47(C_{Ar})$, $127.39(C_{Ar})$, $127.03(C_{Ar})$, 66.90 (CHNCH₃), 60.37(CH₂OH), 58,39 (CH₂CH₂CH=), 42.40 (CH₂Ar), 38,79 (CH₃N), 26.85 (CH₂CH₂CH=), 21.09 (CH₃Ar).

4.1.1.7.9. N-Benzyl-2-((3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-3-hydroxypropanamide (56a). The synthesis was done according to GP7 with amine C (21)(1.2 mmol, 315 mg), amide 53a (1 mmol, 257 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 56a (132 mg, 30%, R_f = 0.70 or 0.57 (\tilde{S}_{12})). ¹H NMR (chloroform-*d*): δ ppm 7.57 (br s, 1H, NHCO), 6.98-7.37 (m, 13H, Ar), 5.76 (t, 1H, CH=), 4.37-4.48 (m, 3H, CH₂'OH, CH₂Ar), 4.06 (t, 1H, CH-NCH₃), 3,13-3,44 (m, 3H, $ArCH_2-CH_2Ar$, $CH_2'OH$), 2.83–3,03 (m, 2H, $ArCH_2-CH_2Ar$), 2.68-2.81 (m, 2H, $CH_2CH_2C=$), 2.21-2.34 (m, 2H, CH₂CH₂C=), 2.17 (s, 3H, CH₃). OH proton was not detected. ¹³C NMR (chloroform-d): δ ppm 172.97 (CONH), 144.42 (C_{Ar}), 140.95 (CH=), 139.75 (C_{Ar}), 139.25 (C_{Ar}), 138,09 (C_{Ar}), 137.02 (C_{Ar}) , 130.04 (C_{Ar}) , 128,64 (C_{Ar}) , 128,47 (C_{Ar}) , 128,33 (C_{Ar}) , 128,11 (C_{Ar}) , 128,04 (C_{Ar}) , 127.57 (C_{Ar}) , 126.07 (C_{Ar}) , 125.76 (C_{Ar}) , 127.19 (C_{Ar}) 126.07 (C_{Ar}) , 125.76 (C_{Ar}) , 66.92 (CHN), 59.98 (CH_2OH) , 57.34 (CH₂CH₂CH=), 42.87 (CH₂NH), 41.25 (CH₃N), 33.70 $(ArCH_2-CH_2Ar)$, 32.01 $(ArCH_2-CH_2Ar)$, 27.19 $(CH_2CH_2CH=)$. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₉H₃₃N₂O₂, 441.2542; found, 441.2530.

4.1.1.7.10. N-(2-Chlorobenzyl)-2-((3-(10.11-dihydro-5H-dibenzo-[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-3-hydroxypropanamide (56b). The synthesis was done according to GP7 with amine C (21) (1.2 mmol, 315 mg), amide 53b (1 mmol, 290 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 µL), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **56b** (128 mg, 30%, R_f = 0.74 or 0.55 (S₁₂)). ¹H NMR (chloroform-d): δ ppm 7.52-7.83 (m, 1H, CONH), 6.89-7.37 (m, 12H, Ar), 5.74 (br s, 1H, CH=C), 3,75-4.51 (m, 4H, CH₂OH, CH₂Ar), 2.84-3,06 (m, 3H, ArCH₂-CH₂Ar, CHN), 2.66–2.81 (m, 2H, ArCH₂CH₂Ar) 2.46–264 (m, 2H, CH₂CH₂CH=), 2.21-2.37 (m, 2H, CH₂CH₂CH=), 2.08-2.19 (m, 3H, CH₃) ppm. OH proton was not detected. ¹³C NMR (chloroform-*d*): δ ppm 173,20 (CONH), 144.43 (C_{Ar}), 140.92 (CH=C), 139.71 (C_{Ar}), 139.27 (C_{Ar}), 136.97(C_{Ar}), 136.68 (C_{Ar}), 130.06(C_{Ar}), 129.48 (C_{Ar}), 128,94 (C_{Ar}), 128,72(C_{Ar}), 128,41 (C_{Ar}), 128,16(C_{Ar}), 127.63(C_{Ar}), 127.47 (C_{Ar}), 126.14 (C_{Ar}), 125.77 (CH= C), 66.94 (CHN), 59.99 (CH₂OH), 57.35 (CH₂CH₂CH=), 42.13 (CH₂NH), 41.21 (CH₃N), 33,71 (ArCH₂-CH₂Ar), 32.01 (ArCH₂-

CH₂Ar), 27.18 (CH₂CH₂CH=) HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₉H₃₂N₂O₂Cl, 475.2152; found, 475.2142

4.1.1.7.11. N-(4-Chlorobenzvl)-2-((3-(10.11-dihvdro-5H-dibenzo-[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-3-hydroxypropanamide (56c). The synthesis was done according to GP7 with amine C (21) (1.2 mmol, 315 mg), amide 53c (1 mmol, 290 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 55c (132 mg, 30%, R_f = 0.74 or 0.57 (S₁₂)). ¹H NMR (chloroform-d): δ ppm 7.73–7.57 (m, 1H, CONH) 7.15-7.10 (m, 10H, Ar) 7.01-6.61 (m, 2H, Ar) 5.78 (d, 1H, J = 8,2 Hz, CH=), 4.49-4.33 (m, 2H, NHCH₂Ar), 3.96 (dd, 1H, J = 11.2; 7.6 Hz, CH₂'OH), 3.81 (dd, 1H, J = 11.2, 4.2 Hz, CH₂"OH), 3,23 (dd, 1H, J = 7.6, 4.1 Hz, CHN), 2.96-2.74 (m, 4H, $ArCH_2CH_2Ar)$, 2.62 (dt, 2H, J = 13.0, 6.5 Hz, $CH_2CH_2CH=$), 2.42-2.26 (m, 2H, CH₂CH₂CH=), 2.20 (s, 3H, CH₃). Proton was not detected. ¹³C NMR (chloroform-d): δ ppm 173.75 (NHCO), 144.57(C_{Ar}), 140.80 (CH=C),139.28 (Ar), 136.91(Ar), 135.40 (C_{Ar}), 133,51 (C_{Ar}), 128,88 (Ar), 128,47 (Ar), 128.56 (Ar), 128,41 (Ar), 128,12 (Ar), 127.60 (C_{Ar}), 127.21(C_{Ar}), 127.23 (C_{Ar}), 126.09 (C_{Ar}) , 125.79 (C_{Ar}) , 86.21 (CH=C), 74.01 (CHN), 60.41 (CH_2OH) , 58,22 (CH₂CH₂CH=), 40.96 (NHCH₂Ar), 38.00 (CH₃N), 32.04 $(ArCH_2-CH_2Ar)$, 28.31 $(CH_2CH_2CH=)$

4.1.1.7.12. N-(4-Fluorobenzyl)-2-((3-(10,11-dihydro-5H-dibenzo-[a,d][7]annulen-5-ylidene)propyl)(methyl)amino)-3-hydroxypropanamide (56d). The synthesis was done according to GP7 with amine C (21) (1.2 mmol, 315 mg), amide 53d (1 mmol, 276 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 µL), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **55d** (132 mg, 30%, $R_f = 0.75$ or 0.56 (S₁₂)). ¹H NMR (chloroform-d): δ ppm 7.76 (s, 1H, CONH), 7.29-6.82 (m, 12H, Ar), 5.71 (s, 1H, CH=C), 4.41-4.18 (m, 2H, NHCH₂Ar₁), 3.96 (dd, 1H, J = 11.2, 7.7 Hz, CH₂'OH), 3,82 (dd, 1H, CH₂'OH, J = 11.2, 4.2 Hz), 3.31 (s, 1H, CHN), 2,96 (d, 1H, J = 13,2 Hz, ArCH₂CH₂'Ar), 2.84–2.71 (m, 3H, ArCH₂'CH₂"Ar), 2.69–2.50 (m, 2H, CH₂CH₂CH=), 2.39-2.22 (m, 2H, CH₂CH₂CH=), 2.15 (s, 3H, CH₃). OH proton was not detected. ¹³C NMR (chloroform*d*): δ ppm 173.66 (NHCO), 162.06 (d, ${}^{1}J_{C-F}$ = 245.6 Hz), 139.73 (CH=C), 136.92 (C_{Ar}) , 136.96 (C_{Ar}) , 134.01 (C_{Ar}) , 133,97 $(d, {}^{4}J_{C-F})$ = 3,3 Hz), 130.18 (C_{Ar}), 129.29 (C_{Ar}), 129.18 (C_{Ar}), 128,17 (C_{Ar}), 128,10 (d, ${}^{3}J_{C-F}$ = 8,3 Hz), 127.63 (C_{Ar}), 126.14 (C=CH), 115.45 (d, ${}^{2}J_{C-F} = 21.6$ Hz), 67.48 (CHN), 57.90 (CH₂OH), 53,20 (CH₂CH₂CH=), 42.11 (NHCH₂Ar), 38.94 (CH₃N), 33.70 (ArCH₂-CH₂Ar), 32.00 (ArCH₂-CH₂Ar), 28.10, (CH₂CH₂CH=). HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₉H₃₂FN₂O₂, 459.2440; found, 459.2448.

4.1.1.7.13. 2-((3-(10.11-Dihvdro-5H-dibenzo[a.d][7]annulen-5ylidene)propyl)(methyl)amino)-3-hydroxy-N-(4-methylbenzyl)propanamide (56e). The synthesis was done according to GP7 with amine C (21) (1.2 mmol, 315 mg), amide 53e (1 mmol, 271 mg), TBAB (0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μL), DCM 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 55e (136 mg, 30%, $R_f = 0.70$ or 0.57 (S₁₂)). ¹H NMR (chloroform-*d*): δ ppm 7.49 (s, 1H, CONH), 7.39–6.84 (m, 12H, Ar), 5.75 (t, 1H, J = 7.3 Hz, CH=C), 4.35 (d, 2H, J = 6.0 Hz, NHCH₂Ar), 4.04–3.72 (m, 2H, CH₂OH), 3,47–3.11 (m, 1H, CHN), 2.98–2.91 (m, 2H, ArCH₂CH₂'Ar), 2.75 (dd, 2H, J = 12.6, 6.3 Hz, ArCH₂CH₂"Ar), 2.56 (ddd, 2H, J = 11.0, 7.6, 3.7 Hz, $CH_2CH_2CH=$), 2.34–2.24 (m, 5H, $CH_2CH_2CH=$, $Ar-CH_3$), 2.16 (s, 3H, CH₃). OH proton was not detected. ¹³C NMR (chloroformd): δ ppm 172.82 (NHCO), 144.41 (C_{Ar}), 140.94 (CH=C), 139.74(C_{Ar}), 139.23 (C_{Ar}), 137.08 (C_{Ar}), 137.01 (C_{Ar} -CH₃), 135.03 (C_{Ar}) , 130.02 (C_{Ar}) , 129.29 (C_{Ar}) , 128.44 (C_{Ar}) , 128.29 (C_{Ar}) , 128,09 (C_{Ar}) , 128,01 (C_{Ar}) , 127.65 (C_{Ar}) , 127.55 (C_{Ar}) , 127.17 (C_{Ar}) , 126.05 (C_{Ar}), 125.75 (CH=C), 66.90 (CHN), 59.98 (CH₂OH), 57.34 (CH₂CH₂CH=), 42.64 (NHCH₂Ar), 41.25 (CH₃N), 33.69 (ArCH₂-CH₂Ar), 32.00 (ArCH₂-CH₂Ar), 27.16 (CH₂CH₂CH=), 21.08 (C_{Ar}- CH_3)

4.1.1.7.14. N-Benzyl-2-[4-(9H-fluoren-9-ylidene)piperidin-1-yl]-3hydroxypropanamide (57). The synthesis was done according to GP7 with amine **D** (25) (0.49 mmol, 120 mg), amide 53a (0.40 mmol, 103 mg), TBAB (0.04 mmol, 13 mg), DIPEA (0.40 mmol, 70 μ L), and DMF (2 mL). The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **57** (55 mg, 33%, R_f = 0.33 and 0.45 (DCM/Ace 7:3)) as a yellow oil. Formula C₂₈H₂₈N₂O₂. FW: 424.54. ¹H NMR (300 MHz, chloroform-*d*) δ ppm 7.63–7.91 (m, 3H), 7.17–7.42 (m, 11H), 5.88–6.00 (m, 1H), 4.50 (d, *J* = 2.93 Hz, 1H), 4.42 (s, 1H), 3.82–4.05 (m, 2H), 3.67–3.83 (m, 1H), 3.18–3.59 (m, 2H), 2.76–3.04 (m, 2H), 2.57 (s, 1H), 2.38–2.49 (m, 1H), 1.20–1.50 (m, 2H).

4.1.1.7.15. N-Benzyl-2-(4-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1-yl)-3-hydroxypropanamide (58). The synthesis was done according to GP7 with amine E (26) (0.70 mmol, 290 mg), amide 53a (0.58 mmol, 150 mg), TBAB (0.06 mmol, 19 mg), DIPEA (0.58 mmol, 100 μ L), and DMF (3 mL). The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 58 (105 mg, 40%, R_f = 0.22 and 0.54 (DCM/Ace 7:3)) as a yellow oil. Formula $C_{30}H_{32}N_2O_2$, FW: 452.60. ¹H NMR (300 MHz, chloroform-d) δ ppm 7.57–7.66 (m, 1H), 7.21–7.33 (m, 5H), 7.07–7.19 (m, 6H), 7.01 (d, *J* = 7.03 Hz, 2H), 4.44 (d, *J* = 5.27 Hz, 3H), 3.21–3.43 (m, 3H), 3.06–3.18 (m, 2H), 2.77–3.02 (m, 3H), 2.49–2.72 (m, 6H).

4.1.1.7.16. N-Benzyl-2-((2-(((diphenylmethylene)amino)oxy)ethyl)(methyl)amino)-3-hydroxypropanamide (59a). The synthesis was done according to GP7 with amine F (32) (1.2 mmol, 305 mg), amide 53a (1 mmol, 257 mg), TBAB ((0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DMF 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **59a** (130 mg, 30%, $R_f = 0.58 (S_{12})$) ¹H NMR (chloroform-*d*): δ ppm 7.71 (s, 1H, NH), 7.49–7.11 (m, 13H, Ar), 7.12–7.00 (m, 2H, Ar), 4.46-4.28 (m, 1H, CH₂CH₂'ON=), 4.27-4.13 (m, 2H, CH₂NH), 4.13-4.03 (m, 1H, CH₂CH₂"ON=), 3,99-3.88 (m, 1H, CH₂'OH), 3,79 (dd, 1H, CHNCH₃, J = 11.4; 4.8 Hz), 3.26 (dd, 1H, CH_2 "OH, J = 7.0; 4.7 Hz,), 2.89 (td, 2H, CH_2CH_2 'ON=), 2.34 (s, 3H, NCH₃). OH proton was not detected. ¹³C NMR (chloroform-*d*): δ ppm 173.46 (CONH), 157.23 (Ph₂C=N), 138.07 (C_{Ar}), 136.09 (C_{Ar}) , 133.08 (C_{Ar}) , 129.47 (C_{Ar}) , 129.03 (C_{Ar}) , 128.99 (C_{Ar}) , 128.90 (C_{Ar}) , 128.67 (C_{Ar}) , 128.58 (C_{Ar}) , 128.49 (C_{Ar}) , 128.25 (C_{Ar}) , 128.11 (C_{Ar}), 128.08 (C_{Ar}), 127.80 (C_{Ar}), 127.77 (C_{Ar}), 127.55 (C_{Ar}), 127.48 (C_{Ar}) , 127.18 (C_{Ar}) , 72.24 (CHN), 67.38 $(CH_2CH_2ON=)$, 58.43 (CH_2OH) , 53.77 $(CH_2CH_2ON=)$, 42.67 (CH_2NH) , 38.87 (CH_3N) HRMS-ESI⁺ $m/z [M + H]^+$ calcd for C₂₆H₃₀N₃O₃, 432.2287; found, 432.2283.

4.1.1.7.17. (2-Chlorobenzyl)-2-((2-(((diphenylmethylene)amino)oxy)ethyl)(methyl)amino)-3-hydroxypropanamide (**59b**). The synthesis was done according to GP7 with amine F (**32**) (1.2 mmol, 305 mg), amide **53b** (1 mmol, 290 mg), TBAB ((0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DMF 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **59b** (130 mg, 30%, $R_f = 0.60$ (S₁₂)). ¹H NMR (300 MHz, chloroform-d) δ ppm 2.39 (s, 3 H, NCH₃) 2.89–3.00 (m, 2 H, CH₂CH₂ON=) 3.33 (dd, J = 7.62. 4.10 Hz, 1 H, CHNCH₃) 3.82 (dd, J = 11.14, 4.69 Hz, 1 H, CH'H"OH) 3.92–4.02 (m, 1 H, CH'H"OH) 4.14–4.35 (m, 4 H, CH₂CH₂ON=, NHCH₂Ar) 7.13– 7.50 (m, 14 H, Ar) 7.73 (t, J = 5.86 Hz, 1 H, NHCO). HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₂₉N₃O₃Cl, 466.1897; found, 466.1900.

4.1.1.7.18. 2-((2-(((Diphenylmethylene)amino)oxy)ethyl)-(methyl)amino)-N-(4-fluorobenzyl)-3-hydroxypropanamide (**59c**). The synthesis was done according to GP7 with amine F (**32**) (1.2 mmol, 305 mg), amide **53c** (1 mmol, 276 mg), TBAB ((0.01 mmol, 0.32 mg), DIPEA (1 mmol, 174 μ L), DMF 5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **59c** (130 mg, 30%, R_f = 0.57 (S₁₂)). ¹H NMR (300 MHz, chloroform-d) δ ppm 2.39 (d, J = 1.76 Hz, 3 H, NCH₃) 2.84–2.99 (m, 2 H, CH₂CH₂ON=) 3.32 (dt, J = 7.18, 3.74 Hz, 1 H, CHNCH₃) 3.83 (dd, J = 11.14, 4.10 Hz, 1 H, CH'H"OH) 3.92–4.03 (m, 1 H, CH'H"OH) 4.04–4.22 (m, 2 H, CH₂CH₂ON=) 4.22–4.31 (m, 2 H, NHCH₂Ar) 6.89–7.50 (m, 14 H, Ar) 7.68 (d, J = 5.27 Hz, 1 H, NHCO)). HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₂₉N₃O₃F, 450,2193; found, 450,2189. 4.1.1.7.19. *N-Benzyl-2-bromopropanamide* (62). The synthesis was done according to GP8 *N*-benzylamine (8.8 mmol, 962 μL) with 2-bromopropanoic acid (60) (8 mmol, 724 μL), TEA (9.6 mmol, 1.24 mL), T3P (8 mmol, 4.76 mL), and DCM (32 mL) to yield 62 (1.64 g, 85%, $R_f = 0.65$ (S₁). Formula: $C_{10}H_{12}BrNO$ (241.01 g/mol). ¹H NMR and ¹³C NMR consistent with literature data^{57,58} (300 MHz, chloroform-d) δ ppm 7.23–7.41 (m, 5H), 6.71 (br s, 1H), 4.44–4.50 (m, 2H), 4.11 (q, J = 7.18 Hz, 1H), 1.91 (d, J = 6.92 Hz, 3H).

4.1.1.7.20. *N-Benzyl-2-bromobutanamide* (**63a**). The synthesis was done according to GP8 *N*-benzylamine (8.8 mmol, 962 μL) with 2-bromopropanoic acid (**61**) (8 mmol, 850 μL), TEA (9.6 mmol, 1.24 mL), T3P (8 mmol, 4.76 mL), and DCM (32 mL) to yield **63** (1.63g, 80%, R_f = 0.60 (S₁)). Formula: C₁₁H₁₄BrNO (255.01 g/mol). ¹H NMR and ¹³C NMR consistent with literature data.^{57,58 1}H NMR (300 MHz, chloroform-*d*) δ ppm 7.30–7.42 (m, 3H), 7.16–7.26 (m, 2H), 6.72 (br s, 1H), 4.40–4.51 (m, 2H), 4.32 (dd, *J* = 5.00, 7.57 Hz, 1H), 1.93–2.28 (m, 2H), 0.98–1.10 (m, 3H).

4.1.1.7.21. 2-Bromo-N-(2-chlorobenzyl)butanamide (**63b**). The synthesis was done according to GP8 (2-chlorophenyl)methanamine (8.8 mmol, 1062 μ L) with 2-bromopropanoic acid (**61**) (8 mmol, 850 μ L), TEA (9.6 mmol, 1.24 mL), T3P (8 mmol, 4.76 mL), and DCM (32 mL) to yield **63** (1.9 g, 82%, $R_f = 0.7$ (S₁)). Formula: C₁₁H₁₃BrClNO (288.98 g/mol). ¹H NMR (500 MHz, chloroform-*d*) δ ppm 7.35–7.42 (m, 2H), 7.20–7.27 (m, 2H), 6.94 (br s, 1H), 4.55 (d, *J* = 6.30 Hz, 2H), 4.34 (dd, *J* = 5.01, 7.59 Hz, 1H), 2.13–2.22 (m, 1H), 2.02–2.10 (m, 1H), 0.97–1.09 (m, 3H). ¹³C NMR (126 MHz, chloroform-*d*) δ ppm 168.6. 134.94, 133.63, 129.7, 129.14, 129.4, 53.6, 42.1, 29.3, 11.7

4.1.1.8. General Procedure for the Synthesis of 2-Substituted Propanamide Derivatives **64***a*,**b**, **65**, **66***a*,**b**, **67**, **68**. The general procedure is corresponding to the GP7 method (general procedures for the synthesis of 2-substituted 3-hydroxypropanamide derivatives described in section 4.1.1.7).

4.1.1.8.1. *N*-Benzyl-2-(4-(bis(3-methylthiophen-2-yl)methylene)piperidin-1-yl)butanamide(**64a**). The synthesis was done according to GP7 with amine **A** (17) (0.48 mmol, 135 mg), amide **63a** (0.4 mmol, 102 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4 mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **59c** (101 mg, 55%, R_f = 0.15 (S_{13})). ¹H NMR (300 MHz, chloroformd) δ 7.23–7.43 (m, 9H), 7.12 (d, J = 4.69 Hz, 2H), 6.78 (d, J = 5.27 Hz, 2H), 5.31–5.31 (m, 1H), 5.32 (t, J = 5.57 Hz, 1H), 4.36–4.50 (m, 4H), 2.89 (t, J = 6.15 Hz, 1H), 2.46–2.69 (m, 4H), 2.24–2.33 (m, 4H), 2.10 (s, 6H), 1.67–1.81 (m, 2H), 0.89–1.03 (m, 5H). ¹³C NMR (75 MHz, chloroform-d) δ 173.0, 168.9, 159.4, 143.6, 138.0, 133.6, 128.1, 124.8, 124.3, 123.8, 119.7, 74.5, 70.1, 51.5, 43.2, 31.9, 25.1, 21.3, 14.5, 11.3, 8.9.

4.1.1.8.2. 2-(4-(*Bis*(3-methylthiophen-2-yl)methylene)piperidin-1-yl)-*N*-(2-chlorobenzyl)butanamide (**64b**). The synthesis was done according to GP7 with amine **A** (17) (0.48 mmol, 135 mg), amide **63b** (0.4 mmol, 115 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4 mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **64b** (119 mg, 60%, R_f = 0.25 (S₁₃)). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 0.89–1.02 (m, 3 H, CH₂CH₃) 1.67–1.78 (m, 2 H, CH₂CH₃) 2.10 (s, 6 H, tiophCH₃) 2.25–2.35 (m, 4 H, Ppd) 2.42–2.53 (m, 2 H, Ppd) 2.54–2.64 (m, 2 H, Ppd) 2.87 (t, *J* = 6.15 Hz, 1 H, CHNCH₃) 4.46–4.59 (m, 2 H, NHCH₂Ar) 6.73–6.81 (m, 2 H, Ar) 7.12 (d, *J* = 5.27 Hz, 2 H, Tiof) 7.18–7.27 (m, 3 H, Tiof, Ar) 7.31–7.42 (m, 3 H, Ar) 7.60 (br s, 1 H, NHCO).

4.1.1.8.3. N-Benzyl-2-((2-(((diphenylmethylene)amino)oxy)ethyl)(methyl)amino)propanamide (65). The synthesis was done according to GP7 with amine F (32) (0.48 mmol, 122 mg), amide 62 (0.4 mmol, 96 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4 mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 65 (191 mg, 55%, R_f = 0.3 (S_{13})). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.22 (d, *J* = 7.03 Hz, 3 H, COCHCH₃) 1.48–1.59 (m, 2 H,) 2.26 (s, 3 H) 2.76 (t, *J* = 5.57 Hz, 2 H) 3.27 (q, *J* = 7.03 Hz, 1 H) 4.09–4.31 (m, 4 H) 4.46 (d, J = 5.86 Hz, 1 H) 7.06–7.52 (m, 16 H) 7.57–7.70 (m, 1 H). ¹³C NMR (75 MHz, chloroform-*d*) δ 173.8, 159.2, 138.7, 136.1, 129.3, 129.0, 128.3, 128.1, 127.9, 127.7, 127.2, 72.3, 63.0, 53.3, 42.7, 38.4. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₃₀N₃O₂, 416.2338; found, 416.2327.

4.1.1.8.4. N-Benzyl-2-((2-(((diphenylmethylene)amino)oxy)ethyl)(methyl)amino)butanamide (66a). The synthesis was done according to GP7 with amine F (32) (0.48 mmol, 122 mg), amide 63a (0.4 mmol, 102 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4 mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3)to yield **66a** (106 mg, 62%, $R_f = 0.3$ (S₁₃)). ¹H NMR (300 MHz, chloroform-d) δ ppm 0.98 (t, J = 7.33 Hz, 3 H, CH₂CH₃) 1.58–1.76 (m, 1 H, CH'H"CH₃) 1.78–1.92 (m, 1 H, CH'H"CH₃) 2.30 (s, 3 H, NCH₃) 2.75–2.92 (m, 2 H, CH₂CH₂ON=) 3.00 (t, I = 6.45 Hz, 1 H, CHNCH₃) 4.05-4.17 (m, 1 H, CH₂CH'H"ON=) 4.21-4.28 (m, 2 H, NHCH₂Ar) 4.30-4.52 (m, 1 H, CH₂CH'H"ON=) 7.07-7.50 (m, 16 H, Ar, NHCO). ¹³C NMR (75 MHz, chloroform-d) δ 173.33, 156.90, 138.86, 136.26, 133.22, 129.40, 129.11, 128.86, 128.66, 128.44, 128.27, 128.10, 127.83, 127.44, 127.03, 72.69, 69.51, 54.23, 42.80, 38.53, 20.67, 11.87. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C27H32N3O2, 430.2495; found, 430.2494.

4.1.1.9. General Procedure for the Synthesis of N-Benzyl-2bromopropanamide and N-Benzyl-2-bromobutanamide Derivatives **62**, **63a**,**b** (GP8). Under an argon atmosphere, 2-bromopropanoic acid (**60**) or 2-bromobutanoic acid (**61**)(1 equiv) was dissolved in anhydrous DCM, and *n*-propanephosphonic anhydride (T_3P , 50% in EtOAc, 1 equiv) was added. Acid activation was carried out for 30 min at -17° C, and then TEA (1.2 equiv) and the appropriate *N*benzylamine (1.1 equiv) were added dropwise to the mixture. The mixture was warmed up to room temperature and stirred for 2 h. The solvent was evaporated, maintaining the water bath at a temperature below 30 °C. The residue was purified by column chromatography over silica gel (PE/EtOAc 7:3).

4.1.1.9.1. N-(2-Chlorobenzyl)-2-((2-(((diphenylmethylene)amino)oxy)ethyl)(methyl)amino)butanamide (66b). The synthesis was done according to GP7 with amine F (32) (0.48 mmol, 122 mg), amide 63b (0.4 mmol, 115 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4 mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3)to yield **66b** (133 mg, 60%, $R_f = 0.35$ (S₁₃)). ¹H NMR (300 MHz, chloroform-d) δ ppm 0.96 (t, J = 7.33 Hz, 3 H, CH₂CH₃) 1.58–1.74 (m, 1 H, CH'H"CH₃) 1.78-1.93 (m, 1 H, CH'H"CH₃) 2.30 (s, 3 H, NCH₃) 2.78–2.94 (m, 2 H, CH₂CH₂ON=) 3.01 (t, J = 6.45 Hz, 1 H, CHNCH₃) 4.07-4.23 (m, 1 H, CH₂CH'H"ON=) 4.23-4.33 (m, 2 H, NHCH₂Ar) 4.33-4.62 (m, 1 H, CH₂CH'H"ON=) 7.08-7.51 (m, 15 H, Ar, NHCO). ¹³C NMR (75 MHz, chloroform-d) δ 173.53, 156.93, 140.43, 136.24, 136.12, 133.15, 130.22, 129.42, 129.38, 129.27, 129.11, 129.08, 128.84, 128.34, 128.23, 128.04, 127.81, 126.82, 72.74, 69.36, 54.29, 40.87, 38.48, 20.50, 12.02. HRMS-ESI+ $m/z [M + H]^+$ calcd for C₂₇H₃₁N₃O₂Cl, 464.2105; found, 464.2104.

4.1.1.9.2. N-Benzyl-2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)amino)propanamide (67). The synthesis was done according to GP7 with amine G (33) (0.48 mmol, 133 mg), amide 62 (0.4 mmol, 96 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4 mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 67 (105 mg, 60%, R_f = 0.35 (S_{13})). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.17–1.26 (m, 3 H), 1.90 (s, 3 H), 2.00 (s, 3 H), 2.12 (s, 3 H), 2.23–2.31 (m, 2 H), 2.47–2.59 (m, 2 H), 3.22 (q, *J* = 6.45 Hz, 1 H), 4.29–4.52 (m, 2 H), 5.99 (t, *J* = 7.33 Hz, 1 H), 6.70–6.77 (m, 1 H), 6.83 (d, *J* = 4.69 Hz, 1 H), 7.02 (d, *J* = 5.28 Hz, 1 H), 7.18–7.32 (m, 6 H), 7.62 (br s, 1 H). ¹³C NMR (75 MHz, chloroform-*d*) δ 183.1, 131.3, 129.6, 128.5, 127.7, 127.2, 124.4, 122.6, 62.9, 54.1, 43.1, 37.8, 28.2, 14.7, 14.4, 9.6. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₅H₄₀N₂OS₂, 439.1872; found, 439.1877.

4.1.1.9.3. N-Benzyl-2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)amino)butanamide (68). The synthesis was done according to GP7 with amine G (33) (0.48 mmol, 133 mg), amide 63a (0.4 mmol, 105 mg), TBAB (0.04 mmol, 0.12 mg), TEA (0.4

mmol, 55 μ L), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield **68** (90 mg, 50%, $R_f = 0.35$ (S_{13})). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 0.97 (t, J = 7.33 Hz, 3 H, CH₂CH₃) 1.56–1.87 (m, 3 H, thiopCH₃) 1.88–1.92 (m, 3 H, thiopCH₃) 1.98–2.04 (m, 3 H, NCH₃) 2.18 (s, 2 H, CH₂CH=) 2.28 (q, J = 7.03 Hz, 2 H) 2.54–2.68 (m, 2 H, CH₂CH₂CH=) 2.95 (d, J = 18.17 Hz, 1 H, CHNCH₃) 4.33–4.55 (m, 2 H, NHCH₂Ar) 5.98 (t, J = 7.33 Hz, 1 H, CH=) 6.74 (d, J = 5.27 Hz, 1 H, thiop) 6.83 (d, J = 5.27 Hz, 1 H, thiop) 7.44 (br s, 1 H, NHCO). ¹³C NMR HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₆H₃₂N₂OS₂, 453.2029; found, 453.2015

4.1.1.10. General Procedure for the Synthesis of Ethyl 2-Substituted Propanoate 71, 73 and Benzyl 2-Substituted Butanoate 72 (GP11). The corresponding amine B or G (1.2 equiv), a relevant ester 69 or 70 (1 equiv), and K_2CO_3 (3.5 equiv) in DCM was stirred at 40 °C (oil bath) for 12 h. The mixture was extracted with 2 M HCl and DCM. Organic phases were dried with anhydrous Na_2SO_4 and concentrated, and the residue was purified by column chromatography over silica gel (S_1 PE/EtOAc 7:3, v/v).

4.1.1.10.1. Ethyl N-(3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-N-methylalaninate (71). The synthesis was done according to GP11 with amine **B** (20) (0.48 mmol, 125 mg), ethyl 2bromopropanoate (0.4 mmol, 52 μ L), K₂CO₃ (194 mg, 1,4 mmol), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 71 (101 mg, 70%, R_f = 0.5 (S₁). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 7.21–7.41 (m, 8H), 6.86 (d, *J* = 1.17 Hz, 2H), 5.57 (ddd, *J* = 3.52, 6.74, 7.91 Hz, 1H), 4.07–4.21 (m, 2H), 3.26–3.43 (m, 1H), 2.45– 2.77 (m, 2H), 2.14–2.43 (m, 6H), 1.15–1.37 (m, 9H). ¹³C NMR (75 MHz, chloroform-*d*) δ 173.7, 142.7, 137.7, 134.3, 132.1, 131.5, 129.0, 128.3, 128.0, 127.2, 60.5, 54.4, 38.4, 27.8. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₄H₂₈NO₂, 362.2120; found, 362.2117.

4.1.1.10.2. Benzyl N-(3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-N-methylalaninate (72). The synthesis was done according to GP11 with amine B (20) (0.48 mmol, 125 mg), benzyl 2bromopropanoate (0.4 mmol, 67 μ L), K₂CO₃ (194 mg, 1,4 mmol), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 72 (1735 mg, 80%, R_f = 0.6 (S₁). ¹H NMR (300 MHz, chloroform-d) δ 7.19– 7.42 (m, 13H), 6.86 (s, 2H), 5.49–5.62 (m, 1H), 5.09–5.16 (m, 2H), 3.33–3.49 (m, 1H), 2.46–2.74 (m, 2H), 2.13–2.41 (m, 6H), 1.27 (dd, J = 7.03, 12.89 Hz, 3H). HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₄H₃₀NO₂, 424.2277; found, 424.2274

4.1.1.10.3. Ethyl 2-((4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)amino)propanoate (73). The synthesis was done according to GP11 with amine G (23) (0.48 mmol, 133 mg), ethyl 2-bromopropanoate (0.4 mmol, 52 μ L), K₂CO₃ (194 mg, 1,4 mmol), DCM 0.5 mL. The obtained crude product was purified by column chromatography over silica gel (DCM/Ace = 7:3) to yield 73 (106 mg, 70%, R_f = 0.5 (S₁). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.20–1.34 (m, 6 H) 2.03 (d, *J* = 8.79 Hz, 6 H) 2.26–2.36 (m, 5 H) 2.48–2.77 (m, 2 H) 3.37 (q, *J* = 7.03 Hz, 1 H) 4.15 (q, *J* = 7.03 Hz, 2 H) 6.06 (t, *J* = 7.33 Hz, 1 H) 6.75 (d, *J* = 5.28 Hz, 1 H) 6.84 (d, *J* = 5.27 Hz, 1 H) 7.04 (d, *J* = 5.27 Hz, 1 H) 7.20 (d, *J* = 5.27 Hz, 1 H). HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₀H₂₇NO₂S₂, 378.1556; found, 378.1560.

4.1.1.11. General Procedure for the Hydrolysis of Ethyl and Benzyl 2-Substituted Butanoate **71** and **73** to **74** and **75** (GP12). An aqueous 10 wt % NaOH (0.15 g/1.5 mL) solution was added to compounds **71** and **73** (0.3 mmol) and stirred for 4.5 h at 35 °C. The aqueous phase was acidified to pH = 3 with aq HC1 (1 M) and extracted with DCM twice. The combined organic phases are dried over anhydrous Na₂S0₄, filtered, and then concentrated to give product.

4.1.1.11.1. N-(3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)propyl)-N-methylalanine (74). The synthesis was done according to GP12 with ethyl <math>N-(3-(5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)-N-methylalaninate (71) (108 mg, 0.3 mmol) in 2 mL of 10 wt % NaOH to give the oil (quantitative) (100 mg). ¹H NMR (300 MHz,

chloroform-*d*) δ 7.20 (d, J = 2.34 Hz, 2H), 7.00–7.20 (m, 8H), 6.99–7.21 (m, 8H), 6.73–6.77 (m, 2H), 5.37 (t, J = 5.28 Hz, 1H), 3.14–3.35 (m, 1H), 2.53–3.03 (m, 3H), 2.33 (br s, 4H), 1.10–1.22 (m, 3H). COOH proton was not detected. HRMS-ESI⁺ m/z [M + H]⁺ calcd for C₂₂H₂₄N₂O, 334.1870; found, 334.1805

4.1.1.11.2. 2-((4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)-(methyl)amino)propanoic Acid (**75**). Ethyl 2-((4,4-bis(3-methyl-thiophen-2-yl)but-3-en-1-yl)(methyl)amino)propanoate (**73**) (113 mg, 0.3 mmol) in 2 mL 10 wt % NaOH was used, giving the oil (quantitative) (105 mg). ¹H NMR (300 MHz, chloroform-*d*) δ 7.23 (d, *J* = 5.28 Hz, 1H), 7.07 (d, *J* = 5.27 Hz, 1H), 6.86 (d, *J* = 5.28 Hz, 1H), 6.76 (d, *J* = 5.28 Hz, 1H), 5.98 (t, *J* = 6.74 Hz, 1H), 3.50 (br s, 1H), 3.11 (br s, 1H), 2.95 (d, *J* = 6.45 Hz, 1H), 2.49–2.68 (m, SH), 2.00–2.05 (m, 3H), 1.97 (s, 3H), 1.39 (d, *J* = 4.10 Hz, 3H). COOH proton was not detected.

4.2. In Vitro Activity. 4.2.1. $[^{3}H]GABA$ Uptake Assay. The inhibitory activities of the synthesized compounds were determined from $[^{3}H]GABA$ uptake assays with mGAT1, mGAT2, mGAT3, and mGAT4 as described previously,^{19,59} and all compounds were tested at a screening concentration of 100 μ M.

4.2.2. MS Binding Assays. MS binding assays for mGAT1 were performed as described earlier.⁴⁸ Inhibition of mGAT1 binding by the synthesized compounds was determined in MS binding assays at a screening concentration of 100 μ M and analyzed by LC–ESI-MS/MS.

4.3. Molecular Modeling. *4.3.1. Docking Studies.* For the docking studies, we used models of human GAT-1, GAT-2, and GAT-3 that were selected in our previous work.⁵¹ They were built with the SWISS-MODEL server based on the 4XP9 template from the Protein Data Bank (PDB). For BGT-1 we decided to apply the extra model built on the same template, according to previously described procedure.⁵¹ In this model, the nonhelical fragment of TM10 (residues 455–459) was additionally optimized using the MyLoop class in the Modeller program. From among 100 refined models, the best one was selected according to the QMEAN score. For each type of GABA transporter we used sequence alignment generated automatically by SWISS-MODEL. The N- and C-termini were omitted because of their low homology. Sodium and chloride ions were transferred directly from the templates.

The ligand 3D structures were created in the Maestro program. Ionization states were predicted under physiological conditions (pH 7.4) using the Epik and Marvin programs. Ligands were optimized in the LigPrep module. All possible stereoisomers for each ligand were generated. Models were prepared with Protein Preparation Wizard using the default settings.

The most active compound representatives were initially docked into the models of each type of GABA transporter using the inducedfit docking protocol available in the Schrödinger Suite. The box center was defined by residues PHE294, TYR140, TYR452, and ARG69 in GAT-1 and by the corresponding amino acids in BGT-1, GAT-2, and GAT-3. The box size was $10\text{ \AA} \times 10\text{ \AA} \times 10\text{ \AA}$. The obtained complexes were then visually inspected in terms of the created interactions, frequency, and score of the poses as well as their coherency between the particular types of GATs. After selection of the best optimized models, all studied compounds were docked into the models using the GLIDE program and the final conformations of the models were selected based on ligand pose coherency. The grid center in GLIDE was set as the centroid of the ligand from the complex, and the inner box size was $15\text{ Å} \times 15\text{ Å} \times 15\text{ Å}$. The OPLS2005 force field was applied during grid generation as well as GLIDE and IFD docking.

4.3.2. Molecular Dynamics. MD simulations were performed with NAMD using the CHARMM36m force field. Before simulations, all models were positioned in the membrane using the OPM server, and input files for NAMD were prepared with the CHARMM-GUI online server. The protein–ligand complexes were embedded in a 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) membrane and solvated with TIP3P water molecules. The system size was 100 Å \times 100 Å. A water pore for each complex was generated. Sodium and chloride ions (0.15 M NaCl) were added to provide standard

physiological ionic strength. The system was equilibrated via a six step protocol recommended by CHARMM-GUI for the NAMD program. MD simulations were run at 303.15 K with a time step of 2 fs and a total duration of 10 ns. The intervals for both the energy and trajectory recordings were 10 ps. The results were analyzed with the VMD program.

4.4. Hepatotoxicity and Cytotoxicity. Hepatotoxicity and cytotoxicity were estimated according to previously described protocols⁶⁰ using the hepatoma HepG2 (ATCC HB-8065) and human embryonic kidney HEK-293 (ATCC CRL1573) cell lines, respectively. In brief, cells were seeded in 96-well plates at a density of 0.7×10^4 and cultured at 37 °C in an atmosphere containing 5% CO₂. Next, the compounds were added and investigated in quadruplicate at concentrations ranging from 0.1 to 100 μ M for 72 h. The antiproliferative drug DX was used as the reference. The CellTiter 96 AQueous nonradioactive cell proliferation assay (MTS) purchased from Promega (Madison, WI, USA) was used for the determination of cell viability. The absorbance at 492 nm was measured using an EnSpire microplate reader (PerkinElmer, Waltham, MA, USA).

4.5. In Vivo Evaluation. 4.5.1. Materials and Methods. 4.5.1.1. Animals and Housing Conditions. Behavioral experiments were carried out at the Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow. Tests were performed between 9 a.m. and 2 p.m. All experimental in vivo procedures were approved by the second Local Ethics Committee in Krakow (Approval Numbers 32/2018 and 508/2021). The treatment of animals was in full accordance with the ethical standards laid down by both Polish and EU regulations (Directive 2010/63/EU). To avoid potential bias in data recording, the investigators who were involved in behavioral assays were blinded to the experimental groups. Adult male albino Swiss (CD-1) mice weighing 18-22 g were supplied by the Animal Breeding Farm of the Jagiellonian University Faculty of Pharmacy. Before the in vivo tests, the mice were kept in groups of 10 in standard plastic cages. Bedding material (Transwiór, Poland) was at least 2 cm deep to allow the mice to dig, and animals were housed under controlled laboratory conditions (room temperature of 22 ± 2 °C, light/dark (12:12) cycle, lights on at 8 a.m., humidity 50 \pm 10%, and free access to food (Murigran, Agropol, Poland) and tap water). Experimental groups consisted of 8-10 animals/dose. For behavioral tests, the mice were selected randomly After completion of the assays, the mice were euthanized by cervical dislocation.

4.5.1.2. Chemicals Used in the in Vivo Tests. Before the *in vivo* tests, the test compounds were suspended in 1% Tween 80 (Baxter, Poland). The compounds were then administered intraperitoneally. The dose of 30 mg/kg of each compound was the starting dose, and if activity was observed in the pain tests, a dose of 10 mg/kg was also tested. The test compounds were administered only once daily on days 1 and 7 of oxaliplatin- or paclitaxel-induced neuropathy. In STZ-treated mice, test compounds were administered 21 days after STZ injection. Control mice used in oxaliplatin and paclitaxel NP models were injected with an appropriate amount of vehicle (0.9% saline). Oxaliplatin was purchased from Activate Scientific GmbH (Germany). Paclitaxel and STZ were purchased from Sigma-Aldrich (Poland).

4.5.1.3. Induction of Neuropathy and NP. For pain studies, oxaliplatin was dissolved in 5% glucose solution (Polfa Kutno, Poland). The dose of oxaliplatin used to induce peripheral neuropathy (10 mg/kg, intraperitoneal injection) was chosen on the basis of previous research^{61,62} and available literature data.⁶³

Doses of both paclitaxel and STZ used for the induction of neuropathy were selected based on our previous research.^{64,65} To induce neuropathy, paclitaxel was used at a dose of 18 mg/kg. It was prepared by dissolving in ethanol (100% (v/v); Polskie Odczynniki Chemiczne, Gliwice, Poland) at 10% of the final desired volume and vortexed for 2 min. An equal volume of Cremophor EL (10% of the final volume) was then added, and the mixture was vortexed for the next 10 min. Prior to injection, ice-cold physiological saline (80% of the final volume) was added to make up a final volume and the solution was maintained on ice during dosing.⁶⁴ To induce type I

diabetes, mice were intraperitoneally injected with STZ (a single injection of STZ, 200 mg/kg) dissolved in 0.1 N citrate buffer. Agematched control mice received an equal volume of citrate buffer. Blood glucose level was measured 1 day before (referred to as "day 0") and repeatedly 1, 2, and 3 weeks after STZ injection using a blood glucose monitoring system (Accu-Chek Active, Roche, France). Blood samples for measurement of glucose concentration were obtained from the tail vein of the mice. The animals were considered as diabetic when their blood glucose concentration exceeded 300 mg/ dL,⁶⁶ and only these mice (diabetic mice) were used in subsequent pain tests.⁶⁵

4.5.1.4. Assessment of Tactile (Mechanical) Allodynia (von Frey Test). The ability of the test compounds to attenuate tactile allodynia caused by oxaliplatin, paclitaxel, and STZ was assessed using the von Frey test. For this purpose, 3 h after oxaliplatin or paclitaxel and 21 days after STZ injection, the predrug paw withdrawal threshold was measured for each mouse. Then, the test compounds were administered, and 1 h later, the postdrug paw withdrawal threshold was collected for each animal. This part of the experiment aimed to establish the effect of treatment on early phase (acute) pain hypersensitivity induced by cytotoxic drugs. Additionally, in the oxaliplatin model and the paclitaxel model, to assess the effect of test compounds on late phase tactile allodynia, 7 days later, measurements of the predrug and postdrug paw withdrawal thresholds were made in a similar manner to the measurements performed during early phase neuropathy. At this stage of the experiment, there was no additional oxaliplatin/paclitaxel administration.

An electronic von Frey unit (Bioseb, France) was used to assess the mechanical nociceptive threshold (tactile allodynia) in mice. This device has a single flexible filament that applies increasing force (from 0 to 10 g) against the plantar surface of the hind paw of each mouse. In the von Frey test, the paw withdrawal response of the animals automatically turns off the stimulus, and the mechanical pressure that evokes this response is recorded. On the day of the experiment, the mice were placed individually in test compartments with a wire mesh bottom and left there for 1 h of habituation. Subsequently, to obtain baseline values, each mouse was tested 3 times alternately in each hind paw. Then, the test compounds were administered, and 1 h later, 3 additional measurements were taken and averaged to obtain the mean postdrug values for each mouse.⁶⁷

4.5.1.5. Assessment of Cold Nociceptive Threshold (Cold Plate Test). A cold plate apparatus (hot/cold plate, Bioseb, France) set at 2.5 °C was used to assess the effect of treatment on cold hyperalgesia in oxaliplatin-treated mice. The cold plate test was conducted immediately after the von Frey test. Three hours after oxaliplatin administration, the animals were placed on a cold plate apparatus, and predrug latencies to pain reaction (i.e., lifting, biting, shaking of hind paws, jumping, movement deficits, or writhing response) were collected. Finally, the test compounds were injected, and 1 h later, the postdrug latencies to pain reaction were measured. In this assay, a cutoff time of 60 s was established to avoid potential thermally induced damage to the paw tissues, and animals not responding within 60 s were removed from the apparatus and assigned a score of 60 s.^{68,69}

4.5.1.6. Assessment of Heat Nociceptive Threshold (Hot Plate Test). Thermal (heat) nociceptive threshold was assessed in the hot plate test as previously described.⁶⁵ First, baseline (predrug) latencies to pain reaction were established for each mouse. Then, the mice were treated intraperitoneally with either the test compound or vehicle. Sixty minutes later the animals were placed on the hot plate apparatus again (hot/cold plate, Bioseb, France). This apparatus has an electrically heated surface and is supplied with a temperature-controller that maintains the temperature at 55 °C. The time until the animal licked its hind paws or jumped was recorded by means of a stop-watch. In this assay a cutoff time was established (60 s) to avoid tissue damage, and the mice not responding within 60 s were removed from the apparatus and assigned a score of 60 s.

4.5.1.7. Rotarod Test. Before the rotarod test, the experimental animals underwent 3 d of training on the rotarod apparatus (totarod apparatus, May Commat RR0711, Turkey; rod diameter 2 cm) that

rotated at a fixed speed of 18 rotations per minute (rpm). During this training session, the mice were placed on the rotating rod for 3 min with an unlimited number of trials. The proper test was performed 24 h after the last training session. Sixty minutes after administration of the test compounds or vehicle, the mice were tested on rods that revolved at 6, 18, and 24 rpm. Motor deficits in the mice were defined as their inability to remain on the rotarod apparatus for 1 min. The results are expressed as the mean time spent on the rotarod.⁶⁸

4.5.1.8. Data Analysis. Data analysis of the *in vivo* results was performed using GraphPad Prism software (version 8.0, CA, USA). Numerical results obtained in behavioral tests are expressed as the mean \pm SEM. Statistical analysis was performed using the Shapiro–Wilk normality test, followed by one-way analysis of variance (ANOVA) and Tukey's post hoc comparison (NP models). One-way ANOVA and Dunnett's post hoc comparison were used to test differences between the drug-treated groups and the control group in the rotarod test. A value of p < 0.05 was considered significant.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acschemneuro.1c00351.

Synthesis of building blocks 17 (A), 20 (B), 21 (C), 25 (D), 26 (E), 32 (F), and 33 (G); RMSD changes over the course of the molecular dynamics simulations; 1 H and 13 C NMR spectra of synthesized compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

Paula Zaręba – Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; orcid.org/ 0000-0002-5037-6183; Phone: +4812 6205464; Email: paula.zareba@uj.edu.pl; Fax: +4812 6205450

Authors

Beata Gryzło – Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland

- Katarzyna Malawska Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Gabriela Mazur Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Anna Rapacz Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Kamil Łątka Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Georg C. Höfner Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
- Gniewomir Latacz Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Marek Bajda Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; Occid.org/ 0000-0001-6032-0354
- Kinga Sałat Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Klaus T. Wanner Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, 81377 Munich, Germany; orcid.org/0000-0003-4399-1425
- Barbara Malawska Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; orcid.org/0000-0003-4637-5820

⁸Katarzyna Kulig – Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland

Complete contact information is available at:

https://pubs.acs.org/10.1021/acschemneuro.1c00351

Author Contributions

P.Z. and K.K. designed and coordinated the study and analyzed the data. B.G., P.Z., and K.S. wrote the manuscript. B.G., P.Z., K.M., and G.M. synthesized the compounds. G.C.H. coordinated [³H] GABA uptake assay and MS binding assays. K.Ł. and M.B. performed molecular modeling. G.L. performed *in vitro* studies (hepatotoxicity and cytotoxicity). K.S. and A.R. performed *in vivo* pharmacological evaluation (mouse models of neuropathic pain). B.M., K.S., K.T.W., and G.C.H. corrected the manuscript. All the authors contributed to and approved the final manuscript.

Funding

This study was financially supported by the National Science Center in Poland as part of Grant 2014/15/B/NZ7/00930. The molecular modeling studies were financially supported by the National Science Center, Poland, Grant 2016/23/D/NZ7/ 01172.

Notes

The authors declare no competing financial interest. [§]K.K.: deceased, June, 26, 2016.

ABBREVIATIONS

GABA, γ -aminobutyric acid; CNS, central nervous system; GABA_A, γ -aminobutyric acid type A receptor; GABA_B, γ aminobutyric acid type B receptor; GABA_C, γ -aminobutyric acid type C receptor; GAT, GABA transporter protein; SLC6, solute carrier 6 family; BGT1, betaine/GABA transporter 1; IUPHAR, International Union of Basic and Clinical Pharmacology; GAT1, GABA transporter 1; GAT2, GABA transporter 2; RMSD, root-mean-square deviation; GAT3, GABA transporter 3; NP, neuropathic pain; FDA, U.S. Food and Drug Administration; BOC, *tert*-butyloxycarbonyl protecting group; TEA, triethylamine; THF, tetrahydrofuran; DCM, dichloromethane; STZ, streptozotocin

REFERENCES

(1) Roberts, E., and Frankel, S. (1950) Gamma-aminobutyric acid in brain: its formation from glutamic acid. J. Biol. Chem. 187, 55–63.

(2) Awapara, J., Landua, A. J., Fuerst, R., and Seale, B. (1950) Free gamma-aminobutyric acid in brain. *J. Biol. Chem.* 187, 35–39.

(3) Erlander, M. G., Tillakaratne, N. J., Feldblum, S., Patel, N., and Tobin, A. J. (1991) Two genes encode distinct glutamate decarboxylases. *Neuron* 7, 91–100.

(4) Hull, C., and Von Gersdorff, H. (2004) Fast endocytosis is inhibited by GABA-mediated chloride influx at a presynaptic terminal. *Neuron* 44, 469–482.

(5) Connolly, C. N., Krishek, B. J., McDonald, B. J., Smart, T. G., and Moss, S. J. (1996) Assembly and cell surface expression of heteromeric and homomeric γ -aminobutyric acid type A receptors. J. Biol. Chem. 271, 89–96.

(6) Schousboe, A. (1981) Transport and metabolism of glutamate and gaba in neurons and glial cells. *Int. Rev. Neurobiol.* 22, 1–45.

(7) Alexander, S. P. H., Davenport, A. P., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., and Davies, J. A. (2015) The Concise Guide To Pharmacology 2015/16: G protein-coupled receptors. *Br. J. Pharmacol.* 172, 5744–5869.

(8) Madsen, K. K., Clausen, R. P., Larsson, O. M., Krogsgaard-Larsen, P., Schousboe, A., and Steve White, H. (2009) Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. *J. Neurochem.* 109, 139–144. (9) Kempson, S. A., Zhou, Y., and Danbolt, N. C. (2014) The betaine/GABA transporter and betaine: Roles in brain, kidney, and liver. *Front. Physiol.* 5, 1–16.

(10) Zhou, Y., Holmseth, S., Hua, R., Lehre, A. C., Olofsson, A. M., Poblete-Naredo, I., Kempson, S. A., and Danbolt, N. C. (2012) The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. *Am. J. Physiol.: Renal Physiol.* 302, F316–F328.

(11) Conti, F., Zuccarello, L. V., Barbaresi, P., Minelli, A., Brecha, N. C., and Melone, M. (1999) Neuronal, glial, and epithelial localization of gamma-aminobutyric acid transporter 2, a high-affinity gamma-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures. J. Comp. Neurol. 409, 482–494.

(12) Li, Y., Li, Y., Gu, P., Fu, B., Liu, F., and Li, E. (2011) Analgesic effect of intrathecally γ -aminobutyric acid transporter-1 inhibitor NO-711 administrating on neuropathic pain in rats. *Neurosci. Lett.* 494, 6–9.

(13) Giardina, W. J., Decker, M. W., Porsolt, R. D., Roux, S., Collins, S. D., Kim, D. J. B., and Bannon, A. W. (1998) An evaluation of the GABA uptake blocker tiagabine in animal models of neuropathic and nociceptive pain. *Drug Dev. Res.* 44, 106–113.

(14) Collins, S., Deaton, R., Giardina, W., and Gilbert, A. Use of tiagabine for treatment of diabetic neuropathy and migraine, US2002103236(A1), 2002.

(15) Sałat, K., Podkowa, A., Malikowska, N., Kern, F., Pabel, J., Wojcieszak, E., Kulig, K., Wanner, K. T., Strach, B., and Wyska, E. (2017) Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. *Neuropharmacology* 113, 331–342.

(16) Kataoka, K., Hara, K., Haranishi, Y., Terada, T., and Sata, T. (2013) The antinociceptive effect of SNAP5114, a gamma-aminobutyric acid transporter-3 inhibitor, in rat experimental pain models. *Anesth. Analg. 116*, 1162–1169.

(17) Narita, M., Niikura, K., Nanjo-Niikura, K., Narita, M., Furuya, M., Yamashita, A., Saeki, M., Matsushima, Y., Imai, S., Shimizu, T., Asato, M., Kuzumaki, N., Okutsu, D., Miyoshi, K., Suzuki, M., Tsukiyama, Y., Konno, M., Yomiya, K., Matoba, M., and Suzuki, T. (2011) Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex. *Pain 152*, 1358–1372.

(18) Sarup, A., Larsson, O. M., and Schousboe, A. (2003) GABA transporters and GABA-transaminase as drug targets. *Curr. Drug Targets: CNS Neurol. Disord. 2,* 269–77.

(19) Kragler, A., Höfner, G., and Wanner, K. T. (2008) Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4. *Eur. J. Med. Chem.* 43, 2404–2411.

(20) Kern, F. T., and Wanner, K. T. (2015) Generation and Screening of Oxime Libraries Addressing the Neuronal GABA Transporter GAT1. *ChemMedChem 10*, 396–410.

(21) Lutz, T., Wein, T., Höfner, G., and Wanner, K. T. (2017) Development of highly potent GAT1 inhibitors: Synthesis of nipecotic acid derivatives with N-arylalkynyl substituents. *Chem*-*MedChem* 12, 362–371.

(22) Pabel, J., Faust, M., Prehn, C., Wörlein, B., Allmendinger, L., Höfner, G., and Wanner, K. T. (2012) Development of an (S)-1-{2-[Tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114] Carba Analogue Inhibitor for Murine γ -Aminobutyric Acid Transporter Type4. *ChemMedChem* 7, 1245–1255.

(23) Böck, A. M. C., Höfner, G., and Wanner, K. T. (2020) N-Substituted Nipecotic Acids as (S)-SNAP-5114 Analogues with Modified Lipophilic Domains. *ChemMedChem 15*, 756–771.

(24) Damgaard, M., Al-Khawaja, A., Vogensen, S. B., Jurik, A., Sijm, M., Lie, M. E. K., Bæk, M. I., Rosenthal, E., Jensen, A. A., Ecker, G. F., Frolund, B., Wellendorph, P., and Clausen, R. P. (2015) Identification of the First Highly Subtype-Selective Inhibitor of Human GABA Transporter GAT3. *ACS Chem. Neurosci.* 6, 1591–1599.

(25) Zaręba, P., Gryzło, B., Malawska, K., Sałat, K., Höfner, G. C., Nowaczyk, A., Fijałkowski, Ł., Rapacz, A., Podkowa, A., Furgała, A., Żmudzki, P., Wanner, K.T., Malawska, B., and Kulig, K. (2020) Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice. *Eur. J. Med. Chem.* 188, 111920.

(26) Jurik, A., Zdrazil, B., Holy, M., Stockner, T., Sitte, H. H., and Ecker, G. F. (2015) A binding mode hypothesis of tiagabine confirms liothyronine effect on γ -aminobutyric acid transporter 1 (GAT1). *J. Med. Chem.* 58, 2149–2158.

(27) Lee, J., Kang, S. U., Lim, J. O., Choi, H. K., Jin, M. K., Toth, A., Pearce, L. V., Tran, R., Wang, Y., Szabo, T., and Blumberg, P. M. (2004) N-[4-(Methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: Analysis of structure-activity relationships for the "C-Region". *Bioorg. Med. Chem.* 12, 371–385.

(28) Chen, G., Xia, H., Cai, Y., Ma, D., Yuan, J., and Yuan, C. (2011) Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers. *Bioorg. Med. Chem. Lett.* 21, 234–239.

(29) Boyle, C. D., Greenlee, W. J., and Chackalamannil, S. Muscarine Antagonists WO03/091220A1, 2003.

(30) Stach, K. DE1203253, 1965.

(31) Zareba, P., Sałat, K., Hoefner, G. C., Łątka, K., Bajda, M., Latacz, G., Kotniewicz, K., Rapacz, A., Podkowa, A., Maj, M., Jóźwiak, K., Filipek, B., Wanner, K. T., Malawska, B., and Kulig, K. (2021) Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity. *Eur. J. Med. Chem.* 221, 113512.

(32) Jackson, P.W. Process for the preparation of 10,11-dihydro-5Hdibenzo[a,d]cyclohept-5-enes and derivatives thereof. WO98/ 38166A1, 1998.

(33) Kastrinsky, D. B., Sangodkar, J., Zaware, N., Izadmehr, S., Dhawan, N. S., Narla, G., and Ohlmeyer, M. (2015) Reengineered tricyclic anti-cancer agents. *Bioorg. Med. Chem.* 23, 6528–6534.

(34) Kung, P. P., Bharadwaj, R., Fraser, A. S., Cook, D. R., Kawasaki, A. M., and Cook, P. D. (1998) Solution-phase synthesis of novel linear oxyamine combinatorial libraries with antibacterial activity. *J. Org. Chem.* 63, 1846–1852.

(35) Li, X., Hou, J., Wang, C., Liu, X., He, H., Xu, P., Yang, Z., Chen, Z., Wu, Y., and Zhang, L. (2013) Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy. *Molecules* 18, 13957–13978.

(36) Andersen, K. E., Braestrup, C., Grønwald, F. C., Jørgensen, A. S., Nielsen, E. B., Sonnewald, U., Sørensen, P. O., Suzdak, P. D., and Knutsen, L. J. (1993) The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. *J. Med. Chem.* 36, 1716–1725.

(37) Clausen, R. P., Moltzen, E. K., Perregaard, J., Lenz, S. M., Sanchez, C., Falch, E., Frølund, B., Bolvig, T., Sarup, A., Larsson, O. M., Schousboe, A., and Krogsgaard-Larsen, P. (2005) Selective inhibitors of GABA uptake: Synthesis and molecular pharmacology of 4-N-methylamino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol analogues. *Bioorg. Med. Chem.* 13, 895–908.

(38) Vogensen, S. B., Jørgensen, L., Madsen, K. K., Borkar, N., Wellendorph, P., Skovgaard-Petersen, J., Schousboe, A., White, H. S., Krogsgaard-Larsen, P., and Clausen, R. P. (2013) Selective mGAT2 (BGT-1) GABA uptake inhibitors: Design, synthesis, and pharmacological characterization. *J. Med. Chem.* 56, 2160–2164.

(39) Song, S., Zhu, S. F., Pu, L. Y., and Zhou, Q. L. (2013) Iridiumcatalyzed enantioselective hydrogenation of unsaturated heterocyclic acids. *Angew. Chem., Int. Ed.* 52, 6072–6075.

(40) Kowalczyk, P., Sałat, K., Höfner, G. C., Guzior, N., Filipek, B., Wanner, K. T., and Kulig, K. (2013) 2-Substituted 4-hydroxybutanamides as potential inhibitors of γ -aminobutyric acid transporters mGAT1-mGAT4: Synthesis and biological evaluation. *Bioorg. Med. Chem.* 21, 5154–5167.

(41) Kulig, K., Więckowski, K., Więckowska, A., Gajda, J., Pochwat, B., Höfner, G. C., Wanner, K. T., and Malawska, B. (2011) Synthesis and biological evaluation of new derivatives of 2-substituted 4-

hydroxybutanamides as GABA uptake inhibitors. Eur. J. Med. Chem. 46, 183-190.

(42) Sałat, K., Kulig, K., Sałat, R., Filipek, B., and Malawska, B. (2012) Analgesic and anticonvulsant activity of new derivatives of 2-substituted 4-hydroxybutanamides in mice. *Pharmacol. Rep. 64*, 102–112.

(43) Kowalczyk, P., Höfner, G. H., Wanner, K. T., and Kulig, K. (2012) Synthesis and Pharmacological Evaluation of New 4, 4-Diphenylbut-3-Enyl Derivatives of 4-Hydroxybutanamides As Gaba Uptake Inhibitors. *Acta Pol. Pharm. Drug Res.* 69, 157–160.

(44) Kowalczyk, P., Sałat, K., Höfner, G. C., Mucha, M., Rapacz, A., Podkowa, A., Filipek, B., Wanner, K. T., and Kulig, K. (2014) Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides. *Eur. J. Med. Chem.* 83, 256–273.

(45) Guénin, E., Monteil, M., Bouchemal, N., Prangé, T., and Lecouvey, M. (2007) Syntheses of phosphonic esters of alendronate, pamidronate and neridronate. *Eur. J. Org. Chem.* 2007, 3380–3391.

(46) Sauvagnat, B., Kulig, K., Lamaty, F., Lazaro, R., and Martinez, J. (2000) Soluble polymer supported synthesis of alpha-amino acid derivatives. *J. Comb. Chem. 2*, 134–142.

(47) Rajadhyaksha, M. N., Nair, R., Shrigadi, N. B., and Panandikar, A. M. WO2012014226A1, 2012.

(48) Zepperitz, C., Höfner, G., and Wanner, K. T. (2006) MSbinding assays: Kinetic, saturation, and competitive experiments based on quantitation of bound marker as exemplified by the GABA transporter mGAT1. *ChemMedChem 1*, 208–217.

(49) Petrera, M., Wein, T., Allmendinger, L., Sindelar, M., Pabel, J., Höfner, G., and Wanner, K. T. (2016) Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives by Suzuki-Miyaura Cross-Coupling Reactions. *ChemMedChem* 11, 519–538.

(50) Schmitt, S., Höfner, G., and Wanner, K. T. (2015) Application of MS Transport Assays to the Four Human γ -Aminobutyric Acid Transporters. *ChemMedChem 10*, 1498–1510.

(51) Łątka, K., Jończyk, J., and Bajda, M. (2020) Structure modeling of γ -aminobutyric acid transporters – Molecular basics of ligand selectivity. *Int. J. Biol. Macromol.* 158, 1380–1389.

(52) Nizi, M.G., Desantis, J., Nakatani, Y., Massari, S., Mazzarella, M.A., Shetye, G., Sabatini, S., Barreca, M.L., Manfroni, G., Felicetti, T., Rushton-Green, R., Hards, K., Latacz, G., Satała, G., Bojarski, A.J., Cecchetti, V., Kolář, M. H., Handzlik, J., Cook, G.M., Franzblau, S.G., and Tabarrini, O. (2020) Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. *Eur. J. Med. Chem. 201*, 112420.

(53) Sałat, K. (2020) Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity. *Pharmacol. Rep.* 72, 508–527.

(54) Nassini, R., Gees, M., Harrison, S., De Siena, G., Materazzi, S., Moretto, N., Failli, P., Preti, D., Marchetti, N., Cavazzini, A., Mancini, F., Pedretti, P., Nilius, B., Patacchini, R., and Geppetti, P. (2011) Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. *Pain* 152, 1621–1631.

(55) xiao, w.h., Zheng, h., and bennett, g.j. (2012) characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. *Neuroscience* 203, 194–206.

(56) Rondón, L. J., Privat, A. M., Daulhac, L., Davin, N., Mazur, A., Fialip, J., Eschalier, A., and Courteix, C. (2010) Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain. *J. Physiol.* 588, 4205–4215.

(57) Zanotti, G., Filira, F., Del Pra, A., Cavicchioni, G., Veronese, C., and D'Angeli, F. (1980) Base-catalysed Reactions of a-Bromo-Nbenzyl-propionamide and-isobutyramide. Formation of 2-Aminooxazolidinones. J. Chem. Soc., Perkin Trans. 1, 2249.

(58) Westerbeek, A., Szymański, W., Wijma, H. J., Marrink, S. J., Feringa, B. L., and Janssen, D. B. (2011) Kinetic Resolution of α -Bromoamides: Experimental and Theoretical Investigation of Highly Enantioselective Reactions Catalyzed by Haloalkane Dehalogenases. *Adv. Synth. Catal.* 353, 931–944.

(59) Kragler, A., Höfner, G., and Wanner, K. T. (2005) Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4. *Eur. J. Pharmacol. 519*, 43–47.

(60) Łażewska, D., Kaleta, M., Hagenow, S., Mogilski, S., Latacz, G., Karcz, T., Lubelska, A., Honkisz, E., Handzlik, J., Reiner, D., Satała, G., Filipek, B., Stark, H., and Kieć-kononowicz, K. (2018) Novel naphthyloxy derivatives - potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation. *Bioorg. Med. Chem.* 26, 2573–2585.

(61) Sałat, K., Cios, A., Wyska, E., Sałat, R., Mogilski, S., Filipek, B., Wieckowski, K., and Malawska, B. (2014) Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. *Pharmacol., Biochem. Behav.* 122, 173–181.

(62) Sałat, K., Furgała, A., and Sałat, R. (2018) Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain. *Inflammopharmacology 26*, 361–374.

(63) Zhao, M., Isami, K., Nakamura, S., Shirakawa, H., Nakagawa, T., and Kaneko, S. (2012) Acute Cold Hypersensitivity Characteristically Induced by Oxaliplatin is Caused by the Enhanced Responsiveness of TRPA1 in Mice. *Mol. Pain 8*, 1744-8069-855.

(64) Sałat, K., and Filipek, B. (2015) Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice *. *J. Zhejiang Univ., Sci., B 16*, 167–178.

(65) Sałat, K., Gawlik, K., Witalis, J., Pawlica-Gosiewska, D., Filipek, B., Solnica, B., Wieckowski, K., and Malawska, B. (2013) Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoro-methyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 386, 493–505.

(66) Tanabe, M., Murakami, T., and Ono, H. (2008) Zonisamide Suppresses Pain Symptoms of Formalin-Induced Inflammatory and Streptozotocin-Induced Diabetic Neuropathy. *J. Pharmacol. Sci.* 107, 213–220.

(67) Sałat, K., Kołaczkowski, M., Furgała, A., Rojek, A., Śniecikowska, J., Varney, M. A., and Newman-Tancredi, A. (2017) Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT 1A receptor selective agonist, NLX-112 in mouse models of pain. *Neuropharmacology* 125, 181–188.

(68) Furgała, A., Fijałkowski, Ł., Nowaczyk, A., Sałat, R., and Sałat, K. (2018) Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin attenuates oxaliplatin-induced cold allodynia in mice. *Biomed. Pharmacother.* 106, 930–940.

(69) Sałat, K., Furgała, A., and Malikowska-Racia, N. (2019) Searching for analgesic drug candidates alleviating oxaliplatin-induced cold hypersensitivity in mice. *Chem. Biol. Drug Des.*, 1–12.